[{"category":"Human","referral_name":"Oxbryta","international_non_proprietary_name_inn_common_name":"voxelotor","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Oxbryta","associated_names_non_centrally_authorised_medicines":"","class":"Haemoglobin S (HbS) polymerization inhibitor","reference_number":"EMEA/H/A-20/1538/C/004869/0014","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/10/2025","european_commission_decision_date":"09/12/2025","first_published_date":"30/07/2024","last_updated_date":"17/12/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/oxbryta"},{"category":"Human","referral_name":"Melatomed and associated names","international_non_proprietary_name_inn_common_name":"melatonin","current_status":"CHMP opinion","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000303296","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"16/10/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/12/2025","european_commission_decision_date":"","first_published_date":"12/12/2025","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/melatomed-associated-names"},{"category":"Human","referral_name":"Levamisole-containing medicinal products","international_non_proprietary_name_inn_common_name":"levamisole","current_status":"Under evaluation","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Decaris  ;Levamisol Arena","class":"Anthelmintic products","reference_number":"EMA/REF/0000293746","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"04/09/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"05/09/2025","last_updated_date":"28/11/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/levamisole-containing-medicinal-products"},{"category":"Human","referral_name":"Ipidacrine-containing medicinal products","international_non_proprietary_name_inn_common_name":"ipidacrine","current_status":"Under evaluation","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000271842","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"22/05/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"23/05/2025","last_updated_date":"14/11/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ipidacrine-containing-medicinal-products"},{"category":"Human","referral_name":"Tecovirimat SIGA","international_non_proprietary_name_inn_common_name":"tecovirimat","current_status":"Under evaluation","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Tecovirimat SIGA","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000287477","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"24/07/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"25/07/2025","last_updated_date":"14/11/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tecovirimat-siga"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing amoxicillin","international_non_proprietary_name_inn_common_name":"amoxicillin","current_status":"Procedure started","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000290626","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"06/11/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"06/11/2025","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-amoxicillin"},{"category":"Human","referral_name":"Sodium oxybate-containing syrup and oral solution for alcohol dependence","international_non_proprietary_name_inn_common_name":"sodium oxybate","current_status":"Under evaluation","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000278933","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"19/06/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"20/06/2025","last_updated_date":"28/10/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sodium-oxybate-containing-syrup-oral-solution-alcohol-dependence"},{"category":"Human","referral_name":"Azithromycin-containing medicinal products for systemic use","international_non_proprietary_name_inn_common_name":"azithromycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Macrolides","reference_number":"EMEA/H/A-31/1532","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"09/11/2023","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/05/2025","european_commission_decision_date":"08/09/2025","first_published_date":"10/11/2023","last_updated_date":"21/10/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/azithromycin-containing-medicinal-products-systemic-use"},{"category":"Veterinary","referral_name":"Quarter-based selective dry cow therapy","international_non_proprietary_name_inn_common_name":"","current_status":"Procedure started","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000285673","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"","procedure_start_date":"16/07/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"18/07/2025","last_updated_date":"13/10/2025","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/quarter-based-selective-dry-cow-therapy"},{"category":"Human","referral_name":"Ixchiq","international_non_proprietary_name_inn_common_name":"Chikungunya vaccine (live)","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Ixchiq","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1540","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"08/05/2025","prac_recommendation_date":"10/07/2025","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2025","european_commission_decision_date":"12/09/2025","first_published_date":"07/05/2025","last_updated_date":"19/09/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ixchiq"},{"category":"Human","referral_name":"Finasteride- and dutasteride-containing medicinal products","international_non_proprietary_name_inn_common_name":"finasteride;dutasteride","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"genito-urinary system and sex hormones; dermatologicals","reference_number":"EMEA/H/A-31/1539","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"03/10/2024","prac_recommendation_date":"","cmdh_position_date":"19/06/2025","chmp_cvmp_opinion_date":"","european_commission_decision_date":"22/08/2025","first_published_date":"04/10/2024","last_updated_date":"19/09/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing albendazole as a single active substance presented as oral suspension in sheep","international_non_proprietary_name_inn_common_name":"albendazole","current_status":"Procedure started","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/REF/0000271819","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"11/06/2025","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"13/06/2025","last_updated_date":"24/07/2025","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-albendazole-single-active-substance-presented-oral-suspension-sheep"},{"category":"Human","referral_name":"Mysimba","international_non_proprietary_name_inn_common_name":"naltrexone;bupropion","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Mysimba","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1530/C/3687/0065","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/03/2025","european_commission_decision_date":"22/05/2025","first_published_date":"15/09/2023","last_updated_date":"03/06/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/mysimba"},{"category":"Human","referral_name":"Metamizole-containing medicinal products","international_non_proprietary_name_inn_common_name":"metamizole","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-107i/1537","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"13/06/2024","prac_recommendation_date":"05/09/2024","cmdh_position_date":"18/09/2024","chmp_cvmp_opinion_date":"","european_commission_decision_date":"22/11/2024","first_published_date":"14/06/2024","last_updated_date":"29/01/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products-0"},{"category":"Human","referral_name":"Ocaliva","international_non_proprietary_name_inn_common_name":"obeticholic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Ocaliva","associated_names_non_centrally_authorised_medicines":"","class":"Bile acids and derivatives","reference_number":"EMEA/H/A-20/1531/C/004093/0045","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2024","european_commission_decision_date":"30/08/2024","first_published_date":"13/10/2023","last_updated_date":"07/01/2025","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ocaliva"},{"category":"Human","referral_name":"Lorazepam Macure 4 mg/ml, solution for injection","international_non_proprietary_name_inn_common_name":"lorazepam","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-13/1536","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"22/02/2024","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2024","european_commission_decision_date":"29/08/2024","first_published_date":"28/06/2024","last_updated_date":"08/10/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lorazepam-macure-4-mg-ml-solution-injection"},{"category":"Human","referral_name":"Havrix","international_non_proprietary_name_inn_common_name":"hepatitis A virus (inactivated, adsorbed)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Havrix and associated names","class":"","reference_number":"EMEA/H/A-30/1527","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2024","european_commission_decision_date":"26/08/2024","first_published_date":"15/09/2023","last_updated_date":"04/09/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/havrix"},{"category":"Human","referral_name":"Hydroxyprogesterone caproate-containing medicinal products","international_non_proprietary_name_inn_common_name":"hydroxyprogesterone caproate","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Lentogest  ;Progesterone Retard Pharlon  ;Proluton Depot","class":"progestogens","reference_number":"EMEA-H-A-31-1528","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"12/05/2023","prac_recommendation_date":"16/05/2024","cmdh_position_date":"26/06/2024","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"12/05/2023","last_updated_date":"05/07/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyprogesterone-caproate-containing-medicinal-products"},{"category":"Human","referral_name":"Micrazym and associated names","international_non_proprietary_name_inn_common_name":"porcine pancreas enzymes","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1535","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/03/2024","european_commission_decision_date":"16/05/2024","first_published_date":"22/03/2024","last_updated_date":"11/06/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/micrazym-associated-names"},{"category":"Human","referral_name":"Synapse","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1529","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/03/2024","european_commission_decision_date":"24/05/2024","first_published_date":"21/07/2023","last_updated_date":"05/06/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/synapse"},{"category":"Human","referral_name":"Ibuprofen NVT","international_non_proprietary_name_inn_common_name":"ibuprofen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1533","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/02/2024","european_commission_decision_date":"10/05/2024","first_published_date":"23/02/2024","last_updated_date":"05/06/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ibuprofen-nvt"},{"category":"Veterinary","referral_name":"Kexxtone 32.4 g continuous-release intraruminal device for cattle","international_non_proprietary_name_inn_common_name":"monensin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"Kexxtone","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/150","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"14/03/2024","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/04/2024","european_commission_decision_date":"15/05/2024","first_published_date":"04/06/2024","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/kexxtone-324-g-continuous-release-intraruminal-device-cattle"},{"category":"Veterinary","referral_name":"Procaine benzylpenicillin","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/145","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"16/02/2022","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/09/2023","european_commission_decision_date":"11/12/2023","first_published_date":"23/02/2022","last_updated_date":"29/05/2024","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/procaine-benzylpenicillin"},{"category":"Human","referral_name":"Pseudoephedrine-containing medicinal products","international_non_proprietary_name_inn_common_name":"pseudoephedrine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Aerinaze","associated_names_non_centrally_authorised_medicines":"","class":"Nasal decongestants for systemic use","reference_number":"EMEA/H/A-31/1526","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"","procedure_start_date":"09/02/2023","prac_recommendation_date":"30/11/2023","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/01/2024","european_commission_decision_date":"27/03/2024","first_published_date":"10/02/2023","last_updated_date":"04/04/2024","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pseudoephedrine-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing N-methyl pyrrolidone as an excipient","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"Vectra 3D;Melovem","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/146","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/12/2022","european_commission_decision_date":"28/03/2023","first_published_date":"18/05/2022","last_updated_date":"22/03/2024","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-n-methyl-pyrrolidone-excipient"},{"category":"Human","referral_name":"Topiramate","international_non_proprietary_name_inn_common_name":"topiramate","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1520","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"01/09/2022","prac_recommendation_date":"31/08/2023","cmdh_position_date":"10/11/2023","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"02/09/2022","last_updated_date":"23/11/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/topiramate"},{"category":"Human","referral_name":"Adakveo","international_non_proprietary_name_inn_common_name":"crizanlizumab","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Adakveo","associated_names_non_centrally_authorised_medicines":"","class":"Other haematological agents","reference_number":"EMEA/H/A-20/1525/C/4874/0013","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"26/01/2023","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/05/2023","european_commission_decision_date":"03/08/2023","first_published_date":"27/01/2023","last_updated_date":"29/08/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/adakveo"},{"category":"Human","referral_name":"Quinolone- and fluoroquinolone-containing medicinal products","international_non_proprietary_name_inn_common_name":"nalidixic acid;pipemidic acid;cinoxacin;enoxacin;pefloxacin;lomefloxacin;ciprofloxacin;levofloxacin;ofloxacin;moxifloxacin;norfloxacin;prulifloxacin;rufloxacin;flumequin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Quinsair","associated_names_non_centrally_authorised_medicines":"","class":"Quinolones and fluoroquinolones","reference_number":"EMEA/H/A-31/1452","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"09/02/2017","prac_recommendation_date":"04/10/2018","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/11/2018","european_commission_decision_date":"11/03/2019","first_published_date":"10/02/2017","last_updated_date":"08/06/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products"},{"category":"Human","referral_name":"Janus kinase inhibitors (JAKi)","international_non_proprietary_name_inn_common_name":"tofacitinib;abrocitinib;baricitinib;upadacitinib;filgotinib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Xeljanz;Cibinqo;Olumiant;Rinvoq;Jyseleca;Xeljanz","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"10/02/2022","prac_recommendation_date":"12/01/2023","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/01/2023","european_commission_decision_date":"10/03/2023","first_published_date":"11/02/2022","last_updated_date":"22/05/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki"},{"category":"Veterinary","referral_name":"Catophos 100 mg/ml+0.05 mg/ml solution for injection for horses, cattle, dogs and cats and associated names","international_non_proprietary_name_inn_common_name":"butafosfan;cyanocobalamin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/147","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/02/2023","european_commission_decision_date":"03/04/2023","first_published_date":"25/04/2023","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/catophos-100-mg-ml005-mg-ml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names"},{"category":"Veterinary","referral_name":"Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats and associated names","international_non_proprietary_name_inn_common_name":"butafosfan;cyanocobalamin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/148","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/02/2023","european_commission_decision_date":"03/04/2023","first_published_date":"25/04/2023","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/vey-tosal-100-mg-ml-005-mg-ml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names"},{"category":"Human","referral_name":"Pholcodine-containing medicinal products","international_non_proprietary_name_inn_common_name":"pholcodine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Cough and cold preparations","reference_number":"EMEA/H/A-107i/1521","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Revocation","procedure_start_date":"01/09/2022","prac_recommendation_date":"01/12/2022","cmdh_position_date":"14/12/2022","chmp_cvmp_opinion_date":"","european_commission_decision_date":"06/03/2023","first_published_date":"02/09/2022","last_updated_date":"29/03/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pholcodine-containing-medicinal-products"},{"category":"Human","referral_name":"Gelisia and associated names","international_non_proprietary_name_inn_common_name":"timolol maleate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Genoptol  ;Gelisia  ;Timolol sifi 1 mg/g gel oftalmico","class":"","reference_number":"EMEA/H/A-29(4)/1522","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2022","european_commission_decision_date":"27/02/2023","first_published_date":"16/12/2022","last_updated_date":"16/03/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gelisia-and-associated-names"},{"category":"Human","referral_name":"Rambis and associated names","international_non_proprietary_name_inn_common_name":"ramipril;bisoprolol fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Ralbior","class":"","reference_number":"EMEA/H/A-29(4)/1519","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2022","european_commission_decision_date":"15/02/2023","first_published_date":"16/12/2022","last_updated_date":"08/03/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/rambis-and-associated-names"},{"category":"Human","referral_name":"Amfepramone-containing medicinal products","international_non_proprietary_name_inn_common_name":"amfepramone","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Regenon  ;Tenuate Retard  ;Amfepramon-Hormosan  ;Regenon Retard","class":"","reference_number":"EMEA/H/A-31/1501","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Revocation","procedure_start_date":"11/02/2021","prac_recommendation_date":"27/10/2022","cmdh_position_date":"10/11/2022","chmp_cvmp_opinion_date":"","european_commission_decision_date":"13/01/2023","first_published_date":"12/02/2021","last_updated_date":"20/01/2023","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/amfepramone-containing-medicinal-products"},{"category":"Human","referral_name":"Synchron","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1515","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2022","european_commission_decision_date":"28/11/2022","first_published_date":"28/01/2022","last_updated_date":"16/12/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/synchron"},{"category":"Human","referral_name":"Nomegestrol and chlormadinone","international_non_proprietary_name_inn_common_name":"nomegestrol;chlormadinone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Zoely","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1510","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"30/09/2021","prac_recommendation_date":"07/07/2022","cmdh_position_date":"","chmp_cvmp_opinion_date":"01/09/2022","european_commission_decision_date":"28/11/2022","first_published_date":"01/10/2021","last_updated_date":"14/12/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nomegestrol-chlormadinone"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing toltrazuril to be administered orally to chickens","international_non_proprietary_name_inn_common_name":"toltrazuril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/144","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/07/2022","european_commission_decision_date":"09/11/2022","first_published_date":"14/12/2022","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens"},{"category":"Human","referral_name":"Terlipressin-containing medicinal products indicated in the treatment of hepatorenal syndrome","international_non_proprietary_name_inn_common_name":"terlipressin","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"vasopressin and analogues","reference_number":"EMEA/H/A-31/1514","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"13/01/2022","prac_recommendation_date":"29/09/2022","cmdh_position_date":"10/11/2022","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"21/02/2022","last_updated_date":"22/11/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/terlipressin-containing-medicinal-products-indicated-treatment-hepatorenal-syndrome"},{"category":"Human","referral_name":"Rubraca","international_non_proprietary_name_inn_common_name":"rucaparib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Rubraca","associated_names_non_centrally_authorised_medicines":"","class":"Other antineoplastic agents","reference_number":"EMEA/H/A-20/1518/C/4272/0033","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"22/04/2022","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/07/2022","european_commission_decision_date":"21/09/2022","first_published_date":"22/04/2022","last_updated_date":"17/10/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/rubraca"},{"category":"Human","referral_name":"Daruph and Anafezyn","international_non_proprietary_name_inn_common_name":"dasatinib (anhydrous)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1516","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2022","european_commission_decision_date":"18/07/2022","first_published_date":"20/05/2022","last_updated_date":"09/08/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/daruph-and-anafezyn"},{"category":"Human","referral_name":"Zynteglo","international_non_proprietary_name_inn_common_name":"betibeglogene autotemcel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Zynteglo","associated_names_non_centrally_authorised_medicines":"","class":"Haematological agents","reference_number":"EMEA/H/A-20/1504/C/003691/0023","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CAT-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"11/03/2021","prac_recommendation_date":"09/07/2021","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/07/2021","european_commission_decision_date":"16/09/2021","first_published_date":"12/03/2021","last_updated_date":"08/07/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zynteglo"},{"category":"Human","referral_name":"Nasolam and associated names","international_non_proprietary_name_inn_common_name":"midazolam","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Hypnotics and sedatives (benzodiazepine derivatives)","reference_number":"EMEA/H/A-29(4)/1511","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/01/2022","european_commission_decision_date":"01/04/2022","first_published_date":"28/01/2022","last_updated_date":"29/04/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nasolam-and-associated-names"},{"category":"Human","referral_name":"Lidocain/Prilocain Idetec and associated names","international_non_proprietary_name_inn_common_name":"lidocaine;prilocaine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Lidocaïne / Prilocaïne 5% Focus, Crème","class":"","reference_number":"EMEA/H/A-29(4)/1506","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/10/2021","european_commission_decision_date":"","first_published_date":"15/10/2021","last_updated_date":"21/04/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lidocain-prilocain-idetec-associated-names"},{"category":"Human","referral_name":"Etifoxine-containing medicinal products","international_non_proprietary_name_inn_common_name":"etifoxine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Stresam","class":"Non-benzodiazepine anxiolytic","reference_number":"EMEA/H/A-31/1509","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/06/2021","european_commission_decision_date":"24/03/2022","first_published_date":"25/06/2021","last_updated_date":"21/04/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/etifoxine-containing-medicinal-products"},{"category":"Human","referral_name":"Hydroxyethyl starch (HES) containing medicinal products","international_non_proprietary_name_inn_common_name":"hydroxyethyl starch","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-107i/1457","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"26/10/2017","prac_recommendation_date":"12/01/2018","cmdh_position_date":"26/10/2017","chmp_cvmp_opinion_date":"","european_commission_decision_date":"17/07/2018","first_published_date":"27/10/2017","last_updated_date":"11/02/2022","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyethyl-starch-hes-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Injectable veterinary medicinal products containing vitamin A for use in food producing species","international_non_proprietary_name_inn_common_name":"vitamin A (retinol and its esters)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/141","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/05/2021","european_commission_decision_date":"18/08/2021","first_published_date":"27/09/2021","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species"},{"category":"Veterinary","referral_name":"Ronaxan and its associated names","international_non_proprietary_name_inn_common_name":"doxycycline","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/135","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/06/2021","european_commission_decision_date":"30/08/2021","first_published_date":"27/09/2021","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/ronaxan-and-its-associated-names"},{"category":"Human","referral_name":"Intravenous iron-containing medicinal products","international_non_proprietary_name_inn_common_name":"ferric carboxymaltose;iron dextran;sodium ferric gluconate;iron isomaltoside;iron sucrose","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1322","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2013","european_commission_decision_date":"13/09/2013","first_published_date":"28/06/2013","last_updated_date":"28/07/2021","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Modified live porcine respiratory and reproductive syndrome (PRRS) virus vaccines","international_non_proprietary_name_inn_common_name":"porcine respiratory and reproductive syndrome virus vaccine (live)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA-V-A-142","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/04/2021","european_commission_decision_date":"13/07/2021","first_published_date":"28/07/2021","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines"},{"category":"Human","referral_name":"Ifosfamide solutions","international_non_proprietary_name_inn_common_name":"ifosfamide","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Ifosfamide Eg  ;Ifo-Cell  ;Ifo-Cell N  ;Ifo-Cell N 2000","class":"alkylating agent","reference_number":"EMEA/H/A-31/1495","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"12/03/2020","prac_recommendation_date":"11/03/2021","cmdh_position_date":"21/04/2021","chmp_cvmp_opinion_date":"","european_commission_decision_date":"21/06/2021","first_published_date":"12/03/2020","last_updated_date":"19/07/2021","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ifosfamide-solutions"},{"category":"Human","referral_name":"Varilrix","international_non_proprietary_name_inn_common_name":"live attenuated varicella virus (OKA strain)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1499","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/02/2021","european_commission_decision_date":"21/04/2021","first_published_date":"26/06/2020","last_updated_date":"09/06/2021","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/varilrix"},{"category":"Veterinary","referral_name":"Adjusol trimethoprim sulfa liquide and its associated names","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/134","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/12/2020","european_commission_decision_date":"25/02/2021","first_published_date":"19/03/2021","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/adjusol-trimethoprim-sulfa-liquide-and-its-associated-names"},{"category":"Human","referral_name":"Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group","international_non_proprietary_name_inn_common_name":"valsartan;candesartan;irbesartan;losartan;olmesartan","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Karvezide;Karvea;Irbesartan/Hydrochlorothiazide Teva;Irbesartan Zentiva (previously Irbesartan Winthrop);Irbesartan Teva;Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop);Ifirmasta (previously Irbesartan Krka);Ifirmacombi;Aprovel;Neparvis;Exforge;Exforge HCT;Entresto;Dafiro HCT;Dafiro;Copalia HCT;Copalia;Amlodipine  / Valsartan Mylan;CoAprovel","associated_names_non_centrally_authorised_medicines":"","class":"angiotensin-II-receptor antagonist","reference_number":"EMEA/H/A-31/1471","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/11/2020","european_commission_decision_date":"19/02/2021","first_published_date":"17/07/2018","last_updated_date":"19/03/2021","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group"},{"category":"Veterinary","referral_name":"Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products","international_non_proprietary_name_inn_common_name":"albendazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA-V-A-140","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"05/11/2020","european_commission_decision_date":"18/01/2021","first_published_date":"22/02/2021","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/valbazen-100-mg-ml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generic-hybrid-products"},{"category":"Human","referral_name":"Ranitidine-containing medicinal products","international_non_proprietary_name_inn_common_name":"ranitidine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1491","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/09/2020","european_commission_decision_date":"24/11/2020","first_published_date":"26/06/2020","last_updated_date":"17/02/2021","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Tiamulin hydrogen fumarate presented as premix for medicated feeding stuff and oral powder for in-feed use to be administered to pigs","international_non_proprietary_name_inn_common_name":"tiamulin hydrogen fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/137","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/09/2020","european_commission_decision_date":"09/12/2020","first_published_date":"05/02/2021","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-oral-powder-feed-use-be-administered-pigs"},{"category":"Human","referral_name":"Ulipristal acetate 5mg medicinal products","international_non_proprietary_name_inn_common_name":"ulipristal acetate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Esmya;Ulipristal Acetate Gedeon Richter","associated_names_non_centrally_authorised_medicines":"","class":"Progesterone receptor modulators","reference_number":"EMEA/H/A-31/1496","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"","procedure_start_date":"12/03/2020","prac_recommendation_date":"04/09/2020","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/11/2020","european_commission_decision_date":"11/01/2021","first_published_date":"13/03/2020","last_updated_date":"03/02/2021","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products"},{"category":"Human","referral_name":"Picato","international_non_proprietary_name_inn_common_name":"ingenol mebutate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Picato","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1489/C/002275/0030","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"05/09/2019","prac_recommendation_date":"17/04/2020","cmdh_position_date":"","chmp_cvmp_opinion_date":"30/04/2020","european_commission_decision_date":"06/07/2020","first_published_date":"06/09/2019","last_updated_date":"16/11/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/picato"},{"category":"Veterinary","referral_name":"Betamox LA 150 mg/ml suspension for injection and associated names, and generics products thereof","international_non_proprietary_name_inn_common_name":"amoxicillin trihydrate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Stresnil","class":"","reference_number":"EMEA/V/A/132","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2020","european_commission_decision_date":"12/10/2020","first_published_date":"12/11/2020","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/betamox-la-150-mg-ml-suspension-injection-and-associated-names-and-generics-products-thereof"},{"category":"Veterinary","referral_name":"Stresnil 40 mg/ml solution for injection for pigs and associated names, and generic products thereof","international_non_proprietary_name_inn_common_name":"azaperone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Stresnil","class":"","reference_number":"EMEA/V/A/138","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2020","european_commission_decision_date":"12/10/2020","first_published_date":"30/10/2020","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/stresnil-40-mg-ml-solution-injection-pigs-associated-names-generic-products-thereof"},{"category":"Human","referral_name":"Ibuprofen Kabi 400 mg Infusionslösung and associated names","international_non_proprietary_name_inn_common_name":"ibuprofen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Ibuprofen Fresenius Kabi 400 mg oplossing voor infusie  ;Ibuprofen Fresenius Kabi 400 mg solution pour perfusion  ;Ibuprofen Kabi  ;Ibuprofen Kabi 400 mg oldatos infúzió  ;Ibuprofen Kabi 400 mg soluţie perfuzabilă  ;Ibuprofen Kabi 400 mg  ;Ibuprofen Kabi 400 mg raztopina za infundiranje  ;Ibuprofeno Kabi 400 mg solución para perfusion  ;Ibuprofen Kabi 400 mg Solution for Infusion","class":"","reference_number":"EMEA/H/A-29(4)/1498","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/07/2020","european_commission_decision_date":"15/10/2020","first_published_date":"24/07/2020","last_updated_date":"26/10/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ibuprofen-kabi-400-mg-infusionslosung-and-associated-names"},{"category":"Human","referral_name":"Panexcell","international_non_proprietary_name_inn_common_name":"atazanavir;atazanavir sulfate;amoxicillin trihydrate;iron sucrose;amoxicillin;azithromycin dihydrate;carbocisteine;trimethoprim","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1494","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/02/2020","european_commission_decision_date":"24/09/2020","first_published_date":"28/02/2020","last_updated_date":"22/10/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/panexcell"},{"category":"Human","referral_name":"Yondelis","international_non_proprietary_name_inn_common_name":"trabectedin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Yondelis","associated_names_non_centrally_authorised_medicines":"","class":"Antineoplastic agents","reference_number":"EMEA/H/A-20/1493/C/0773/0060","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2020","european_commission_decision_date":"24/09/2020","first_published_date":"28/02/2020","last_updated_date":"09/10/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/yondelis"},{"category":"Veterinary","referral_name":"Dinolytic 12.5 mg/ml and 5 mg/ml solutions for injection and associated names, and generic products thereof","international_non_proprietary_name_inn_common_name":"dinoprost","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA-V-A-136","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/06/2020","european_commission_decision_date":"16/09/2020","first_published_date":"06/10/2020","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/dinolytic-125-mg-ml-5-mg-ml-solutions-injection-associated-names-generic-products-thereof"},{"category":"Human","referral_name":"Budesonide SUN","international_non_proprietary_name_inn_common_name":"budesonide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1492","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/06/2020","european_commission_decision_date":"19/08/2020","first_published_date":"27/03/2020","last_updated_date":"16/09/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/budesonide-sun"},{"category":"Human","referral_name":"Leuprorelin-containing depot medicinal products","international_non_proprietary_name_inn_common_name":"leuprorelin","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Daronda  ;Depo-Eligard  ;Eligard  ;Eligard Depot  ;Eligard Mensua  ;Eligard Semestral  ;Eligard Trimestral  ;Elityran 1 Month Depot (Dps)  ;Elityran 3 Month Depot (Dps)  ;Enanton Depot Dual  ;Enanton Depot Set  ;Enantone  ;Enantone L.P  ;Enantone Lp  ;Enantone Monats-Depot  ;Ginecrin Depot  ;Klebrocid 3-Monats-Depot  ;Klebrocid Depot Zweikammerspritze  ;Leptoprol  ;Lerin  ;Leugon  ;Leuprex 3  ;Leuprol  ;Leuprolin Ratiopharm  ;Leuprone 1-Monatsdepot  ;Leuprone 3-Monatsdepot  ;Leuprorelin 1-Month Depot Gp-Pharm  ;Leuprorelin Hexal  ;Leuprorelin Sandoz  ;Leuprorelina Gp-Pharm  ;Leupro-Sandoz 1-Monats-Depot  ;Leupro-Sandoz 3-Monats-Depot  ;Leuprorelina Trimestral Sandoz  ;Leuprostin  ;Leuproreline Sandoz  ;Lucrin  ;Lucrin Depot  ;Lucrin Pds Depot  ;Lucrin Pds Depot 1 Maand  ;Lucrin Pds Depot 3 Maanden  ;Lucrin Pds Depot 6 Maanden  ;Lupron Depo  ;Lutrate 1 Month Depot  ;Lutrate 3 Month Depot  ;Lutrate Depo  ;Lutrate Depot  ;Lutrate Depot Trimestral  ;Politrate  ;Politrate Depot  ;Procren Depot  ;Procren Depot Pds  ;Procrin Mensual  ;Procrin Semestral  ;Procrin Trimestral  ;Prostap 3 Dcs  ;Prostap 6 Dcs  ;Prostap Sr Dcs  ;Prostaplant  ;Sixantone  ;Trenantone  ;Trenantone-Gyn  ;Zeulide  ;Елигард  ;Лутрат Депо","class":"","reference_number":"EMEA/H/A-31/1486","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"14/05/2020","cmdh_position_date":"25/06/2020","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"14/06/2019","last_updated_date":"31/07/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/leuprorelin-containing-depot-medicinal-products"},{"category":"Human","referral_name":"Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products","international_non_proprietary_name_inn_common_name":"capecitabine;fluorouracil;tegafur;flucytosine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Xeloda;Teysuno;Capecitabine Accord;Capecitabine Medac;Capecitabine Teva;Ecansya (previously Capecitabine Krka)","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1481","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Variation","procedure_start_date":"15/03/2019","prac_recommendation_date":"12/03/2020","cmdh_position_date":"","chmp_cvmp_opinion_date":"30/04/2020","european_commission_decision_date":"07/07/2020","first_published_date":"15/03/2019","last_updated_date":"23/07/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products"},{"category":"Human","referral_name":"Carbamazepin Tillomed","international_non_proprietary_name_inn_common_name":"carbamazepin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Carbamazepin Tillomed  ;Carbamazepina Tillomed  ;Karbamazepin Tillomed  ;Karbamazepina Tillomed","class":"","reference_number":"EMEA/H/A-29(4)/1497","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"30/04/2020","european_commission_decision_date":"25/06/2020","first_published_date":"30/04/2020","last_updated_date":"21/07/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/carbamazepin-tillomed"},{"category":"Human","referral_name":"Fosfomycin-containing medicinal products","international_non_proprietary_name_inn_common_name":"fosfomycin calcium;fosfomycin disodium;fosfomycin sodium;fosfomycin trometamol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Afastural  ;Berny Adulti  ;Danifos Adulti  ;Fomicyt  ;Fosfocin  ;Fosfocina  ;Fosfocine  ;Fosfopharm  ;Fosfuro  ;Fosmol  ;Fostrofemge  ;Gynofostrome  ;Infectofos  ;Infeur Adulti  ;Interfos  ;Monural  ;Monuril  ;Monurol  ;Rapidnorm  ;Solufos  ;Symural  ;Uridoz  ;Urifos  ;Urinex  ;Urofast  ;Uromaste  ;Uroseptic","class":"Antibiotics","reference_number":"EMEA/H/A-31/1476","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/03/2020","european_commission_decision_date":"09/06/2020","first_published_date":"14/12/2018","last_updated_date":"06/07/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fosfomycin-containing-medicinal-products"},{"category":"Human","referral_name":"Methocarbamol / paracetamol-containing medicinal products","international_non_proprietary_name_inn_common_name":"methocarbamol;paracetamol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Robaxisal compuesto","class":"Analgesic","reference_number":"EMEA/H/A-31/1484","non_prac_decision_making_model":"CHMP-EC","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/03/2020","european_commission_decision_date":"09/06/2020","first_published_date":"29/05/2019","last_updated_date":"17/06/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methocarbamol-paracetamol-containing-medicinal-products"},{"category":"Human","referral_name":"Cyproterone-containing medicinal products","international_non_proprietary_name_inn_common_name":"cyproterone","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"antiandrogens","reference_number":"EMEA/H/A-31/1488","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"11/07/2019","prac_recommendation_date":"13/02/2020","cmdh_position_date":"25/03/2020","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"12/07/2019","last_updated_date":"20/05/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing tylosin base (as a single active substance) presented as solutions for injection for intramuscular use in pigs","international_non_proprietary_name_inn_common_name":"tylosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/V/A/131","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"05/12/2019","european_commission_decision_date":"17/04/2020","first_published_date":"13/05/2020","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-tylosin-base-single-active-substance-presented-solutions-injection-intramuscular-use-pigs"},{"category":"Veterinary","referral_name":"Ketabel 100 mg/ml solution for injection and associated names","international_non_proprietary_name_inn_common_name":"ketamine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/133","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"05/12/2019","european_commission_decision_date":"04/03/2020","first_published_date":"16/04/2020","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/ketabel-100-mg-ml-solution-injection-and-associated-names"},{"category":"Human","referral_name":"Estradiol-containing (0.01% w/w) medicinal products for topical use","international_non_proprietary_name_inn_common_name":"estradiol","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Linoladiol  ;Linoladiol N  ;Linoladiol Estradiol  ;Estradiol Wolff  ;Montadiol","class":"Hormonal","reference_number":"EMEA/H/A-31/1482","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"11/04/2019","prac_recommendation_date":"16/01/2020","cmdh_position_date":"30/01/2020","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"12/07/2019","last_updated_date":"08/04/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/estradiol-containing-001-w-w-medicinal-products-topical-use"},{"category":"Human","referral_name":"Xeljanz","international_non_proprietary_name_inn_common_name":"tofacitinib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Xeljanz","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1485","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"16/05/2019","prac_recommendation_date":"31/10/2019","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/11/2019","european_commission_decision_date":"31/01/2020","first_published_date":"17/05/2019","last_updated_date":"06/03/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz"},{"category":"Human","referral_name":"Lemtrada","international_non_proprietary_name_inn_common_name":"alemtuzumab","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Lemtrada","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1483/C/3718/0028","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"11/04/2019","prac_recommendation_date":"31/10/2019","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/11/2019","european_commission_decision_date":"16/01/2020","first_published_date":"12/04/2019","last_updated_date":"04/02/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada"},{"category":"Human","referral_name":"Flurbiprofen Geiser","international_non_proprietary_name_inn_common_name":"flurbiprofen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Flurbiprofen Sejmet  ;Mentocaína Spray  ;Flurbiprofeno Geiser","class":"","reference_number":"EMEA/H/A-29(4)/1487","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/10/2019","european_commission_decision_date":"16/12/2019","first_published_date":"18/10/2019","last_updated_date":"20/01/2020","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/flurbiprofen-geiser"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing paromomycin to be administered parenterally to pigs","international_non_proprietary_name_inn_common_name":"paromycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/129","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/07/2019","european_commission_decision_date":"11/10/2019","first_published_date":"20/11/2019","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-paromomycin-be-administered-parenterally-pigs"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing tylosin presented as solution for injection to be administered to sheep","international_non_proprietary_name_inn_common_name":"tylosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/130","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/06/2019","european_commission_decision_date":"20/09/2019","first_published_date":"19/11/2019","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-tylosin-presented-solution-injection-be-administered-sheep"},{"category":"Human","referral_name":"Methotrexate containing medicinal products","international_non_proprietary_name_inn_common_name":"methotrexate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Nordimet;Jylamvo","associated_names_non_centrally_authorised_medicines":"Jylamvo  ;Nordimet  ;Ledertrexate  ;Maxtrex  ;Metex  ;Metoject","class":"","reference_number":"EMEA/H/A-31/1463","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"12/04/2018","prac_recommendation_date":"11/07/2019","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/08/2019","european_commission_decision_date":"21/10/2019","first_published_date":"13/04/2018","last_updated_date":"31/10/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methotrexate-containing-medicinal-products"},{"category":"Human","referral_name":"Bacterial lysates-containing medicinal products indicated for respiratory conditions","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1465","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2019","european_commission_decision_date":"09/09/2019","first_published_date":"29/06/2018","last_updated_date":"16/09/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions"},{"category":"Human","referral_name":"Lartruvo","international_non_proprietary_name_inn_common_name":"olaratumab","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Lartruvo","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1479/C/4216/015","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"31/01/2019","european_commission_decision_date":"19/07/2019","first_published_date":"01/02/2019","last_updated_date":"22/08/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lartruvo"},{"category":"Human","referral_name":"Basiron AC and associated names","international_non_proprietary_name_inn_common_name":"benzoyl peroxide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/H/A-13/1475","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/03/2019","european_commission_decision_date":"04/07/2019","first_published_date":"29/03/2019","last_updated_date":"19/07/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/basiron-ac-associated-names"},{"category":"Veterinary","referral_name":"Closantel","international_non_proprietary_name_inn_common_name":"closantel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/126","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/02/2019","european_commission_decision_date":"20/05/2019","first_published_date":"27/06/2019","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/closantel"},{"category":"Human","referral_name":"Fenspiride containing medicinal products","international_non_proprietary_name_inn_common_name":"fenspiride","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Drugs for obstructive airway diseases","reference_number":"EMEA/H/A-107i/1480","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"14/02/2019","prac_recommendation_date":"17/05/2019","cmdh_position_date":"29/05/2019","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"15/02/2019","last_updated_date":"26/06/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fenspiride-containing-medicinal-products"},{"category":"Human","referral_name":"Septanest and associated names","international_non_proprietary_name_inn_common_name":"articaine (hydrochloride);adrenaline (tartrate)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"local anaesthetic","reference_number":"EMEA/H/A-30/1461","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/06/2018","european_commission_decision_date":"28/03/2019","first_published_date":"29/06/2018","last_updated_date":"19/06/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/septanest-associated-names"},{"category":"Human","referral_name":"Omega-3 acid ethyl esters - containing medicinal products for oral in use in secondary prevention after myocardial infarction","international_non_proprietary_name_inn_common_name":"omega-3 fatty acid ethyl esters","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1464","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2018","european_commission_decision_date":"06/06/2019","first_published_date":"23/03/2018","last_updated_date":"13/06/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/omega-3-acid-ethyl-esters-containing-medicinal-products-oral-use-secondary-prevention-after-myocardial-infarction"},{"category":"Human","referral_name":"Syner-Kinase and associated names","international_non_proprietary_name_inn_common_name":"urokinase","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA-H-A-29(4)-1472","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/02/2019","european_commission_decision_date":"16/05/2019","first_published_date":"01/03/2019","last_updated_date":"03/06/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/syner-kinase-associated-names"},{"category":"Human","referral_name":"Metamizole containing medicinal products","international_non_proprietary_name_inn_common_name":"metamizole","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1469","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2018","european_commission_decision_date":"20/03/2019","first_published_date":"01/06/2018","last_updated_date":"28/03/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Fortekor","international_non_proprietary_name_inn_common_name":"benazepril hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/055","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/11/2011","european_commission_decision_date":"06/02/2012","first_published_date":"24/02/2012","last_updated_date":"11/03/2019","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/fortekor"},{"category":"Human","referral_name":"Diotop capsules","international_non_proprietary_name_inn_common_name":"diclofenac;omeprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1474","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/11/2018","european_commission_decision_date":"31/01/2019","first_published_date":"16/11/2018","last_updated_date":"15/02/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diotop-capsules"},{"category":"Human","referral_name":"Diclofenac Sodium Spray Gel 4%","international_non_proprietary_name_inn_common_name":"diclofenac sodium","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1467","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/11/2018","european_commission_decision_date":"18/01/2019","first_published_date":"29/01/2019","last_updated_date":"14/02/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-sodium-spray-gel-4"},{"category":"Human","referral_name":"Perlinring and associated names","international_non_proprietary_name_inn_common_name":"etonogestrel;ethinylestradiol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1473","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/10/2018","european_commission_decision_date":"18/12/2018","first_published_date":"19/10/2018","last_updated_date":"21/01/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/perlinring-and-associated-names"},{"category":"Human","referral_name":"Paclitaxel Hetero and associated names","international_non_proprietary_name_inn_common_name":"paclitaxel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29(4)/1466","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/10/2018","european_commission_decision_date":"11/01/2019","first_published_date":"19/10/2018","last_updated_date":"21/01/2019","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/paclitaxel-hetero-associated-names"},{"category":"Human","referral_name":"Xofigo","international_non_proprietary_name_inn_common_name":"radium Ra223 dichloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Xofigo","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1459/C/002653/0028","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"30/11/2017","prac_recommendation_date":"12/07/2018","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/07/2018","european_commission_decision_date":"28/09/2018","first_published_date":"01/12/2017","last_updated_date":"11/10/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/xofigo"},{"category":"Human","referral_name":"Esmya","international_non_proprietary_name_inn_common_name":"ulipristal acetate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Esmya","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1460/C/2041/0043","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"30/11/2017","prac_recommendation_date":"17/05/2018","cmdh_position_date":"","chmp_cvmp_opinion_date":"31/05/2018","european_commission_decision_date":"26/07/2018","first_published_date":"01/12/2017","last_updated_date":"08/08/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/esmya"},{"category":"Human","referral_name":"Scandonest and associated names","international_non_proprietary_name_inn_common_name":"mepivacaine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Biocaine  ;Scandicaine","class":"Anaesthetic","reference_number":"EMEA/H/A-30/1455","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"31/05/2018","european_commission_decision_date":"02/08/2018","first_published_date":"15/09/2017","last_updated_date":"07/08/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/scandonest-associated-names"},{"category":"Human","referral_name":"Zinbryta","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Zinbryta","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1462/C/003862/0018","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"02/03/2018","prac_recommendation_date":"17/05/2018","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"27/03/2018","first_published_date":"02/03/2018","last_updated_date":"11/07/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta"},{"category":"Veterinary","referral_name":"Seresto and its associated name Foresto","international_non_proprietary_name_inn_common_name":"imidacloprid;flumethrin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/125","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/02/2018","european_commission_decision_date":"25/05/2018","first_published_date":"10/07/2018","last_updated_date":"10/07/2018","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/seresto-its-associated-name-foresto"},{"category":"Human","referral_name":"Maci","international_non_proprietary_name_inn_common_name":"matrix applied characterised autologous cultured chondrocytes","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Maci","associated_names_non_centrally_authorised_medicines":"","class":"Advanced therapies","reference_number":"EMEA/H/A20/1409/C/002522/0004","non_prac_decision_making_model":"CAT-CHMP-EC","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/09/2014","european_commission_decision_date":"19/11/2014","first_published_date":"26/09/2014","last_updated_date":"05/07/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/maci"},{"category":"Human","referral_name":"Retinoid-containing medicinal products","international_non_proprietary_name_inn_common_name":"acitretin;adapalene;alitretinoin;bexarotene;isotretinoin;tretinoin;tazarotene","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Targretin;Panretin","associated_names_non_centrally_authorised_medicines":"","class":"dermatological agents","reference_number":"EMEA/H/A-31/1446","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"07/07/2016","prac_recommendation_date":"08/02/2018","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/03/2018","european_commission_decision_date":"21/06/2018","first_published_date":"08/07/2016","last_updated_date":"02/07/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/retinoid-containing-medicinal-products"},{"category":"Veterinary","referral_name":"Girolan and its associated name Apralan","international_non_proprietary_name_inn_common_name":"apramycin sulfate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA-V-A-122","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"15/06/2018","last_updated_date":"15/06/2018","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/girolan-its-associated-name-apralan"},{"category":"Human","referral_name":"Valproate and related substances","international_non_proprietary_name_inn_common_name":"sodium valproate;valproate magnesium;valproate semisodium;valproic acid;valpromide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Absenor  ;Convival Chrono  ;Convulex  ;Delepsine  ;Depakin  ;Depakine  ;Depakote  ;Depamag  ;Depamide  ;Deprakine  ;Diplexil  ;Dipromal  ;Epilim  ;Episenta  ;Epival  ;Ergenyl  ;Espa-Valept  ;Hexaquin  ;Kentlim  ;Leptilan  ;Micropakine L.P.  ;Orfiril  ;Petilin  ;Valepil  ;Valhel PR  ;Valpal  ;Valpro and Valprolek","class":"","reference_number":"EMEA/H/A-31/1454","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"09/03/2017","prac_recommendation_date":"08/02/2018","cmdh_position_date":"21/03/2018","chmp_cvmp_opinion_date":"","european_commission_decision_date":"31/05/2018","first_published_date":"10/03/2017","last_updated_date":"07/06/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances-0"},{"category":"Human","referral_name":"Flupirtine-containing medicinal products","international_non_proprietary_name_inn_common_name":"flupirtine","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Analgesics","reference_number":"EMEA/H/A-31/1458","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Revocation","procedure_start_date":"26/10/2017","prac_recommendation_date":"08/02/2018","cmdh_position_date":"21/03/2018","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"27/10/2017","last_updated_date":"04/05/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/flupirtine-containing-medicinal-products"},{"category":"Human","referral_name":"Paracetamol modified-release","international_non_proprietary_name_inn_common_name":"paracetamol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Alvedon","class":"analgesics/antipyretics","reference_number":"EMEA/H/A-31/1445","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"07/07/2016","prac_recommendation_date":"01/09/2017","cmdh_position_date":"13/12/2017","chmp_cvmp_opinion_date":"","european_commission_decision_date":"19/02/2018","first_published_date":"08/07/2016","last_updated_date":"01/03/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/paracetamol-modified-release"},{"category":"Human","referral_name":"Hydroxyethyl starch solutions for infusion","international_non_proprietary_name_inn_common_name":"hydroxyethyl starch","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1348","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"29/11/2012","prac_recommendation_date":"10/10/2013","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2013","european_commission_decision_date":"19/12/2013","first_published_date":"30/11/2012","last_updated_date":"12/01/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyethyl-starch-solutions-infusion"},{"category":"Human","referral_name":"Alcover and associated names","international_non_proprietary_name_inn_common_name":"sodium oxybate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"n/a","class":"-","reference_number":"EMEA/H/A-29(4)/1451","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/01/2017","european_commission_decision_date":"18/12/2017","first_published_date":"23/06/2017","last_updated_date":"12/01/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/alcover-associated-names"},{"category":"Human","referral_name":"Zinbryta","international_non_proprietary_name_inn_common_name":"daclizumab","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Zinbryta","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-20/1456/C/003862/0010","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"09/06/2017","prac_recommendation_date":"26/10/2017","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/11/2017","european_commission_decision_date":"08/01/2018","first_published_date":"09/06/2017","last_updated_date":"12/01/2018","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta-0"},{"category":"Human","referral_name":"Factor VIII","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Iblias;Elocta;Kovaltry;Nuwiq;Obizur;NovoEight;Voncento;ReFacto AF;Kogenate Bayer;Helixate NexGen;Advate","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1448","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"07/07/2016","prac_recommendation_date":"01/09/2017","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/09/2017","european_commission_decision_date":"10/10/2017","first_published_date":"08/07/2016","last_updated_date":"05/12/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/factor-viii"},{"category":"Human","referral_name":"Gadolinium-containing contrast agents","international_non_proprietary_name_inn_common_name":"gadobenic acid;gadobutrol;gadodiamide;gadopentetic acid;gadoteric acid;gadoteridol;gadoversetamide;gadoxetic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Optimark","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1437","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Suspension","procedure_start_date":"17/03/2016","prac_recommendation_date":"06/07/2017","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/07/2017","european_commission_decision_date":"23/11/2017","first_published_date":"18/03/2016","last_updated_date":"04/12/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents"},{"category":"Human","referral_name":"Vancomycin-containing medicines","international_non_proprietary_name_inn_common_name":"vancomycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1440","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/05/2017","european_commission_decision_date":"21/09/2017","first_published_date":"01/04/2016","last_updated_date":"17/11/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vancomycin-containing-medicines"},{"category":"Veterinary","referral_name":"Lincocin and its associated names","international_non_proprietary_name_inn_common_name":"lincomycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/123","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/07/2017","european_commission_decision_date":"05/10/2017","first_published_date":"14/11/2017","last_updated_date":"14/11/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/lincocin-its-associated-names"},{"category":"Veterinary","referral_name":"Zanil and associated names, and generic products thereof","international_non_proprietary_name_inn_common_name":"oxyclozanide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/124","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/07/2017","european_commission_decision_date":"28/09/2017","first_published_date":"25/10/2017","last_updated_date":"25/10/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/zanil-associated-names-generic-products-thereof"},{"category":"Veterinary","referral_name":"Moxidectin-containing veterinary medicines used in cattle, sheep and horses","international_non_proprietary_name_inn_common_name":"moxidectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/116","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/05/2017","european_commission_decision_date":"","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/moxidectin-containing-veterinary-medicines-used-cattle-sheep-horses"},{"category":"Human","referral_name":"Symbioflor 2","international_non_proprietary_name_inn_common_name":"escherichia coli bacteria (cells and autolysate)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Symbioflor E. Coli  ;Symbioflor® 2  ;Symbioflor Escherichia","class":"Other immunostimulants, Antidiarrheal microorganisms","reference_number":"EMEA/H/A-31/1441","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"22/06/2017","first_published_date":"01/04/2016","last_updated_date":"07/09/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/symbioflor-2"},{"category":"Human","referral_name":"Medicinal products containing lactose of bovine origin for IV/IM use in acute allergic reactions","international_non_proprietary_name_inn_common_name":"methylprednisolone","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1449","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"01/12/2016","prac_recommendation_date":"06/07/2017","cmdh_position_date":"31/07/2017","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"02/12/2016","last_updated_date":"04/09/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions"},{"category":"Human","referral_name":"Paracetamol/Ibuprofen 500 mg/150 mg film-coated tablets","international_non_proprietary_name_inn_common_name":"paracetamol;ibuprofen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Paracomb","class":"","reference_number":"EMEA/H/A-29(4)/1447","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/05/2017","european_commission_decision_date":"07/08/2017","first_published_date":"19/05/2017","last_updated_date":"18/08/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/paracetamol-ibuprofen-500-mg-150-mg-film-coated-tablets"},{"category":"Veterinary","referral_name":"Zinc oxide","international_non_proprietary_name_inn_common_name":"zinc oxide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/118","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/03/2017","european_commission_decision_date":"26/06/2017","first_published_date":"14/08/2017","last_updated_date":"14/08/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/zinc-oxide"},{"category":"Veterinary","referral_name":"Denagard 45%","international_non_proprietary_name_inn_common_name":"tiamulin hydrogen fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/114","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/04/2017","european_commission_decision_date":"14/07/2017","first_published_date":"11/08/2017","last_updated_date":"11/08/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/denagard-45"},{"category":"Veterinary","referral_name":"Methylprednisolone injection for cattle","international_non_proprietary_name_inn_common_name":"methylprednisolone hydrogen succinate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/119","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/03/2017","european_commission_decision_date":"20/06/2017","first_published_date":"04/08/2017","last_updated_date":"04/08/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/methylprednisolone-injection-cattle"},{"category":"Veterinary","referral_name":"Tylosin injection for mastitis","international_non_proprietary_name_inn_common_name":"tylosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA-V-A-121","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/03/2017","european_commission_decision_date":"10/07/2017","first_published_date":"31/07/2017","last_updated_date":"31/07/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/tylosin-injection-mastitis"},{"category":"Human","referral_name":"Cardioxane","international_non_proprietary_name_inn_common_name":"dexrazoxane","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-13/1453","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2017","european_commission_decision_date":"19/07/2017","first_published_date":"19/05/2017","last_updated_date":"26/07/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cardioxane"},{"category":"Human","referral_name":"Vepesid","international_non_proprietary_name_inn_common_name":"etoposide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1425","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/04/2017","european_commission_decision_date":"26/06/2017","first_published_date":"21/04/2017","last_updated_date":"14/07/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vepesid"},{"category":"Human","referral_name":"Etopophos","international_non_proprietary_name_inn_common_name":"etoposide phosphate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1417","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/04/2017","european_commission_decision_date":"26/06/2017","first_published_date":"21/04/2017","last_updated_date":"14/07/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/etopophos"},{"category":"Human","referral_name":"Micro Therapeutic Research","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1450","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/03/2017","european_commission_decision_date":"23/06/2017","first_published_date":"16/12/2016","last_updated_date":"10/07/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/micro-therapeutic-research"},{"category":"Human","referral_name":"Saroten and associated names","international_non_proprietary_name_inn_common_name":"amitriptyline","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Saroten Retard  ;Redomex  ;Redomex Diffucaps  ;Saroten Tabs  ;Saroten retard Tabs  ;Saroten 2ml  ;Sarotex  ;Sarotex Retard  ;Sarotex Retard 25  ;Sarotex Retard 50","class":"antidepressant","reference_number":"EMEA/H/A-30/1430","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/02/2017","european_commission_decision_date":"08/05/2017","first_published_date":"24/02/2017","last_updated_date":"06/06/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/saroten-associated-names"},{"category":"Human","referral_name":"Haldol Decanoate and associated names","international_non_proprietary_name_inn_common_name":"haloperidol decanoate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Haldol Decanoat  ;Haldol Decanoas  ;Serenase Dekanoat  ;Serenase Depot  ;Haldol - Janssen Decanoat Depot  ;Haldol Decanoato  ;Haldol Depot","class":"","reference_number":"EMEA/H/A-30/1405","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/02/2017","european_commission_decision_date":"28/04/2017","first_published_date":"24/02/2017","last_updated_date":"11/05/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/haldol-decanoate-associated-names"},{"category":"Human","referral_name":"SGLT2 inhibitors (previously canagliflozin)","international_non_proprietary_name_inn_common_name":"canagliflozin;empagliflozin;dapagliflozin;metformin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Xigduo;Ebymect;Edistride;Synjardy;Forxiga;Jardiance;Vokanamet;Invokana","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1442","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"15/04/2016","prac_recommendation_date":"09/02/2017","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/02/2017","european_commission_decision_date":"04/05/2017","first_published_date":"15/04/2016","last_updated_date":"08/05/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors-previously-canagliflozin"},{"category":"Human","referral_name":"Haldol and associated names","international_non_proprietary_name_inn_common_name":"haloperidol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Aloperidin  ;Haldol-Janssen  ;Serenase","class":"","reference_number":"EMEA/H/A-30/1393","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/02/2017","european_commission_decision_date":"28/04/2017","first_published_date":"24/02/2017","last_updated_date":"05/05/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/haldol-associated-names"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing gentamicin presented as solutions for injection to be administered to cattle and pigs","international_non_proprietary_name_inn_common_name":"gentamicin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/117","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/11/2016","european_commission_decision_date":"27/02/2017","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-pigs"},{"category":"Human","referral_name":"Dienogest/ethinylestradiol-containing medicinal products indicated in acne","international_non_proprietary_name_inn_common_name":"dienogest;ethinyl estradiol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1435","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/01/2017","european_commission_decision_date":"22/03/2017","first_published_date":"26/02/2016","last_updated_date":"24/03/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/dienogest-ethinylestradiol-containing-medicinal-products-indicated-acne"},{"category":"Human","referral_name":"Lovenox and associated names","international_non_proprietary_name_inn_common_name":"enoxaparin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1429","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2016","european_commission_decision_date":"09/03/2017","first_published_date":"16/12/2016","last_updated_date":"22/03/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lovenox-associated-names"},{"category":"Human","referral_name":"Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)","international_non_proprietary_name_inn_common_name":"daclatasvir;dasabuvir;sofosbuvir;ledipasvir;simeprevir;ombitasvir;paritaprevir;ritonavir","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Sovaldi;Olysio;Viekirax;Harvoni;Exviera;Daklinza","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1438","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"17/03/2016","prac_recommendation_date":"01/12/2016","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2016","european_commission_decision_date":"23/02/2017","first_published_date":"18/03/2016","last_updated_date":"09/03/2017","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free"},{"category":"Human","referral_name":"Metformin and metformin-containing medicines","international_non_proprietary_name_inn_common_name":"metformin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Xigduo;Vipdomet;Velmetia;Synjardy;Ristfor;Komboglyze;Jentadueto;Janumet;Icandra (previously Vildagliptin / metformin hydrochloride Novartis);Glubrava;Eucreas;Efficib;Ebymect;Competact","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1432","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/10/2016","european_commission_decision_date":"12/12/2016","first_published_date":"29/01/2016","last_updated_date":"21/12/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/metformin-metformin-containing-medicines"},{"category":"Human","referral_name":"Pharmaceutics International Inc.","international_non_proprietary_name_inn_common_name":"sodium phenylbutyrate;progesterone;dutasteride;colecalciferol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Ammonaps","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1444","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/09/2016","european_commission_decision_date":"05/12/2016","first_published_date":"24/06/2016","last_updated_date":"14/12/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pharmaceutics-international-inc"},{"category":"Human","referral_name":"Clenil and associated names","international_non_proprietary_name_inn_common_name":"beclometasone dipropionate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Becloneb  ;Beclospin and Sanasthmax","class":"","reference_number":"EMEA/H/A-30/1418","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/09/2016","european_commission_decision_date":"11/11/2016","first_published_date":"16/09/2016","last_updated_date":"18/11/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/clenil-associated-names"},{"category":"Human","referral_name":"Semler","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1443","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/07/2016","european_commission_decision_date":"22/09/2016","first_published_date":"29/04/2016","last_updated_date":"17/11/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/semler"},{"category":"Human","referral_name":"Durogesic and associated names","international_non_proprietary_name_inn_common_name":"fentanyl","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1413","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/07/2016","european_commission_decision_date":"22/09/2016","first_published_date":"22/07/2016","last_updated_date":"19/10/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/durogesic-associated-names"},{"category":"Human","referral_name":"Diclofenac epolamine 50 mg tablets","international_non_proprietary_name_inn_common_name":"diclofenac","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1434","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/02/2016","european_commission_decision_date":"22/09/2016","first_published_date":"22/07/2016","last_updated_date":"10/10/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-epolamine-50-mg-tablets"},{"category":"Human","referral_name":"Alkem","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1436","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2016","european_commission_decision_date":"08/09/2016","first_published_date":"01/04/2016","last_updated_date":"07/10/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/alkem"},{"category":"Human","referral_name":"Zydelig","international_non_proprietary_name_inn_common_name":"idelalisib","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Zydelig","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1439/C/3843/0023","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"17/03/2016","prac_recommendation_date":"07/07/2016","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/07/2016","european_commission_decision_date":"15/09/2016","first_published_date":"18/03/2016","last_updated_date":"03/10/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zydelig"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and, or poultry","international_non_proprietary_name_inn_common_name":"lincomycin;spectinomycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/110","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2016","european_commission_decision_date":"22/08/2016","first_published_date":"16/09/2016","last_updated_date":"16/09/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-combination-lincomycin-spectinomycin-be-administered-orally-pigs-or-poultry"},{"category":"Veterinary","referral_name":"Altrenogest","international_non_proprietary_name_inn_common_name":"altrenogest","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/095","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2016","european_commission_decision_date":"29/07/2016","first_published_date":"08/09/2016","last_updated_date":"08/09/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/altrenogest"},{"category":"Human","referral_name":"Levonelle 1500 microgram tablets and associated names","international_non_proprietary_name_inn_common_name":"levonorgestrel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-13/1427","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/05/2016","european_commission_decision_date":"01/08/2016","first_published_date":"27/05/2016","last_updated_date":"09/08/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/levonelle-1500-microgram-tablets-associated-names"},{"category":"Veterinary","referral_name":"Colistin combinations","international_non_proprietary_name_inn_common_name":"colistin sulfate;oxytetracycline hydrochloride;trimethoprim;enrofloxacin;amoxicillin trihydrate;spiramycin adipate;ampicillin trihydrate;erythromycin estolate;scopolamine;sulfaguanidine;neomycin sulfate;sulfadimethoxine;sulfamethoxypyridazine;doxycycline hyclate;sulfadimidine sodium;chlortetracycline hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/111","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/04/2016","european_commission_decision_date":"14/07/2016","first_published_date":"05/08/2016","last_updated_date":"05/08/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/colistin-combinations"},{"category":"Veterinary","referral_name":"Benzathine benzylpenicillin intended for administration to food-producing species","international_non_proprietary_name_inn_common_name":"benzathine benzylpenicillin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/20/002","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/01/2003","european_commission_decision_date":"22/04/2003","first_published_date":"13/08/2014","last_updated_date":"26/07/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/benzathine-benzylpenicillin-intended-administration-food-producing-species"},{"category":"Veterinary","referral_name":"CattleMarker IBR Inactivated","international_non_proprietary_name_inn_common_name":"infectious bovine rhinotracheitis vaccine (inactivated)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/115","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/03/2016","european_commission_decision_date":"10/06/2016","first_published_date":"19/07/2016","last_updated_date":"19/07/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/cattlemarker-ibr-inactivated"},{"category":"Human","referral_name":"Inhaled corticosteroids containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease","international_non_proprietary_name_inn_common_name":"beclometasone;budesonide;flunisolide;fluticasone propionate;fluticasone furoate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1415","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Variation","procedure_start_date":"07/05/2015","prac_recommendation_date":"17/03/2016","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/04/2016","european_commission_decision_date":"29/06/2016","first_published_date":"08/05/2015","last_updated_date":"15/07/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive-pulmonary-disease"},{"category":"Human","referral_name":"Novantrone and associated names","international_non_proprietary_name_inn_common_name":"mitoxantrone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Elsep  ;Ralenova","class":"Antineoplastic agent","reference_number":"EMEA/H/A-30/1399","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/04/2016","european_commission_decision_date":"24/06/2016","first_published_date":"29/04/2016","last_updated_date":"05/07/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/novantrone-associated-names"},{"category":"Human","referral_name":"Cymevene","international_non_proprietary_name_inn_common_name":"ganciclovir","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Cymevan  ;Citovirax","class":"Antiviral","reference_number":"EMEA/H/A-30/1406","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/02/2016","european_commission_decision_date":"28/04/2016","first_published_date":"26/02/2016","last_updated_date":"21/06/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cymevene"},{"category":"Veterinary","referral_name":"Closamectin Pour-on Solution and associated names","international_non_proprietary_name_inn_common_name":"ivermectin;closantel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/113","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/10/2015","european_commission_decision_date":"22/03/2016","first_published_date":"31/05/2016","last_updated_date":"31/05/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/closamectin-pour-solution-associated-names"},{"category":"Human","referral_name":"Amoxil","international_non_proprietary_name_inn_common_name":"amoxicillin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-30/1372","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/06/2015","european_commission_decision_date":"20/08/2015","first_published_date":"26/06/2015","last_updated_date":"19/05/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/amoxil"},{"category":"Human","referral_name":"SGLT2 inhibitors","international_non_proprietary_name_inn_common_name":"canagliflozin;dapagliflozin;empagliflozin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Edistride;Ebymect;Xigduo;Vokanamet;Synjardy;Jardiance;Invokana;Forxiga","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1419","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"11/06/2015","prac_recommendation_date":"11/02/2016","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/02/2016","european_commission_decision_date":"28/04/2016","first_published_date":"12/06/2015","last_updated_date":"18/05/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors"},{"category":"Human","referral_name":"Tysabri","international_non_proprietary_name_inn_common_name":"natalizumab","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Tysabri","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-20/1416/C/000603/0083","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"07/05/2015","prac_recommendation_date":"11/02/2016","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/02/2016","european_commission_decision_date":"25/04/2016","first_published_date":"08/05/2015","last_updated_date":"12/05/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tysabri"},{"category":"Human","referral_name":"Tobramycin VVB and associated names","international_non_proprietary_name_inn_common_name":"tobramycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1428","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/01/2015","european_commission_decision_date":"04/04/2016","first_published_date":"29/01/2016","last_updated_date":"04/05/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tobramycin-vvb-associated-names"},{"category":"Human","referral_name":"Fusafungine containing medicinal products for oromucosal and nasal use","international_non_proprietary_name_inn_common_name":"fusafungine","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1420","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Revocation","procedure_start_date":"10/09/2015","prac_recommendation_date":"11/02/2016","cmdh_position_date":"","chmp_cvmp_opinion_date":"31/03/2016","european_commission_decision_date":"","first_published_date":"11/09/2015","last_updated_date":"14/04/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fusafungine-containing-medicinal-products-oromucosal-nasal-use"},{"category":"Human","referral_name":"Ambroxol and bromhexine-containing medicines","international_non_proprietary_name_inn_common_name":"ambroxol;bromhexine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1397","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"10/04/2014","prac_recommendation_date":"10/09/2015","cmdh_position_date":"18/11/2015","chmp_cvmp_opinion_date":"","european_commission_decision_date":"14/01/2016","first_published_date":"11/04/2014","last_updated_date":"05/02/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ambroxol-bromhexine-containing-medicines"},{"category":"Veterinary","referral_name":"Solamocta 697 mg/g powder for use in drinking water for chickens, ducks and turkeys","international_non_proprietary_name_inn_common_name":"amoxicillin trihydrate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/112","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"04/11/2015","european_commission_decision_date":"07/01/2016","first_published_date":"05/02/2016","last_updated_date":"05/02/2016","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/solamocta-697-mg-g-powder-use-drinking-water-chickens-ducks-turkeys"},{"category":"Human","referral_name":"Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard","international_non_proprietary_name_inn_common_name":"bivalent human papillomavirus vaccine (types 16, 18);quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18);9-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Silgard;Gardasil 9;Gardasil;Cervarix","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1421","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"No further action","procedure_start_date":"09/07/2015","prac_recommendation_date":"06/11/2015","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2015","european_commission_decision_date":"12/01/2016","first_published_date":"13/07/2015","last_updated_date":"20/01/2016","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard"},{"category":"Human","referral_name":"Inductos","international_non_proprietary_name_inn_common_name":"dibotermin alfa","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Inductos","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-20/1422/C/0408/0082","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/10/2015","european_commission_decision_date":"20/11/2015","first_published_date":"24/07/2015","last_updated_date":"07/12/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/inductos"},{"category":"Veterinary","referral_name":"Gutal","international_non_proprietary_name_inn_common_name":"zinc oxide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/108","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/05/2015","european_commission_decision_date":"22/10/2015","first_published_date":"26/11/2015","last_updated_date":"26/11/2015","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/gutal"},{"category":"Veterinary","referral_name":"Coglapix suspension for injection for pigs","international_non_proprietary_name_inn_common_name":"inactivated porcine actinobacillosis vaccine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/109","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"03/06/2015","european_commission_decision_date":"28/08/2015","first_published_date":"02/10/2015","last_updated_date":"02/10/2015","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/coglapix-suspension-injection-pigs"},{"category":"Human","referral_name":"Adrenaline auto-injectors","international_non_proprietary_name_inn_common_name":"adrenaline (epinephrine)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1398","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/06/2015","european_commission_decision_date":"14/08/2015","first_published_date":"25/04/2014","last_updated_date":"26/08/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/adrenaline-auto-injectors"},{"category":"Human","referral_name":"GVK Biosciences","international_non_proprietary_name_inn_common_name":"esomeprazole magnesium;candesartan cilexetil;nebivolol;desloratadine;donepezil;repaglinide;candesartan;esomeprazole;alendronic acid;ropinirole;cefpodoxime;quetiapine;trimetazidine;bosentan;tramadol;paracetamol;escitalopram;trimetazidine hydrochloride;entacapone;valsartan;hydrochlorothiazide;donepezil hydrochloride;ropinirole hydrochloride;clopidogrel hydrochloride;escitalopram oxalate;metformin hydrochloride;trimetazidine dihydrochloride;rizatriptan benzoate;metformin;fluconazole;eletriptan;rizatriptan;ebastine;ibuprofen;desmopressin;aciclovir;levetiracetam;irbesartan;venlafaxine;ciprofloxacin;cefpodoxime proxetil;tacrolimus;fexofenadine hydrochloride;phenoxymethylpenicillin;amlodipine besilate;metoclopramide;clopidogrel;levodopa;carbidopa;entacapone;atorvastatin;telmisartan;clindamycin hydrochloride;metoclopramide hydrochloride;clonazepam;clobazam;dexamethasone;thiamine hydrochloride;tramadol hydrochloride;pioglitazone;dipyridamole;fexofenadine;amlodipine;pantoprazole;hydrocortisone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1408","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/05/2015","european_commission_decision_date":"16/07/2015","first_published_date":"26/09/2014","last_updated_date":"04/08/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gvk-biosciences"},{"category":"Human","referral_name":"Myoson and associated names","international_non_proprietary_name_inn_common_name":"tolperisone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1411 EMEA/H/A-29/1412","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/04/2015","european_commission_decision_date":"","first_published_date":"28/07/2015","last_updated_date":"28/07/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/myoson-associated-names"},{"category":"Human","referral_name":"Merisone and associated names","international_non_proprietary_name_inn_common_name":"tolperisone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1411","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/04/2015","european_commission_decision_date":"25/06/2015","first_published_date":"24/04/2015","last_updated_date":"28/07/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/merisone-associated-names"},{"category":"Human","referral_name":"Ibuprofen- and dexibuprofen-containing medicines","international_non_proprietary_name_inn_common_name":"ibuprofen;dexibuprofen","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1401","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"13/06/2014","prac_recommendation_date":"10/04/2015","cmdh_position_date":"20/05/2015","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"13/06/2014","last_updated_date":"14/07/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ibuprofen-dexibuprofen-containing-medicines"},{"category":"Human","referral_name":"Ikorel and Dancor","international_non_proprietary_name_inn_common_name":"nicorandil","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"cardiovascular","reference_number":"EMEA/H/A-30/1380","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/03/2015","european_commission_decision_date":"05/06/2015","first_published_date":"27/03/2015","last_updated_date":"30/06/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ikorel-dancor"},{"category":"Human","referral_name":"Hydroxyzine","international_non_proprietary_name_inn_common_name":"hydroxyzine","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Atarax","class":"","reference_number":"EMEA/H/A-31/1400","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"08/05/2014","prac_recommendation_date":"12/02/2015","cmdh_position_date":"25/03/2015","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"08/05/2014","last_updated_date":"08/06/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyzine"},{"category":"Human","referral_name":"Codeine-containing medicinal products for the treatment of cough or cold in paediatric patients","international_non_proprietary_name_inn_common_name":"","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1394","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"10/04/2014","prac_recommendation_date":"12/03/2015","cmdh_position_date":"22/04/2015","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"11/04/2014","last_updated_date":"18/05/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/codeine-containing-medicinal-products-treatment-cough-or-cold-paediatric-patients"},{"category":"Veterinary","referral_name":"Colistin oral","international_non_proprietary_name_inn_common_name":"colistin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Polymyxins","reference_number":"EMEA/V/A/106","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/12/2014","european_commission_decision_date":"16/03/2015","first_published_date":"13/04/2015","last_updated_date":"13/04/2015","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/colistin-oral"},{"category":"Veterinary","referral_name":"Gentamicin","international_non_proprietary_name_inn_common_name":"gentamicin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Aminoglycosides","reference_number":"EMEA/V/A/104","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/11/2014","european_commission_decision_date":"11/02/2015","first_published_date":"10/04/2015","last_updated_date":"","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/gentamicin"},{"category":"Human","referral_name":"Plendil and associated names","international_non_proprietary_name_inn_common_name":"felodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1385","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2014","european_commission_decision_date":"16/12/2014","first_published_date":"24/10/2014","last_updated_date":"30/03/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/plendil-associated-names"},{"category":"Human","referral_name":"Iclusig","international_non_proprietary_name_inn_common_name":"ponatinib","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Iclusig","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/C/2695/A20/0003","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"05/12/2013","prac_recommendation_date":"09/10/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2014","european_commission_decision_date":"15/01/2015","first_published_date":"06/12/2013","last_updated_date":"02/03/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/iclusig"},{"category":"Human","referral_name":"Corlentor and Procoralan","international_non_proprietary_name_inn_common_name":"ivabradine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Corlentor and Procoralan","class":"","reference_number":"EMEA/H/A20/1404/C/000598/0031 EMEA/H/A20/1404/C/000597/0032","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"08/05/2014","prac_recommendation_date":"06/11/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/11/2014","european_commission_decision_date":"15/01/2015","first_published_date":"08/05/2014","last_updated_date":"16/02/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/corlentor-procoralan"},{"category":"Veterinary","referral_name":"Suanovil 20 / Captalin associated names and generic products thereof","international_non_proprietary_name_inn_common_name":"spiramycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/086","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/09/2014","european_commission_decision_date":"11/12/2014","first_published_date":"03/02/2015","last_updated_date":"03/02/2015","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/suanovil-20-captalin-associated-names-generic-products-thereof"},{"category":"Human","referral_name":"Nasonex","international_non_proprietary_name_inn_common_name":"mometasone furoate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1374","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/11/2014","european_commission_decision_date":"19/01/2015","first_published_date":"21/11/2014","last_updated_date":"03/02/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nasonex"},{"category":"Human","referral_name":"Seasonique and associated names","international_non_proprietary_name_inn_common_name":"levonorgestrel;ethinylestradiol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/139","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/11/2014","european_commission_decision_date":"12/01/2015","first_published_date":"27/06/2014","last_updated_date":"29/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/seasonique-associated-names"},{"category":"Human","referral_name":"Valproate and related substances","international_non_proprietary_name_inn_common_name":"sodium valproate;valproic acid;valproate semisodium;valpromide","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Absenor  ;Convival Chrono  ;Convulex  ;Convulsofin Tabletten  ;Delepsine  ;Depakine  ;Deprakine  ;Diplexil  ;Dipromal  ;Epilim  ;Episenta  ;Epival  ;Ergenyl  ;Espa-Valept  ;Hexaquin  ;Leptilan  ;Micropakine L.P.  ;Orfiril  ;Orlept  ;Petilin  ;Valberg  ;Valepil and Valhel","class":"","reference_number":"EMEA/H/A-31/1387","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"10/10/2013","prac_recommendation_date":"09/10/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2014","european_commission_decision_date":"","first_published_date":"11/10/2013","last_updated_date":"29/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances"},{"category":"Human","referral_name":"Oxynal Targin and associated names","international_non_proprietary_name_inn_common_name":"oxycodone hydrochloride;naloxone hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-13/1402","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2014","european_commission_decision_date":"22/12/2014","first_published_date":"24/10/2014","last_updated_date":"27/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/oxynal-targin-associated-names"},{"category":"Human","referral_name":"EMLA cream and associated names","international_non_proprietary_name_inn_common_name":"lidocaine;prilocaine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1388","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/09/2014","european_commission_decision_date":"28/11/2014","first_published_date":"26/09/2014","last_updated_date":"15/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/emla-cream-associated-names"},{"category":"Veterinary","referral_name":"Resflor solution injectable and associated names","international_non_proprietary_name_inn_common_name":"florfenicol;flunixin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/101","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/10/2014","european_commission_decision_date":"05/12/2014","first_published_date":"09/01/2015","last_updated_date":"09/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/resflor-solution-injectable-associated-names"},{"category":"Human","referral_name":"Testosterone-containing medicines","international_non_proprietary_name_inn_common_name":"testosterone","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1396","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"10/04/2014","prac_recommendation_date":"09/10/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2014","european_commission_decision_date":"","first_published_date":"11/04/2014","last_updated_date":"08/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/testosterone-containing-medicines"},{"category":"Human","referral_name":"Polymyxin-containing medicines","international_non_proprietary_name_inn_common_name":"colistimethate sodium","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Colobreathe","associated_names_non_centrally_authorised_medicines":"Colobreathe","class":"antibiotics","reference_number":"EMEA/H/A-31/1383","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2014","european_commission_decision_date":"16/12/2014","first_published_date":"24/10/2014","last_updated_date":"05/01/2015","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/polymyxin-containing-medicines"},{"category":"Veterinary","referral_name":"Baytril injectable and generics","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/097","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/04/2014","european_commission_decision_date":"01/09/2014","first_published_date":"10/12/2014","last_updated_date":"10/12/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/baytril-injectable-generics"},{"category":"Veterinary","referral_name":"Baytril injectable","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/091","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/04/2014","european_commission_decision_date":"01/09/2014","first_published_date":"10/12/2014","last_updated_date":"10/12/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/baytril-injectable"},{"category":"Human","referral_name":"Bromocriptine-containing medicines indicated in the prevention or suppression of physiological lactation post-partum","international_non_proprietary_name_inn_common_name":"bromocriptine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1379","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"05/09/2013","prac_recommendation_date":"10/07/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/08/2014","european_commission_decision_date":"30/10/2014","first_published_date":"06/09/2013","last_updated_date":"08/12/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum"},{"category":"Human","referral_name":"Emergency contraceptives","international_non_proprietary_name_inn_common_name":"levonorgestrel;ulipristal acetate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Norlevo  ;Levonelle/Postinor and Levodonna  ;ellaOne","class":"","reference_number":"EMEA/H/A-31/1391","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2014","european_commission_decision_date":"30/09/2014","first_published_date":"24/07/2014","last_updated_date":"24/10/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/emergency-contraceptives"},{"category":"Human","referral_name":"Renin-angiotensin-system (RAS)-acting agents","international_non_proprietary_name_inn_common_name":"captopril;imidapril;zofenopril;candesartan;delapril;telmisartan;aliskiren;moexipril;enalapril;valsartan;fosinopril;irbesartan;perindopril;quinapril;ramipril;eprosartan;olmesartan;trandolapril;losartan;azilsartan;lisinopril;spirapril;benazepril;cilazapril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Tolucombi;Telmisartan Teva;Telmisartan Teva Pharma;Tolura;Onduarp;Twynsta;Actelsar HCT;Kinzalkomb;MicardisPlus;PritorPlus;Copalia HCT;Dafiro HCT;Exforge HCT;Rasilamlo;Rasilez;Rasilez HCT;Rasitrio;Edarbi;Ipreziv;Aprovel;Ifirmasta (previously Irbesartan Krka);Irbesartan Teva;Irbesartan Zentiva (previously Irbesartan Winthrop);Karvea;Sabervel;CoAprovel;Ifirmacombi;Irbesartan/Hydrochlorothiazide Teva;Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop);Karvezide;Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG);Micardis;Pritor;Telmisartan Actavis","associated_names_non_centrally_authorised_medicines":"","class":"angiotensin-receptor blockers (ARBs), angiotensin-converting-enzyme inhibitors (ACEIs), direct renin inhibitors (aliskiren)","reference_number":"EMEA/H/A-31/1370","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"16/05/2013","prac_recommendation_date":"10/04/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/05/2014","european_commission_decision_date":"04/09/2014","first_published_date":"17/05/2013","last_updated_date":"08/10/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents"},{"category":"Human","referral_name":"Diacerein-containing medicines for oral administration","international_non_proprietary_name_inn_common_name":"diacerein","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Zondar","class":"-","reference_number":"EMEA/H/A-31/1349","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"29/11/2012","prac_recommendation_date":"06/03/2014","cmdh_position_date":"23/07/2014","chmp_cvmp_opinion_date":"","european_commission_decision_date":"04/09/2014","first_published_date":"30/11/2012","last_updated_date":"19/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diacerein-containing-medicines-oral-administration"},{"category":"Human","referral_name":"Protelos and Osseor","international_non_proprietary_name_inn_common_name":"strontium ranelate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A20/1371/C/00560-561/0039-0034","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"16/05/2013","prac_recommendation_date":"09/01/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/02/2014","european_commission_decision_date":"15/04/2014","first_published_date":"17/05/2013","last_updated_date":"18/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/protelos-osseor"},{"category":"Human","referral_name":"Linoladiol N and Linoladiol HN","international_non_proprietary_name_inn_common_name":"estradiol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"hormonal","reference_number":"EMEA/H/A-31/1336","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/04/2014","european_commission_decision_date":"19/08/2014","first_published_date":"20/12/2013","last_updated_date":"11/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/linoladiol-n-linoladiol-hn"},{"category":"Human","referral_name":"Domperidone-containing medicines","international_non_proprietary_name_inn_common_name":"domperidone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1365","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"07/03/2013","prac_recommendation_date":"06/06/2014","cmdh_position_date":"24/04/2014","chmp_cvmp_opinion_date":"","european_commission_decision_date":"01/09/2014","first_published_date":"08/03/2013","last_updated_date":"11/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/domperidone-containing-medicines"},{"category":"Human","referral_name":"Seroquel / Seroquel XR and associated names","international_non_proprietary_name_inn_common_name":"quetiapine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1362","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/05/2014","european_commission_decision_date":"06/08/2014","first_published_date":"23/05/2014","last_updated_date":"09/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-seroquel-xr-associated-names"},{"category":"Veterinary","referral_name":"Veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs","international_non_proprietary_name_inn_common_name":"tylosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/100","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/05/2014","european_commission_decision_date":"31/07/2014","first_published_date":"05/09/2014","last_updated_date":"05/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs"},{"category":"Veterinary","referral_name":"Linco-Spectin 100 and associated names","international_non_proprietary_name_inn_common_name":"lincomycin;spectinomycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/088","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/04/2014","european_commission_decision_date":"11/07/2014","first_published_date":"04/09/2014","last_updated_date":"04/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/linco-spectin-100-associated-names"},{"category":"Human","referral_name":"Dexamed and associated names","international_non_proprietary_name_inn_common_name":"dexamfetamine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1375","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/05/2014","european_commission_decision_date":"06/08/2014","first_published_date":"23/05/2014","last_updated_date":"02/09/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/dexamed-associated-names"},{"category":"Veterinary","referral_name":"Fiprex","international_non_proprietary_name_inn_common_name":"fipronil","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/099","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/04/2014","european_commission_decision_date":"14/07/2014","first_published_date":"14/08/2014","last_updated_date":"14/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/fiprex"},{"category":"Veterinary","referral_name":"Vasotop P","international_non_proprietary_name_inn_common_name":"ramipril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/051","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/12/2009","european_commission_decision_date":"27/04/2010","first_published_date":"14/08/2014","last_updated_date":"14/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/vasotop-p"},{"category":"Veterinary","referral_name":"Dectomax injectable solution and its associated names","international_non_proprietary_name_inn_common_name":"doramectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/12/2004","european_commission_decision_date":"29/03/2005","first_published_date":"13/08/2014","last_updated_date":"13/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/dectomax-injectable-solution-its-associated-names"},{"category":"Veterinary","referral_name":"Porcimectin Injection and its associated names","international_non_proprietary_name_inn_common_name":"ivermectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/003","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/06/2002","european_commission_decision_date":"12/09/2002","first_published_date":"13/08/2014","last_updated_date":"13/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/porcimectin-injection-its-associated-names"},{"category":"Veterinary","referral_name":"Bovimectin Injection and its associated names","international_non_proprietary_name_inn_common_name":"ivermectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/002","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/06/2002","european_commission_decision_date":"19/09/2002","first_published_date":"13/08/2014","last_updated_date":"13/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/bovimectin-injection-its-associated-names"},{"category":"Veterinary","referral_name":"Cobactan DC and its associated names","international_non_proprietary_name_inn_common_name":"cefquinome","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/014","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/07/2006","european_commission_decision_date":"13/10/2006","first_published_date":"12/08/2014","last_updated_date":"12/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/cobactan-dc-its-associated-names"},{"category":"Veterinary","referral_name":"Micotil 300 and its associated names","international_non_proprietary_name_inn_common_name":"tilmicosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/11/2005","european_commission_decision_date":"23/06/2006","first_published_date":"12/08/2014","last_updated_date":"12/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/micotil-300-its-associated-names"},{"category":"Veterinary","referral_name":"Cobactan IV 4.5% powder and solvent for solution for injection and its associated names","international_non_proprietary_name_inn_common_name":"cefquinome","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/012","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/05/2006","european_commission_decision_date":"21/08/2006","first_published_date":"12/08/2014","last_updated_date":"12/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/cobactan-iv-45-powder-solvent-solution-injection-its-associated-names"},{"category":"Veterinary","referral_name":"Eprinex pour-on and its associated names","international_non_proprietary_name_inn_common_name":"eprinomectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/02/2004","european_commission_decision_date":"11/08/2004","first_published_date":"11/08/2014","last_updated_date":"11/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/eprinex-pour-its-associated-names"},{"category":"Veterinary","referral_name":"Orbax","international_non_proprietary_name_inn_common_name":"orbifloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/004","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/01/2003","european_commission_decision_date":"16/04/2003","first_published_date":"11/08/2014","last_updated_date":"11/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/orbax"},{"category":"Human","referral_name":"Caustinerf arsenical and Yranicid arsenical","international_non_proprietary_name_inn_common_name":"ephedrine hydrochloride;lidocaine;arsenous anhydride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Dental pulp devitalising","reference_number":"EMEA/H/A-31/1382","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/04/2014","european_commission_decision_date":"11/07/2014","first_published_date":"25/04/2014","last_updated_date":"06/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/caustinerf-arsenical-yranicid-arsenical"},{"category":"Veterinary","referral_name":"Avinew","international_non_proprietary_name_inn_common_name":"Newcastle disease virus, VG/GA strain, live","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/001","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/09/2001","european_commission_decision_date":"04/02/2002","first_published_date":"05/08/2014","last_updated_date":"05/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/avinew"},{"category":"Veterinary","referral_name":"Bayovac IBR Marker Vivum","international_non_proprietary_name_inn_common_name":"bovine Herpes virus type 1 (BHV-1), strain Difivac (IBR-Marker virus, gE-negative), modified live (attenuated) virus","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/023b/001","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2000","european_commission_decision_date":"10/07/2000","first_published_date":"05/08/2014","last_updated_date":"05/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/bayovac-ibr-marker-vivum"},{"category":"Human","referral_name":"Methadone medicinal products for oral use containing povidone","international_non_proprietary_name_inn_common_name":"methadone","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-107i/1395","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"10/04/2014","prac_recommendation_date":"10/07/2014","cmdh_position_date":"23/07/2014","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"11/04/2014","last_updated_date":"04/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methadone-medicinal-products-oral-use-containing-povidone"},{"category":"Human","referral_name":"Zolpidem-containing medicines","international_non_proprietary_name_inn_common_name":"zolpidem","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1377","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"11/07/2013","prac_recommendation_date":"06/03/2014","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/04/2014","european_commission_decision_date":"23/06/2014","first_published_date":"12/07/2013","last_updated_date":"04/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zolpidem-containing-medicines"},{"category":"Human","referral_name":"Crestor and associated names","international_non_proprietary_name_inn_common_name":"rosuvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29-PAE/1378","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"30/06/2014","european_commission_decision_date":"","first_published_date":"01/08/2014","last_updated_date":"01/08/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/crestor-associated-names"},{"category":"Human","referral_name":"Sandostatin LAR and associated names","international_non_proprietary_name_inn_common_name":"ocreotide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/001355","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2014","european_commission_decision_date":"26/06/2014","first_published_date":"27/06/2014","last_updated_date":"27/06/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sandostatin-lar-associated-names"},{"category":"Human","referral_name":"Sandostatin and associated names","international_non_proprietary_name_inn_common_name":"ocreotide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/001354","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2014","european_commission_decision_date":"26/06/2014","first_published_date":"27/06/2014","last_updated_date":"27/06/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sandostatin-associated-names"},{"category":"Human","referral_name":"Nanotop and associated names","international_non_proprietary_name_inn_common_name":"human albumin, denatured","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1386","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2013","european_commission_decision_date":"28/02/2014","first_published_date":"20/12/2013","last_updated_date":"16/06/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nanotop-associated-names"},{"category":"Human","referral_name":"Ketoconazole-containing medicines","international_non_proprietary_name_inn_common_name":"ketoconazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Nizoral  ;Fungoral","class":"Antifungal","reference_number":"EMEA/H/A-31/1314","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/07/2013","european_commission_decision_date":"11/10/2013","first_published_date":"26/07/2013","last_updated_date":"13/06/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ketoconazole-containing-medicines"},{"category":"Veterinary","referral_name":"Long-acting formulations for injection containing barium selenate for all food producing species","international_non_proprietary_name_inn_common_name":"barium selenate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/077","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/11/2013","european_commission_decision_date":"28/03/2014","first_published_date":"27/05/2014","last_updated_date":"27/05/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species"},{"category":"Human","referral_name":"Methysergide-containing medicines","international_non_proprietary_name_inn_common_name":"methysergide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Deseril  ;Desernil","class":"Ergot alkaloids","reference_number":"EMEA/H/A-31/1335","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/02/2014","european_commission_decision_date":"28/04/2014","first_published_date":"21/02/2014","last_updated_date":"27/05/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methysergide-containing-medicines"},{"category":"Human","referral_name":"Rocephin","international_non_proprietary_name_inn_common_name":"rabbit","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1302","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/01/2014","european_commission_decision_date":"21/03/2014","first_published_date":"24/01/2014","last_updated_date":"19/05/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/rocephin"},{"category":"Veterinary","referral_name":"Norbonex 5 mg/ml pour-on solution for beef and dairy cattle","international_non_proprietary_name_inn_common_name":"eprinomectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/098","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/01/2014","european_commission_decision_date":"21/03/2014","first_published_date":"14/05/2014","last_updated_date":"14/05/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/norbonex-5-mg-ml-pour-solution-beef-dairy-cattle"},{"category":"Veterinary","referral_name":"Veterinary medicines containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/089","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/11/2013","european_commission_decision_date":"28/02/2014","first_published_date":"10/04/2014","last_updated_date":"10/04/2014","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-or-turkeys"},{"category":"Human","referral_name":"Kogenate Bayer and Helixate NexGen","international_non_proprietary_name_inn_common_name":"octocog alfa","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/C/275/A20/150, EMEA/H/C/276/A20/143","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"07/03/2013","prac_recommendation_date":"05/12/2013","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2013","european_commission_decision_date":"20/02/2014","first_published_date":"08/03/2013","last_updated_date":"09/04/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/kogenate-bayer-helixate-nexgen"},{"category":"Human","referral_name":"Tibolona Aristo and Tibocina and associated names","international_non_proprietary_name_inn_common_name":"tibolone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Tibolon Aristo  ;Tibolinia","class":"","reference_number":"EMEA/H/A-29/1389 and EMEA/H/A-29/1390","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2013","european_commission_decision_date":"05/03/2014","first_published_date":"20/12/2013","last_updated_date":"08/04/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tibolona-aristo-tibocina-associated-names"},{"category":"Human","referral_name":"Valebo and associated names","international_non_proprietary_name_inn_common_name":"alendronic acid;alfacalcidol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Tevabone  ;Teboneva","class":"","reference_number":"EMEA/H/A-29/1364","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2013","european_commission_decision_date":"10/03/2014","first_published_date":"20/12/2013","last_updated_date":"31/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/valebo-associated-names"},{"category":"Human","referral_name":"Valtrex","international_non_proprietary_name_inn_common_name":"valaciclovir","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Zelitrex  ;Talavir  ;Valaciclovir Allen  ;Valherpes","class":"","reference_number":"EMEA/H/A-30/1004","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/04/2010","european_commission_decision_date":"13/07/2010","first_published_date":"23/04/2010","last_updated_date":"25/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/valtrex"},{"category":"Human","referral_name":"Substances related to nicotinic acid","international_non_proprietary_name_inn_common_name":"acipimox","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Olbetam","class":"Lipid-lowering agents","reference_number":"EMEA/H/A-31/1366","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Variation","procedure_start_date":"07/03/2013","prac_recommendation_date":"07/11/2013","cmdh_position_date":"18/12/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"20/02/2014","first_published_date":"08/03/2013","last_updated_date":"13/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/substances-related-nicotinic-acid"},{"category":"Human","referral_name":"Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines","international_non_proprietary_name_inn_common_name":"monovalent and multivalent measles, mumps, rubella and varicella vaccines (live)","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Amunovax  ;Priorix  ;Priorix Tetra  ;Provarivax  ;R.O.R. Vax  ;Rouvax  ;Trivivac  ;Varilrix  ;Varivax","class":"Vaccines","reference_number":"EMEA/H/A-31/1333","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2012","european_commission_decision_date":"27/06/2013","first_published_date":"14/12/2012","last_updated_date":"12/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/monovalent-multivalent-measles-mumps-rubella-or-varicella-vaccines"},{"category":"Human","referral_name":"Intravenous nicardipine medicines","international_non_proprietary_name_inn_common_name":"nicardipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Cardene IV  ;Loxen  ;Nicardipine Aguettant  ;Nicardipine Arrow  ;Rydene  ;Vasonase","class":"Antihypertensive","reference_number":"EMEA/H/A-31/1339","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/10/2013","european_commission_decision_date":"20/12/2013","first_published_date":"25/10/2013","last_updated_date":"12/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-nicardipine-medicines"},{"category":"Human","referral_name":"Hydroxyethyl starch solutions for infusion","international_non_proprietary_name_inn_common_name":"hydroxyethyl starch","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-107i/1376","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"11/07/2013","prac_recommendation_date":"10/10/2013","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2013","european_commission_decision_date":"19/12/2013","first_published_date":"12/07/2013","last_updated_date":"06/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyethyl-starch-solutions-infusion-0"},{"category":"Human","referral_name":"Thiocolchicoside-containing medicines","international_non_proprietary_name_inn_common_name":"thiocolchicoside","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Muscoril and Coltramyl","class":"muscle relaxant","reference_number":"EMA/H/A-31/1361","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2013","european_commission_decision_date":"17/01/2014","first_published_date":"22/11/2013","last_updated_date":"06/03/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/thiocolchicoside-containing-medicines"},{"category":"Human","referral_name":"Ergot derivatives","international_non_proprietary_name_inn_common_name":"dihydroergocristine;dihydroergotamine;dihydroergotoxine;nicergoline;dihydroergocryptine;caffeine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Ergot derivatives","reference_number":"EMEA/H/A-31/1325","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2013","european_commission_decision_date":"27/09/2013","first_published_date":"28/06/2013","last_updated_date":"17/02/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ergot-derivatives"},{"category":"Human","referral_name":"Metoclopramide-containing medicines","international_non_proprietary_name_inn_common_name":"metoclopramide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Maxolon  ;Primperan","class":"Anti-emetic","reference_number":"EMEA/H/A-31/1321","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/10/2013","european_commission_decision_date":"20/12/2013","first_published_date":"26/07/2013","last_updated_date":"06/02/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/metoclopramide-containing-medicines"},{"category":"Human","referral_name":"Combined hormonal contraceptives","international_non_proprietary_name_inn_common_name":"desogestrel;gestodene;norgestimate;etonogestrel;drospirenone;dienogest;chlormadinone;nomegestrol;norelgestromin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1356","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally and nationally authorised products (mixed)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"07/02/2013","prac_recommendation_date":"10/10/2013","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/01/2014","european_commission_decision_date":"","first_published_date":"08/02/2013","last_updated_date":"31/01/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/combined-hormonal-contraceptives"},{"category":"Human","referral_name":"Okrido","international_non_proprietary_name_inn_common_name":"prednisolone sodium phosphate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1368","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2013","european_commission_decision_date":"05/09/2013","first_published_date":"28/06/2013","last_updated_date":"03/01/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/okrido"},{"category":"Human","referral_name":"Targocid and associated names","international_non_proprietary_name_inn_common_name":"teicoplanin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Targocid  ;Teicomid","class":"-","reference_number":"EMEA/H/A-30/1301","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"30/05/2013","european_commission_decision_date":"12/09/2013","first_published_date":"31/05/2013","last_updated_date":"03/01/2014","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/targocid-associated-names"},{"category":"Human","referral_name":"Sandimmun and associated names","international_non_proprietary_name_inn_common_name":"ciclosporin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1300, EMEA/H/A-30/1320","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2013","european_commission_decision_date":"31/10/2013","first_published_date":"28/06/2013","last_updated_date":"20/12/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sandimmun-associated-names"},{"category":"Human","referral_name":"Sandimmun Neoral and associated names","international_non_proprietary_name_inn_common_name":"ciclosporin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1300, EMEA/H/A-30/1320","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2013","european_commission_decision_date":"31/10/2013","first_published_date":"28/06/2013","last_updated_date":"20/12/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sandimmun-neoral-associated-names"},{"category":"Human","referral_name":"Didanosine","international_non_proprietary_name_inn_common_name":"didanosine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1367","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/09/2013","european_commission_decision_date":"20/11/2013","first_published_date":"20/09/2013","last_updated_date":"10/12/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/didanosine"},{"category":"Human","referral_name":"Methylphenidate Sandoz","international_non_proprietary_name_inn_common_name":"methylphenidate hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1359","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/07/2013","european_commission_decision_date":"09/10/2013","first_published_date":"26/07/2013","last_updated_date":"05/12/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate-sandoz"},{"category":"Human","referral_name":"Methylphenidate Hexal","international_non_proprietary_name_inn_common_name":"methylphenidate hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1360","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/07/2013","european_commission_decision_date":"09/10/2013","first_published_date":"26/07/2013","last_updated_date":"05/12/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate-hexal"},{"category":"Human","referral_name":"Diclofenac-containing medicines","international_non_proprietary_name_inn_common_name":"diclofenac","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Non-steroidal anti-inflammatory drugs (NSAIDs)","reference_number":"EMEA/H/A-31/1344","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"31/10/2012","prac_recommendation_date":"13/06/2013","cmdh_position_date":"26/06/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"25/09/2013","first_published_date":"31/10/2012","last_updated_date":"27/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-containing-medicines"},{"category":"Veterinary","referral_name":"Dexadreson","international_non_proprietary_name_inn_common_name":"dexamethasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/087","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/07/2013","european_commission_decision_date":"18/10/2013","first_published_date":"27/11/2013","last_updated_date":"27/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/dexadreson"},{"category":"Human","referral_name":"Flupirtine-containing medicines","international_non_proprietary_name_inn_common_name":"flupirtine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-107i/1363","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"07/03/2013","prac_recommendation_date":"13/06/2013","cmdh_position_date":"26/06/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"05/09/2013","first_published_date":"08/03/2013","last_updated_date":"21/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/flupirtine-containing-medicines"},{"category":"Veterinary","referral_name":"Micotil 300 Injectie","international_non_proprietary_name_inn_common_name":"tilmicosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A-34/82","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/07/2013","european_commission_decision_date":"18/10/2013","first_published_date":"20/11/2013","last_updated_date":"20/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/micotil-300-injectie"},{"category":"Human","referral_name":"Baxter dialysis solutions","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"dialysis solutions","reference_number":"EMEA/H/A-31/1290","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/10/2011","european_commission_decision_date":"16/12/2011","first_published_date":"23/09/2011","last_updated_date":"20/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/baxter-dialysis-solutions"},{"category":"Human","referral_name":"Ciclosporin IDL","international_non_proprietary_name_inn_common_name":"ciclosporin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1105","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"22/07/2010","first_published_date":"23/07/2009","last_updated_date":"20/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ciclosporin-idl"},{"category":"Human","referral_name":"Tazocin","international_non_proprietary_name_inn_common_name":"piperacillin;tazobactam","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Tazobac  ;Tazocel  ;Tazonam","class":"","reference_number":"EMEA/H/A-30/001149","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/10/2010","european_commission_decision_date":"21/02/2011","first_published_date":"22/10/2010","last_updated_date":"19/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tazocin"},{"category":"Human","referral_name":"Avalox","international_non_proprietary_name_inn_common_name":"moxifloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1082","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/06/2009","european_commission_decision_date":"02/10/2009","first_published_date":"25/06/2009","last_updated_date":"19/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/avalox"},{"category":"Human","referral_name":"Vivaglobin","international_non_proprietary_name_inn_common_name":"human normal immunoglobulin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-36/1296","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/02/2012","european_commission_decision_date":"07/05/2012","first_published_date":"17/02/2012","last_updated_date":"18/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vivaglobin"},{"category":"Human","referral_name":"Octagam","international_non_proprietary_name_inn_common_name":"human normal immunoglobulin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-107/001278","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/09/2010","european_commission_decision_date":"04/10/2010","first_published_date":"24/09/2010","last_updated_date":"18/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/octagam-0"},{"category":"Human","referral_name":"Augmentin","international_non_proprietary_name_inn_common_name":"amoxicillin;clavulanic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/97898/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/01/2009","european_commission_decision_date":"19/10/2009","first_published_date":"25/06/2009","last_updated_date":"18/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/augmentin"},{"category":"Human","referral_name":"Short-acting beta-agonists","international_non_proprietary_name_inn_common_name":"terbutaline;salbutamol;hexoprenaline;ritodrine;fenoterol;isoxsuprine","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1347","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"27/11/2012","prac_recommendation_date":"05/09/2013","cmdh_position_date":"23/10/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"30/11/2012","last_updated_date":"07/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/short-acting-beta-agonists"},{"category":"Human","referral_name":"Antifibrinolytic medicines","international_non_proprietary_name_inn_common_name":"aprotinin;aminocaproic acid;tranexamic acid","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"B02A, Antihemorrhagics","reference_number":"EMEA/H/A-31/1267","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/06/2012","european_commission_decision_date":"","first_published_date":"17/02/2012","last_updated_date":"06/11/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/antifibrinolytic-medicines"},{"category":"Veterinary","referral_name":"Suifertil 4-mg/ml oral solution for pigs and associated names","international_non_proprietary_name_inn_common_name":"altrenogest","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/094","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/07/2013","european_commission_decision_date":"02/10/2013","first_published_date":"30/10/2013","last_updated_date":"30/10/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/suifertil-4-mg-ml-oral-solution-pigs-associated-names"},{"category":"Veterinary","referral_name":"Cydectin TriclaMox","international_non_proprietary_name_inn_common_name":"moxidectin;triclabendazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/096","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2013","european_commission_decision_date":"25/09/2013","first_published_date":"18/10/2013","last_updated_date":"18/10/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/cydectin-triclamox"},{"category":"Veterinary","referral_name":"Doramectin","international_non_proprietary_name_inn_common_name":"doramectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/081","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/06/2013","european_commission_decision_date":"06/09/2013","first_published_date":"18/10/2013","last_updated_date":"18/10/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/doramectin"},{"category":"Veterinary","referral_name":"Deltanil","international_non_proprietary_name_inn_common_name":"deltamethrin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/093","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/09/2013","european_commission_decision_date":"24/09/2013","first_published_date":"11/10/2013","last_updated_date":"11/10/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/deltanil"},{"category":"Human","referral_name":"Numeta G13%E and Numeta G16%E emulsion for infusion","international_non_proprietary_name_inn_common_name":"","current_status":"CMDh final position","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-107i/1373","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"13/06/2013","prac_recommendation_date":"05/09/2013","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/09/2013","european_commission_decision_date":"","first_published_date":"14/06/2013","last_updated_date":"27/09/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/numeta-g13e-numeta-g16e-emulsion-infusion"},{"category":"Veterinary","referral_name":"Soludox","international_non_proprietary_name_inn_common_name":"doxycycline hyclate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/090","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/06/2013","european_commission_decision_date":"12/08/2013","first_published_date":"24/09/2013","last_updated_date":"24/09/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/soludox"},{"category":"Veterinary","referral_name":"Strenzen 500/125-mg/g powder","international_non_proprietary_name_inn_common_name":"amoxicillin;clavulanic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/085","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/04/2013","european_commission_decision_date":"12/08/2013","first_published_date":"19/09/2013","last_updated_date":"19/09/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/strenzen-500-125-mg-g-powder"},{"category":"Human","referral_name":"Cilostazol-containing medicines","international_non_proprietary_name_inn_common_name":"cilostazol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Pletal  ;Ekistol","class":"antiplatelet agents","reference_number":"EMEA/H/A-31/1306","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/03/2013","european_commission_decision_date":"24/06/2013","first_published_date":"22/03/2013","last_updated_date":"11/09/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cilostazol-containing-medicines"},{"category":"Human","referral_name":"Cyproterone- and ethinylestradiol-containing medicines","international_non_proprietary_name_inn_common_name":"cyproterone;ethinyl estradiol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Acnemine  ;Acneson  ;Chloe  ;Clairette  ;Cyprest  ;Cyprodiol  ;Diane 35  ;Dianette  ;Feminil  ;Minerva  ;Zyrona","class":"","reference_number":"EMEA/H/A-107i/1357","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"07/02/2013","prac_recommendation_date":"16/05/2013","cmdh_position_date":"29/05/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"25/07/2013","first_published_date":"08/02/2013","last_updated_date":"05/08/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-ethinylestradiol-containing-medicines"},{"category":"Human","referral_name":"Codeine-containing medicines","international_non_proprietary_name_inn_common_name":"codeine","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1342","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Risk minimisation measures","procedure_start_date":"03/10/2012","prac_recommendation_date":"13/06/2013","cmdh_position_date":"26/06/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"05/10/2012","last_updated_date":"02/08/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/codeine-containing-medicines"},{"category":"Human","referral_name":"Furosemide Vitabalans","international_non_proprietary_name_inn_common_name":"furosemide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1334","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/02/2013","european_commission_decision_date":"14/05/2013","first_published_date":"22/02/2013","last_updated_date":"30/07/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/furosemide-vitabalans"},{"category":"Human","referral_name":"Simvastatin Vale","international_non_proprietary_name_inn_common_name":"simvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Simvastatin Vale pharmaceuticals","class":"Statin","reference_number":"EMEA/H/A-29/1358","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/03/2013","european_commission_decision_date":"27/05/2013","first_published_date":"03/04/2013","last_updated_date":"22/07/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/simvastatin-vale"},{"category":"Human","referral_name":"Calcitonin","international_non_proprietary_name_inn_common_name":"calcitonin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1291","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2012","european_commission_decision_date":"13/02/2013","first_published_date":"20/07/2012","last_updated_date":"19/07/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/calcitonin"},{"category":"Human","referral_name":"Tetrazepam-containing medicines","international_non_proprietary_name_inn_common_name":"tetrazepam","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107i procedures","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Myolastan and generics","class":"-","reference_number":"EMEA/H/A107i/1352","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"10/01/2013","prac_recommendation_date":"11/04/2013","cmdh_position_date":"24/04/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"29/05/2013","first_published_date":"11/01/2013","last_updated_date":"18/07/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tetrazepam-containing-medicines"},{"category":"Veterinary","referral_name":"Florgane","international_non_proprietary_name_inn_common_name":"florfenicol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/083","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/03/2013","european_commission_decision_date":"23/05/2013","first_published_date":"10/07/2013","last_updated_date":"10/07/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/florgane"},{"category":"Veterinary","referral_name":"Nuflor Swine Once","international_non_proprietary_name_inn_common_name":"florfenicol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/080","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/02/2013","european_commission_decision_date":"16/05/2013","first_published_date":"14/06/2013","last_updated_date":"14/06/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/nuflor-swine-once"},{"category":"Human","referral_name":"Almitrine-containing medicines","international_non_proprietary_name_inn_common_name":"almitrine","current_status":"CMDh final position","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Vectarion  ;Armanor","class":"","reference_number":"EMEA/H/A-31/1346","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CMDh","authorisation_model":"Nationally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"29/11/2012","prac_recommendation_date":"16/05/2013","cmdh_position_date":"29/05/2013","chmp_cvmp_opinion_date":"","european_commission_decision_date":"","first_published_date":"30/11/2012","last_updated_date":"10/06/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/almitrine-containing-medicines"},{"category":"Human","referral_name":"Tredaptive, Pelzont and Trevaclyn","international_non_proprietary_name_inn_common_name":"laropiprant;nicotinic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 20 procedures","associated_names_centrally_authorised_medicines":"Tredaptive;Pelzont;Trevaclyn","associated_names_non_centrally_authorised_medicines":"","class":"cardiovascular","reference_number":"EMEA/H/C/889/A20/37, EMEA/H/C/903/A20/38, EMEA/H/C/897/A20/38","non_prac_decision_making_model":"","prac_decision_making_model":"PRAC-CHMP-EC","authorisation_model":"Centrally authorised product(s)","prac_recommendation":"Suspension","procedure_start_date":"20/12/2012","prac_recommendation_date":"10/01/2013","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"22/03/2013","first_published_date":"21/12/2012","last_updated_date":"17/05/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tredaptive-pelzont-trevaclyn"},{"category":"Human","referral_name":"Kantos Master","international_non_proprietary_name_inn_common_name":"beclometasone dipropionate;formoterol fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Kantos  ;Formodual  ;Foster  ;Inuxair  ;Innovair and associated names","class":"-","reference_number":"EMEA/H/A-13/1350","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/01/2013","european_commission_decision_date":"10/04/2013","first_published_date":"18/01/2013","last_updated_date":"02/05/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/kantos-master"},{"category":"Human","referral_name":"Fibrates","international_non_proprietary_name_inn_common_name":"bezafibrate;ciprofibrate;fenofibrate;gemfibrozil","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Bezalip  ;Lipanor  ;Lipanthyl  ;Lopid","class":"fibrates","reference_number":"EMEA/H/A-31/001238","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/10/2010","european_commission_decision_date":"28/02/2011","first_published_date":"22/10/2010","last_updated_date":"03/04/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fibrates"},{"category":"Human","referral_name":"Fibrinogen-containing solutions for sealant authorised for administration by spray application","international_non_proprietary_name_inn_common_name":"fibrin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"Evicel","associated_names_non_centrally_authorised_medicines":"Quixil","class":"Fibrin sealants","reference_number":"EMEA/H/A-31/1337","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/11/2012","european_commission_decision_date":"13/02/2013","first_published_date":"16/11/2012","last_updated_date":"02/04/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-0"},{"category":"Human","referral_name":"Fibrinogen-containing solutions for sealant authorised for administration by spray application","international_non_proprietary_name_inn_common_name":"fibrin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Tisseel  ;Tissucol  ;Artiss  ;Beriplast P","class":"Fibrin sealants","reference_number":"EMEA/H/A-31/1337","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2012","european_commission_decision_date":"15/03/2013","first_published_date":"14/12/2012","last_updated_date":"02/04/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fibrinogen-containing-solutions-sealant-authorised-administration-spray-application"},{"category":"Human","referral_name":"Tolperisone","international_non_proprietary_name_inn_common_name":"tolperisone","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1311","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/10/2012","european_commission_decision_date":"21/01/2013","first_published_date":"22/06/2012","last_updated_date":"02/04/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tolperisone"},{"category":"Veterinary","referral_name":"Melosolute","international_non_proprietary_name_inn_common_name":"meloxicam","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/084","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/11/2012","european_commission_decision_date":"12/02/2013","first_published_date":"15/03/2013","last_updated_date":"15/03/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/melosolute"},{"category":"Human","referral_name":"Medicines studied at Cetero Research facility","international_non_proprietary_name_inn_common_name":"fenofibrate;cilazapril;leflunomide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Cilazapril Teva  ;Fenofibrato Pensa  ;Fenofibrato Ranbaxy  ;Leflunomide Actavis  ;Leflunomide Apotex","class":"-","reference_number":"EMEA/H/A-31/001340","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2012","european_commission_decision_date":"20/02/2013","first_published_date":"14/12/2012","last_updated_date":"12/03/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/medicines-studied-cetero-research-facility"},{"category":"Human","referral_name":"Loraxin","international_non_proprietary_name_inn_common_name":"loratadine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1325","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/10/2012","european_commission_decision_date":"20/12/2012","first_published_date":"22/06/2012","last_updated_date":"28/02/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/loraxin"},{"category":"Veterinary","referral_name":"Hipralona Enro-S","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/079","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/09/2012","european_commission_decision_date":"17/12/2012","first_published_date":"04/02/2013","last_updated_date":"04/02/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/hipralona-enro-s"},{"category":"Human","referral_name":"Zinacef","international_non_proprietary_name_inn_common_name":"cefuroxime sodium","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Curocef  ;Curoxim  ;Curoxim Monovial  ;Curoxima  ;Curoxime  ;Zinnat  ;Zinocep  ;Zinocep Vena","class":"Anti-infectives","reference_number":"EMEA/H/A-30/1158","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/05/2012","european_commission_decision_date":"10/09/2012","first_published_date":"25/05/2012","last_updated_date":"29/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zinacef"},{"category":"Human","referral_name":"Zinnat","international_non_proprietary_name_inn_common_name":"cefuroxime axetil","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Cefuroxima Solasma  ;Cefuroxima Allen  ;Cefuroxima Duncan  ;Elobact  ;Nivador  ;Oraxim  ;Selan  ;Tilexim  ;Zinadol  ;Zipos  ;Zoref","class":"Anti-infectives","reference_number":"EMEA/H/A-30/1157","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/05/2012","european_commission_decision_date":"23/08/2012","first_published_date":"25/05/2012","last_updated_date":"29/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zinnat"},{"category":"Human","referral_name":"Mometasone Furoate Sandoz","international_non_proprietary_name_inn_common_name":"mometasone furoate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Mometasone Sandoz  ;Mometasone Sandoz 50  ;Mometasone Furoato Sandoz 50  ;Mommox  ;Nasometi  ;Fumomo 50","class":"Glucocorticoids","reference_number":"EMEA/H/A-29/1332","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2012","european_commission_decision_date":"08/10/2012","first_published_date":"20/07/2012","last_updated_date":"24/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/mometasone-furoate-sandoz"},{"category":"Veterinary","referral_name":"Flukicides for which no maximum residue limit has been established in milk and which are intended for use in ruminants producing milk for human consumption","international_non_proprietary_name_inn_common_name":"clorsulon;closantel;nitroxinil;rafoxanide;triclabendazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/069","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/06/2012","european_commission_decision_date":"19/11/2012","first_published_date":"18/01/2013","last_updated_date":"18/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/flukicides-which-no-maximum-residue-limit-has-been-established-milk-which-are-intended-use-ruminants-producing-milk-human-consumption"},{"category":"Human","referral_name":"Ethinylestradiol-Drospirenone 24+4","international_non_proprietary_name_inn_common_name":"ethinyl estradiol;drospirenone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Yaz 24+4","class":"","reference_number":"EMEA/H/A-6(12)/1313","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/04/2012","european_commission_decision_date":"06/07/2012","first_published_date":"20/04/2012","last_updated_date":"11/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ethinylestradiol-drospirenone-244"},{"category":"Human","referral_name":"Yaz 24+4","international_non_proprietary_name_inn_common_name":"ethinylestradiol;drospirenone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Ethinylestradiol-Drospirenone 24+4","class":"","reference_number":"EMEA/H/A-6(12)/1312","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/04/2012","european_commission_decision_date":"03/07/2012","first_published_date":"20/04/2012","last_updated_date":"11/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/yaz-244"},{"category":"Human","referral_name":"Mifepristone Linepharma","international_non_proprietary_name_inn_common_name":"mifepristone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1331","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/06/2012","european_commission_decision_date":"11/09/2012","first_published_date":"22/06/2012","last_updated_date":"03/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/mifepristone-linepharma"},{"category":"Human","referral_name":"Yvidually","international_non_proprietary_name_inn_common_name":"ethinylestradiol;drospirenone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Flexyess","class":"","reference_number":"EMEA/H/A-29/1330","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/04/2012","european_commission_decision_date":"28/09/2012","first_published_date":"20/04/2012","last_updated_date":"03/01/2013","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/yvidually"},{"category":"Human","referral_name":"Orlistat","international_non_proprietary_name_inn_common_name":"orlistat","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-31/1318","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/02/2012","european_commission_decision_date":"24/04/2012","first_published_date":"16/02/2012","last_updated_date":"21/12/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/orlistat"},{"category":"Human","referral_name":"Glimepirida Parke-Davis","international_non_proprietary_name_inn_common_name":"glimepiride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Glimepiride Pfizer  ;Glimepirid Pfizer  ;Glimepiride tablets 2 mg  ;Glimepiride tablets 3 mg  ;Glimepiride tablets 4 mg","class":"Sulfonamides, urea derivatives","reference_number":"EMEA/H/A-29/1338","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2012","european_commission_decision_date":"19/11/2012","first_published_date":"20/07/2012","last_updated_date":"06/12/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/glimepirida-parke-davis"},{"category":"Veterinary","referral_name":"Baytril 10% oral solution","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/067","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/06/2012","european_commission_decision_date":"08/10/2012","first_published_date":"20/11/2012","last_updated_date":"20/11/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/baytril-10-oral-solution"},{"category":"Human","referral_name":"Iffeza","international_non_proprietary_name_inn_common_name":"fluticasone propionate;formoterol fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Flutiform  ;Flofera  ;Flutiformo","class":"","reference_number":"EMEA/H/A-29/001327","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/04/2012","european_commission_decision_date":"28/06/2012","first_published_date":"20/04/2012","last_updated_date":"25/10/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/iffeza"},{"category":"Human","referral_name":"Flutiform","international_non_proprietary_name_inn_common_name":"fluticasone propionate;formoterol fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Iffeza  ;Flofera  ;Flutiformo","class":"","reference_number":"EMEA/H/A-29/001326","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/04/2012","european_commission_decision_date":"28/06/2012","first_published_date":"20/04/2012","last_updated_date":"25/10/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/flutiform"},{"category":"Veterinary","referral_name":"Nuflor","international_non_proprietary_name_inn_common_name":"florfenicol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/078","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/06/2012","european_commission_decision_date":"17/09/2012","first_published_date":"19/10/2012","last_updated_date":"19/10/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/nuflor"},{"category":"Human","referral_name":"Trimetazidine","international_non_proprietary_name_inn_common_name":"trimetazidine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Vastarel","class":"","reference_number":"EMEA/H/A-31/1305","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/06/2012","european_commission_decision_date":"03/09/2012","first_published_date":"22/06/2012","last_updated_date":"17/10/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/trimetazidine"},{"category":"Human","referral_name":"Flolan","international_non_proprietary_name_inn_common_name":"epoprostenol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Epoprostenol","class":"","reference_number":"EMEA/H/A-30/1299","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/05/2012","european_commission_decision_date":"08/08/2012","first_published_date":"25/05/2012","last_updated_date":"14/09/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/flolan"},{"category":"Human","referral_name":"Tavanic","international_non_proprietary_name_inn_common_name":"levofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Levofloxacin","class":"","reference_number":"EMEA/H/A-30/1262","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/05/2012","european_commission_decision_date":"31/07/2012","first_published_date":"25/05/2012","last_updated_date":"12/09/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tavanic"},{"category":"Veterinary","referral_name":"Milaxyn Plus","international_non_proprietary_name_inn_common_name":"praziquantel;pyrantel;febantel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/076","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/03/2012","european_commission_decision_date":"18/06/2012","first_published_date":"23/07/2012","last_updated_date":"23/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/milaxyn-plus"},{"category":"Human","referral_name":"Valproat Ratiopharm Chrono","international_non_proprietary_name_inn_common_name":"valproic acid;valproate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-6(12)/1147","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/05/2010","european_commission_decision_date":"26/05/2010","first_published_date":"23/07/2012","last_updated_date":"23/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/valproat-ratiopharm-chrono"},{"category":"Human","referral_name":"Preflucel","international_non_proprietary_name_inn_common_name":"influenza vaccine, purified antigen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-36/1323","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2012","european_commission_decision_date":"10/12/2012","first_published_date":"20/07/2012","last_updated_date":"20/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/preflucel"},{"category":"Veterinary","referral_name":"All pre-mixes for medicated feedingstuff containing 40 g, 100 g or 200 g tilmicosin per kg pre-mix and administered to rabbits","international_non_proprietary_name_inn_common_name":"tilmicosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/071","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/03/2012","european_commission_decision_date":"14/06/2012","first_published_date":"19/07/2012","last_updated_date":"19/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-administered-rabbits"},{"category":"Veterinary","referral_name":"Prontax 5 mg/ml pour-on solution for cattle","international_non_proprietary_name_inn_common_name":"doramectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/074","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/02/2012","european_commission_decision_date":"25/05/2012","first_published_date":"05/07/2012","last_updated_date":"05/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/prontax-5-mg-ml-pour-solution-cattle"},{"category":"Veterinary","referral_name":"Prontax 10 mg/ml solution for injection for cattle, sheep and pigs","international_non_proprietary_name_inn_common_name":"doramectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A-73","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/02/2012","european_commission_decision_date":"25/05/2012","first_published_date":"05/07/2012","last_updated_date":"05/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/prontax-10-mg-ml-solution-injection-cattle-sheep-pigs"},{"category":"Human","referral_name":"Docetaxel Teva Generics","international_non_proprietary_name_inn_common_name":"docetaxel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/001277","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/02/2011","european_commission_decision_date":"07/07/2011","first_published_date":"18/02/2011","last_updated_date":"03/07/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/docetaxel-teva-generics"},{"category":"Human","referral_name":"Priorix","international_non_proprietary_name_inn_common_name":"measles, mumps and rubella vaccine (live)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1283","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/03/2012","european_commission_decision_date":"25/05/2012","first_published_date":"16/03/2012","last_updated_date":"19/06/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/priorix"},{"category":"Human","referral_name":"Buflomedil","international_non_proprietary_name_inn_common_name":"buflomedil","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"vasoactive agent","reference_number":"EMEA/H/A-107/1293","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/11/2011","european_commission_decision_date":"13/02/2012","first_published_date":"20/05/2011","last_updated_date":"13/06/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/buflomedil"},{"category":"Human","referral_name":"Femara","international_non_proprietary_name_inn_common_name":"letrozole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Femar  ;Fémara  ;Loxifan","class":"","reference_number":"EMEA/H/A-30/1264","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/03/2012","european_commission_decision_date":"22/05/2012","first_published_date":"16/03/2012","last_updated_date":"12/06/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/femara"},{"category":"Human","referral_name":"Meprobamate","international_non_proprietary_name_inn_common_name":"meprobamate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Equanil and other trade names","class":"","reference_number":"EMEA/H/A-107/1316","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/01/2012","european_commission_decision_date":"30/03/2012","first_published_date":"20/01/2011","last_updated_date":"08/06/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/meprobamate"},{"category":"Human","referral_name":"Galantamine Stada","international_non_proprietary_name_inn_common_name":"galantamine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Galantamina  ;Galantamine Tiefenbacher  ;Galantamina Ciclum  ;Galatnax xl  ;Galastad","class":"","reference_number":"EMEA/H/A-29/001268","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/09/2010","european_commission_decision_date":"21/02/2011","first_published_date":"24/09/2010","last_updated_date":"08/06/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/galantamine-stada"},{"category":"Human","referral_name":"Somatropin","international_non_proprietary_name_inn_common_name":"somatropin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Genotropin  ;Humatrope  ;Maxomat  ;Norditropin  ;Saizen  ;Zomacton","class":"","reference_number":"EMEA/H/A-107/001287","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2011","european_commission_decision_date":"27/02/2012","first_published_date":"15/12/2011","last_updated_date":"23/04/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/somatropin"},{"category":"Human","referral_name":"Nimesulide","international_non_proprietary_name_inn_common_name":"nimesulide","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/001261","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2011","european_commission_decision_date":"20/01/2012","first_published_date":"23/06/2011","last_updated_date":"19/04/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide-1"},{"category":"Human","referral_name":"Norditropin","international_non_proprietary_name_inn_common_name":"somatropin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 13 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Norditropin FlexPro  ;Norditropin NordiFlex  ;Norditropin SimpleXx","class":"","reference_number":"EMEA/H/A-13/1304","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2011","european_commission_decision_date":"06/03/2012","first_published_date":"16/12/2011","last_updated_date":"19/04/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/norditropin-0"},{"category":"Human","referral_name":"Terpenic derivatives","international_non_proprietary_name_inn_common_name":"camphor;cineole;niaouli;wild thyme;terpineol;terpine;citral;menthol;essential oils of pine needle, eucalyptus and turpentine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Terpenic derivatives","reference_number":"EMA/CHMP/763180/2011","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/11/2011","european_commission_decision_date":"20/01/2012","first_published_date":"23/09/2011","last_updated_date":"13/04/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/terpenic-derivatives"},{"category":"Human","referral_name":"Lipitor","international_non_proprietary_name_inn_common_name":"atorvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Atorvastatin  ;Atorvastatina Nostrum  ;Atorvastatina Parke-Davis  ;Atorvastatina Pharmacia  ;Cardyl  ;Edovin  ;Liprimar  ;Orbeos  ;Prevencor  ;Sortis  ;Tahor  ;Texzor  ;Torvast  ;Totalip  ;Xarator  ;Zarator","class":"","reference_number":"EMEA/H/A-30/001154","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/09/2010","european_commission_decision_date":"13/12/2010","first_published_date":"24/09/2010","last_updated_date":"10/04/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lipitor"},{"category":"Human","referral_name":"Norvasc","international_non_proprietary_name_inn_common_name":"amlodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Amlodipine Pfizer  ;Amlodipino  ;Amlor  ;Istin  ;Monopina","class":"","reference_number":"EMEA/H/A-30/1288","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/07/2011","european_commission_decision_date":"07/10/2011","first_published_date":"22/07/2011","last_updated_date":"29/03/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/norvasc"},{"category":"Human","referral_name":"Pholcodine","international_non_proprietary_name_inn_common_name":"pholcodine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1292","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2011","european_commission_decision_date":"17/02/2012","first_published_date":"18/11/2011","last_updated_date":"28/03/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pholcodine"},{"category":"Human","referral_name":"Priligy","international_non_proprietary_name_inn_common_name":"dapoxetine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1294","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/10/2011","european_commission_decision_date":"20/01/2012","first_published_date":"21/01/2011","last_updated_date":"28/03/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/priligy"},{"category":"Human","referral_name":"Tienam","international_non_proprietary_name_inn_common_name":"imipenem;cilastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Conet  ;Imipem  ;Primaxin  ;Tenacid  ;Zienam","class":"","reference_number":"EMEA/H/A-30/001187","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/12/2010","european_commission_decision_date":"10/03/2011","first_published_date":"17/12/2010","last_updated_date":"20/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tienam"},{"category":"Human","referral_name":"Canazole","international_non_proprietary_name_inn_common_name":"clotrimazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Canesten","class":"","reference_number":"EMEA/H/A-29/1286","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/03/2011","european_commission_decision_date":"22/09/2011","first_published_date":"18/03/2011","last_updated_date":"09/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/canazole"},{"category":"Human","referral_name":"Novimp","international_non_proprietary_name_inn_common_name":"goserelin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-36/1298","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2011","european_commission_decision_date":"16/09/2011","first_published_date":"06/02/2012","last_updated_date":"06/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/novimp"},{"category":"Human","referral_name":"Novosis Goserelin","international_non_proprietary_name_inn_common_name":"goserelin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Goserelin Novosis  ;Gosacin","class":"","reference_number":"EMEA/H/A-36/1295","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2011","european_commission_decision_date":"16/09/2011","first_published_date":"06/02/2012","last_updated_date":"06/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/novosis-goserelin"},{"category":"Human","referral_name":"Goserelin Cell Pharm","international_non_proprietary_name_inn_common_name":"goserelin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Novosis Goserelin  ;Goserelin Cell Pharm  ;Novimp and associated names","class":"","reference_number":"EMEA/H/A-36/1297","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2011","european_commission_decision_date":"16/09/2011","first_published_date":"24/06/2011","last_updated_date":"06/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/goserelin-cell-pharm"},{"category":"Veterinary","referral_name":"Clavudale 50mg tablet for cats and dogs","international_non_proprietary_name_inn_common_name":"amoxicillin;clavulanic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/068","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/06/2011","european_commission_decision_date":"24/08/2011","first_published_date":"03/02/2012","last_updated_date":"03/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/clavudale-50mg-tablet-cats-dogs"},{"category":"Human","referral_name":"Dexamethasone Alapis","international_non_proprietary_name_inn_common_name":"dexamethasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1308","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/07/2011","european_commission_decision_date":"24/10/2011","first_published_date":"23/07/2011","last_updated_date":"02/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/dexamethasone-alapis"},{"category":"Human","referral_name":"Diflucan","international_non_proprietary_name_inn_common_name":"fluconazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Fluconazole  ;Fungustatin  ;Fungata  ;Triflucan","class":"","reference_number":"EMEA/H/A-30/1156","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2011","european_commission_decision_date":"02/09/2011","first_published_date":"24/06/2011","last_updated_date":"02/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diflucan"},{"category":"Veterinary","referral_name":"Cephalosporins","international_non_proprietary_name_inn_common_name":"ceftiofur;cefquinome","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/V/A/070","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/10/2011","european_commission_decision_date":"13/01/2012","first_published_date":"01/02/2012","last_updated_date":"01/02/2012","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/cephalosporins"},{"category":"Human","referral_name":"Levothyroxine Alapis","international_non_proprietary_name_inn_common_name":"levothyroxine sodium","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/H/A-29/1328","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/10/2012","european_commission_decision_date":"14/01/2013","first_published_date":"19/01/2012","last_updated_date":"19/01/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/levothyroxine-alapis"},{"category":"Human","referral_name":"Protium","international_non_proprietary_name_inn_common_name":"pantoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Anagastra  ;Apton  ;Controloc  ;Eupantol  ;Inipomp  ;Pantec  ;Pantecta  ;Pantipp  ;Panto-Byk-20 / 40 / IV  ;Pantoc  ;Pantoloc  ;PantoLomberg  ;Pantopan  ;Pantorc  ;Pantozol  ;Peptazol  ;Rifun  ;Somac  ;Ulcotenal  ;Zurcal  ;Zurcale  ;Zurcazol","class":"","reference_number":"EMEA/H/A-30/1002","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/12/2009","european_commission_decision_date":"15/04/2010","first_published_date":"17/12/2009","last_updated_date":"17/01/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/protium"},{"category":"Human","referral_name":"Dexrazoxane","international_non_proprietary_name_inn_common_name":"dexrazoxane","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Cardioxane  ;Cyrdanax  ;Dexrazoxane Cyathus  ;Enaxozar  ;Procard","class":"","reference_number":"EMEA/H/A-31/1275","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2011","european_commission_decision_date":"13/09/2011","first_published_date":"24/06/2011","last_updated_date":"16/01/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/dexrazoxane"},{"category":"Human","referral_name":"Cozaar","international_non_proprietary_name_inn_common_name":"irbesartan","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Loortan  ;Loortan Cardio Start  ;Cozaar Startpakkle  ;Cardopal Start  ;Lorzaar  ;Lorzaar start  ;Lorzaar Protect  ;Pinzaar  ;Lorzaar Varipharmstart  ;Lortaan  ;Neo-Lotan  ;Losaprex  ;Cozaar IC  ;Lortaar IC","class":"","reference_number":"EMEA/H/A-29 PAD/1022","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/10/2008","european_commission_decision_date":"22/01/2009","first_published_date":"13/01/2012","last_updated_date":"13/01/2012","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cozaar-0"},{"category":"Veterinary","referral_name":"Hiprabovis Pneumos","international_non_proprietary_name_inn_common_name":"Mannheimia haemolytica biotype A serotype A1, inactivated cell free suspension containing leukotoxoid Ph. Eur.;inactivated Histophilus somni Bailie strain","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/V/A/072","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/07/2011","european_commission_decision_date":"03/11/2011","first_published_date":"09/12/2011","last_updated_date":"12/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/hiprabovis-pneumos"},{"category":"Veterinary","referral_name":"Combimox Lactating Cow","international_non_proprietary_name_inn_common_name":"amoxicillin;clavulanic acid;Prednisolone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/V/A/061","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/04/2011","european_commission_decision_date":"05/08/2011","first_published_date":"08/12/2011","last_updated_date":"09/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/combimox-lactating-cow"},{"category":"Veterinary","referral_name":"APPM Respipharm","international_non_proprietary_name_inn_common_name":"formaldehyde-inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (serotypes 2, 9 and 11) and one strain of Pasteurella multocida (serotype A)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/839689/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/11/2009","european_commission_decision_date":"27/01/2010","first_published_date":"19/02/2010","last_updated_date":"08/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/appm-respipharm"},{"category":"Veterinary","referral_name":"Nisamox Lactating Cow","international_non_proprietary_name_inn_common_name":"amoxicillin;clavulanic acid;Prednisolone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/V/A/062","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/04/2011","european_commission_decision_date":"05/08/2011","first_published_date":"08/12/2011","last_updated_date":"08/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/nisamox-lactating-cow"},{"category":"Veterinary","referral_name":"Combisyn Lactating Cow","international_non_proprietary_name_inn_common_name":"amoxicillin;clavulanic acid;Prednisolone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/V/A/063","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"06/04/2011","european_commission_decision_date":"05/08/2011","first_published_date":"08/12/2011","last_updated_date":"08/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/combisyn-lactating-cow"},{"category":"Veterinary","referral_name":"Unisol","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/215198/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/01/2009","european_commission_decision_date":"05/05/2009","first_published_date":"29/07/2009","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/unisol"},{"category":"Veterinary","referral_name":"Solacyl","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/209536/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/02/2008","european_commission_decision_date":"17/04/2008","first_published_date":"23/05/2008","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/solacyl"},{"category":"Veterinary","referral_name":"Shotaflor","international_non_proprietary_name_inn_common_name":"florfenicol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/313852/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/05/2009","european_commission_decision_date":"03/08/2009","first_published_date":"02/10/2009","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/shotaflor"},{"category":"Veterinary","referral_name":"Fenflor","international_non_proprietary_name_inn_common_name":"florfenicol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/313849/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/05/2009","european_commission_decision_date":"03/08/2009","first_published_date":"02/10/2009","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/fenflor"},{"category":"Veterinary","referral_name":"Enro-K","international_non_proprietary_name_inn_common_name":"enrofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/214378/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/01/2009","european_commission_decision_date":"05/05/2009","first_published_date":"29/07/2009","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/enro-k"},{"category":"Veterinary","referral_name":"Enurace 50","international_non_proprietary_name_inn_common_name":"ephedrine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/532222/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/04/2007","european_commission_decision_date":"10/07/2007","first_published_date":"15/11/2007","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/enurace-50"},{"category":"Veterinary","referral_name":"Ecomectin 18.7mg/g Oral Paste for Horses","international_non_proprietary_name_inn_common_name":"ivermectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/495339/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"08/11/2007","european_commission_decision_date":"17/01/2008","first_published_date":"20/02/2008","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/ecomectin-187mg-g-oral-paste-horses"},{"category":"Veterinary","referral_name":"Equimectin","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/532271/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/01/2007","european_commission_decision_date":"02/04/2007","first_published_date":"15/11/2007","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/equimectin"},{"category":"Veterinary","referral_name":"Equibactin vet.","international_non_proprietary_name_inn_common_name":"trimethoprim;sulfadiazine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/455918/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/12/2007","european_commission_decision_date":"03/03/2008","first_published_date":"09/10/2008","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/equibactin-vet"},{"category":"Veterinary","referral_name":"Doxyprex 100mg Premix","international_non_proprietary_name_inn_common_name":"doxycycline","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/532206/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/02/2007","european_commission_decision_date":"22/05/2007","first_published_date":"15/11/2007","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxyprex-100mg-premix"},{"category":"Veterinary","referral_name":"Compagel","international_non_proprietary_name_inn_common_name":"heparin sodium;levomenthol;hydroxyethyl salicylate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/459391/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/02/2008","european_commission_decision_date":"02/04/2008","first_published_date":"09/10/2008","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/compagel"},{"category":"Veterinary","referral_name":"Bovilis BVD","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP532090/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/04/2007","european_commission_decision_date":"29/06/2007","first_published_date":"15/11/2007","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/bovilis-bvd"},{"category":"Veterinary","referral_name":"Dolovet Rifen","international_non_proprietary_name_inn_common_name":"ketoprofen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/532160/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/11/2006","european_commission_decision_date":"17/04/2007","first_published_date":"15/11/2007","last_updated_date":"07/12/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/dolovet-rifen"},{"category":"Veterinary","referral_name":"Synulox Lactating Cow","international_non_proprietary_name_inn_common_name":"amoxicillin trihydrate;potassium clavulanate;Prednisolone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/512798/2011","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"07/06/2011","european_commission_decision_date":"20/10/2011","first_published_date":"17/11/2011","last_updated_date":"17/11/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/synulox-lactating-cow"},{"category":"Human","referral_name":"Bufexamac","international_non_proprietary_name_inn_common_name":"bufexamac","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Parfenac  ;Bufal  ;Calmaderm  ;Fansamac  ;Mastu S  ;Parfenoide  ;Proctosan","class":"","reference_number":"EMEA/H/A-107/001260","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/04/2010","european_commission_decision_date":"27/07/2010","first_published_date":"22/04/2010","last_updated_date":"10/11/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bufexamac"},{"category":"Human","referral_name":"Vascace Plus","international_non_proprietary_name_inn_common_name":"cilazapril;hydrochlorothiazide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Co-Inhibace  ;Dynorm Plus  ;Inhibace Plus","class":"","reference_number":"EMEA/H/A-30/001153","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/10/2010","european_commission_decision_date":"21/01/2011","first_published_date":"22/10/2010","last_updated_date":"09/11/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vascace-plus"},{"category":"Human","referral_name":"Ketoprofen topical","international_non_proprietary_name_inn_common_name":"ketoprofen","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Fastum  ;Ketum  ;Orudis","class":"","reference_number":"EMEA/H/A-107/001259","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/07/2010","european_commission_decision_date":"29/11/2010","first_published_date":"22/07/2010","last_updated_date":"28/10/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ketoprofen-topical"},{"category":"Human","referral_name":"Bisphosphonates","international_non_proprietary_name_inn_common_name":"alendronic acid;clodronic acid;etidronic acid;ibandronic acid;neridronic acid;pamidronic acid;risedronic acid;tiludronic acid;zoledronic acid","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Actonel  ;Aredia  ;Bonefos  ;Didronel  ;Fosamax  ;Nerixia  ;Skelid","class":"Bisphosphonates","reference_number":"EMA/288359/2011","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/04/2011","european_commission_decision_date":"13/07/2011","first_published_date":"15/04/2011","last_updated_date":"28/10/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bisphosphonates"},{"category":"Human","referral_name":"Atacand Plus","international_non_proprietary_name_inn_common_name":"candesartan;hydrochlorothiazide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Atacand Zid  ;Blopresid  ;Blopress Comp  ;Blopress Plus  ;CoKenzen  ;Hytacand  ;Parapres Plus  ;Ratacand Plus","class":"","reference_number":"EMEA/H/A-30/001152","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/06/2010","european_commission_decision_date":"16/09/2010","first_published_date":"25/06/2010","last_updated_date":"21/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/atacand-plus"},{"category":"Human","referral_name":"Prevora","international_non_proprietary_name_inn_common_name":"chlorhexidine diacetate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1258","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/09/2010","european_commission_decision_date":"03/12/2010","first_published_date":"24/09/2010","last_updated_date":"20/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/prevora"},{"category":"Human","referral_name":"Losec","international_non_proprietary_name_inn_common_name":"omeprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Antra  ;Logastric  ;Losec Forte  ;Mopral  ;Omeprazen  ;Omeprazole  ;AstraZeneca  ;Zoltum","class":"","reference_number":"EMEA/H/A-30/1001","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/01/2010","european_commission_decision_date":"10/06/2010","first_published_date":"22/01/2010","last_updated_date":"19/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/losec"},{"category":"Human","referral_name":"Norsed Combi D","international_non_proprietary_name_inn_common_name":"risedronate sodium;calcium carbonate;colecalciferol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Actonel Combi D  ;Optinate Plus Ca&D  ;Opticalcio D3","class":"","reference_number":"EMEA/H/A-29/001273","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/06/2010","european_commission_decision_date":"05/10/2010","first_published_date":"25/06/2010","last_updated_date":"13/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/norsed-combi-d"},{"category":"Human","referral_name":"Fortipan Combi D","international_non_proprietary_name_inn_common_name":"risedronate sodium;calcium carbonate;colecalciferol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Actocalcio D3  ;Acrelcombi","class":"","reference_number":"EMEA/H/A-29/001272","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/06/2010","european_commission_decision_date":"05/10/2010","first_published_date":"25/06/2010","last_updated_date":"13/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fortipan-combi-d"},{"category":"Human","referral_name":"Lescol","international_non_proprietary_name_inn_common_name":"fluvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Canef  ;Cardiol  ;Cardiol XL  ;Cranoc  ;Digardil  ;Digaril Prolib  ;Fluvastatin Novartis  ;Fluvastatina  ;Fractal  ;Leposit Prolib  ;Lescol Depot  ;Lescol Exel  ;Lescol LP  ;Lescol MR  ;Lescol Prolib  ;Lescol XL  ;Lipaxan  ;Lipaxin  ;Liposit  ;Locol  ;Lymetel  ;Primesin  ;Vaditon  ;Vaditon Prolib","class":"","reference_number":"EMEA/H/A-30/1078","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2009","european_commission_decision_date":"15/03/2010","first_published_date":"20/11/2009","last_updated_date":"13/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lescol"},{"category":"Human","referral_name":"Kytril","international_non_proprietary_name_inn_common_name":"granisetron","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Kevatril","class":"","reference_number":"EMEA/H/A-30/1155","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2011","european_commission_decision_date":"20/07/2011","first_published_date":"20/05/2011","last_updated_date":"12/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/kytril"},{"category":"Human","referral_name":"Famvir","international_non_proprietary_name_inn_common_name":"famciclovir","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Famciclovir-Sandoz  ;Famciclovir-SB  ;Famciclovir-SB Zoster  ;Famvir Zoster and Oravir","class":"","reference_number":"EMEA/H/A-30/001005","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/04/2010","european_commission_decision_date":"27/07/2010","first_published_date":"23/04/2010","last_updated_date":"09/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/famvir"},{"category":"Human","referral_name":"Clopidogrel Teva","international_non_proprietary_name_inn_common_name":"clopidogrel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1246","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/02/2010","european_commission_decision_date":"04/06/2010","first_published_date":"19/02/2010","last_updated_date":"08/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/clopidogrel-teva"},{"category":"Human","referral_name":"Clopidogrel Orion","international_non_proprietary_name_inn_common_name":"clopidogrel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1247","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/02/2010","european_commission_decision_date":"02/06/2010","first_published_date":"19/02/2010","last_updated_date":"08/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/clopidogrel-orion"},{"category":"Human","referral_name":"Levact","international_non_proprietary_name_inn_common_name":"bendamustine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Ribomustin","class":"","reference_number":"EMEA/H/A-29/1238","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"07/07/2010","first_published_date":"19/03/2010","last_updated_date":"08/09/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/levact"},{"category":"Veterinary","referral_name":"Doxyfar 50%","international_non_proprietary_name_inn_common_name":"doxycycline hyclate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/512470/2011","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"04/05/2011","european_commission_decision_date":"13/07/2011","first_published_date":"23/08/2011","last_updated_date":"24/08/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxyfar-50"},{"category":"Veterinary","referral_name":"Doxycycline 50% WSP","international_non_proprietary_name_inn_common_name":"doxycycline hyclate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/507899/2011","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"04/05/2011","european_commission_decision_date":"13/07/2011","first_published_date":"23/08/2011","last_updated_date":"24/08/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxycycline-50-wsp"},{"category":"Human","referral_name":"Benfluorex","international_non_proprietary_name_inn_common_name":"benfluorex","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/811097/2009 Rev. 1","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"14/06/2010","first_published_date":"18/12/2009","last_updated_date":"27/07/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/benfluorex"},{"category":"Human","referral_name":"Arimidex","international_non_proprietary_name_inn_common_name":"anastrozole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/001263","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/03/2011","european_commission_decision_date":"18/05/2011","first_published_date":"18/03/2011","last_updated_date":"27/07/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/arimidex"},{"category":"Human","referral_name":"Isotretinoin","international_non_proprietary_name_inn_common_name":"isotretinoin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/001276","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/12/2010","european_commission_decision_date":"18/05/2011","first_published_date":"17/12/2010","last_updated_date":"15/07/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/isotretinoin-0"},{"category":"Veterinary","referral_name":"Doxycycline hyclate","international_non_proprietary_name_inn_common_name":"doxycycline hyclate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/190025/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/02/2010","european_commission_decision_date":"14/06/2010","first_published_date":"16/07/2010","last_updated_date":"28/06/2011","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxycycline-hyclate"},{"category":"Human","referral_name":"Myderison","international_non_proprietary_name_inn_common_name":"tolperisone hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/675340/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/10/2009","european_commission_decision_date":"06/08/2010","first_published_date":"23/10/2009","last_updated_date":"16/06/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/myderison"},{"category":"Human","referral_name":"Modified-released oral opioids","international_non_proprietary_name_inn_common_name":"hydromorphone;morphine;oxycodone","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Opioids of the World Health Organization level III scale","reference_number":"EMEA/H/A-31/001232","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/11/2010","european_commission_decision_date":"20/04/2011","first_published_date":"19/11/2010","last_updated_date":"06/06/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/modified-released-oral-opioids"},{"category":"Human","referral_name":"Iodocasein- and thiamine-containing medicinal products","international_non_proprietary_name_inn_common_name":"iodocasein;thiamine nitrate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Antiadiposo","class":"","reference_number":"EMEA/H/A-107","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/10/2009","european_commission_decision_date":"","first_published_date":"27/05/2011","last_updated_date":"27/05/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/iodocasein-thiamine-containing-medicinal-products"},{"category":"Human","referral_name":"Ethirfin","international_non_proprietary_name_inn_common_name":"morphine sulphate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/001248","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/09/2010","european_commission_decision_date":"20/12/2010","first_published_date":"23/07/2010","last_updated_date":"29/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ethirfin"},{"category":"Human","referral_name":"Valproate","international_non_proprietary_name_inn_common_name":"valproic acid;valproate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/1163, EMEA/H/A-6(12)/1147","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/12/2009","european_commission_decision_date":"26/08/2010","first_published_date":"18/12/2009","last_updated_date":"29/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/valproate"},{"category":"Human","referral_name":"Sortis","international_non_proprietary_name_inn_common_name":"atorvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Lipitor  ;Zarator  ;Orbeos  ;Tahor  ;Liprimar  ;Atorvastatin  ;Atorvastatina  ;Edovin  ;Obradon  ;Xarator  ;Torvast  ;Totalip  ;Texzor  ;Cardyl  ;Prevencor","class":"","reference_number":"EMEA/H/A-29 PAD/1255","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"01/07/2010","first_published_date":"27/04/2011","last_updated_date":"27/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sortis-2"},{"category":"Human","referral_name":"Sortis","international_non_proprietary_name_inn_common_name":"atorvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Lipitor  ;Zarator  ;Orbeos  ;Tahor  ;Liprimar  ;Atorvastatin  ;Atorvastatina  ;Edovin  ;Obradon  ;Xarator  ;Torvast  ;Totalip  ;Texzor  ;Cardyl  ;Prevencor","class":"","reference_number":"EMEA/H/A-29 PAD/1254","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"01/07/2010","first_published_date":"27/04/2011","last_updated_date":"27/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sortis-0"},{"category":"Human","referral_name":"Sortis","international_non_proprietary_name_inn_common_name":"atorvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Lipitor  ;Zarator  ;Orbeos  ;Tahor  ;Liprimar  ;Atorvastatin  ;Atorvastatina  ;Edovin  ;Obradon  ;Xarator  ;Torvast  ;Totalip  ;Texzor  ;Cardyl  ;Prevencor","class":"","reference_number":"EMEA/H/A-29 PAD/1253","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"01/07/2010","first_published_date":"27/04/2011","last_updated_date":"27/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sortis-1"},{"category":"Human","referral_name":"Modafinil","international_non_proprietary_name_inn_common_name":"modafinil","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Modasomil  ;Modiodal  ;Provigil  ;Vigil","class":"","reference_number":"EMEA/H/A-31/1186","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/11/2010","european_commission_decision_date":"27/01/2011","first_published_date":"19/11/2010","last_updated_date":"26/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/modafinil"},{"category":"Human","referral_name":"Daivobet","international_non_proprietary_name_inn_common_name":"calcipotriol;betamethasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Dovobet","class":"","reference_number":"EMEA/H/A-30/001266","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/07/2010","european_commission_decision_date":"30/09/2010","first_published_date":"23/07/2010","last_updated_date":"26/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/daivobet"},{"category":"Human","referral_name":"Genotropin","international_non_proprietary_name_inn_common_name":"somatropin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Genotonorm","class":"","reference_number":"EMEA/H/C/A-6(12)/001251","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/06/2010","european_commission_decision_date":"02/09/2010","first_published_date":"25/06/2010","last_updated_date":"26/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/genotropin-0"},{"category":"Human","referral_name":"Octagam","international_non_proprietary_name_inn_common_name":"human normal immunoglobulin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-31/001281","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/04/2011","european_commission_decision_date":"30/05/2011","first_published_date":"14/04/2011","last_updated_date":"26/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/octagam"},{"category":"Human","referral_name":"Dextropropoxyphene","international_non_proprietary_name_inn_common_name":"dextropropoxyphene","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/681374/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/10/2009","european_commission_decision_date":"14/06/2010","first_published_date":"22/10/2009","last_updated_date":"07/04/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/dextropropoxyphene"},{"category":"Human","referral_name":"Atacand","international_non_proprietary_name_inn_common_name":"candesartan","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Amias  ;Blopress  ;Kenzen  ;Racanda  ;Ratacand  ;Parapres","class":"","reference_number":"EMEA/H/A-30/001150","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"13/07/2010","first_published_date":"19/03/2010","last_updated_date":"16/03/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/atacand"},{"category":"Human","referral_name":"Pantoprazole Bluefish","international_non_proprietary_name_inn_common_name":"pantoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Pantecta","class":"","reference_number":"EMEA/H/A-29/1216","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2009","european_commission_decision_date":"30/03/2010","first_published_date":"20/11/2009","last_updated_date":"09/03/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pantoprazole-bluefish"},{"category":"Human","referral_name":"Sibutramine","international_non_proprietary_name_inn_common_name":"sibutramine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMA/808179/2009, EMA/H/A-107/1256","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2010","european_commission_decision_date":"06/08/2010","first_published_date":"21/01/2010","last_updated_date":"09/03/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sibutramine"},{"category":"Human","referral_name":"Pantoprazole Olinka (EMEA/H/A-29/1170)","international_non_proprietary_name_inn_common_name":"pantoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Pantecta","class":"","reference_number":"EMEA/H/A-29/1170","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2009","european_commission_decision_date":"30/03/2010","first_published_date":"20/11/2009","last_updated_date":"08/03/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pantoprazole-olinka-emea-h-29-1170"},{"category":"Human","referral_name":"Pantoprazole Olinka (EMEA/H/A-29/1169)","international_non_proprietary_name_inn_common_name":"pantoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Pantecta","class":"","reference_number":"EMEA/H/A-29/1169","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/11/2009","european_commission_decision_date":"30/03/2010","first_published_date":"20/11/2009","last_updated_date":"08/03/2011","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pantoprazole-olinka-emea-h-29-1169"},{"category":"Veterinary","referral_name":"Tildren","international_non_proprietary_name_inn_common_name":"tiludronic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/193771/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/07/2010","european_commission_decision_date":"22/07/2013","first_published_date":"14/12/2010","last_updated_date":"14/12/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/tildren"},{"category":"Human","referral_name":"Xalatan","international_non_proprietary_name_inn_common_name":"latanoprost","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Latanoprost Pharmacia & Upjohn  ;Xalatan 50 mikrogramov/ml kaplijice za oko, raztopina","class":"","reference_number":"EMEA/H/A-29 PAE/1270","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/07/2010","european_commission_decision_date":"15/10/2010","first_published_date":"08/12/2010","last_updated_date":"08/12/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/xalatan"},{"category":"Human","referral_name":"Gadolinium-containing contrast agents","international_non_proprietary_name_inn_common_name":"gadodiamide;gadopentetic acid;gadobenic acid;gadoxetic acid;gadoteridol;gadobutrol;gadoteric acid","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Omniscan  ;Magnevist  ;Magnegita  ;Gado-MRT ratiopharm  ;Primovist  ;MultiHance  ;Dotarem  ;ProHance  ;Gadovist","class":"","reference_number":"EMEA/H/A-31/1097","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/03/2010","european_commission_decision_date":"01/07/2010","first_published_date":"20/11/2009","last_updated_date":"06/12/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents-0"},{"category":"Human","referral_name":"Seroquel XR","international_non_proprietary_name_inn_common_name":"quetiapine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(13) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/6(13)/001188","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/04/2010","european_commission_decision_date":"26/08/2010","first_published_date":"23/04/2010","last_updated_date":"19/11/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-xr"},{"category":"Veterinary","referral_name":"Pregsure BVD","international_non_proprietary_name_inn_common_name":"inactivated Bovine Viral Diarrhoea (BVD) type 1 virus, cytopathogenic strain 5960","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMA/434219/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/07/2010","european_commission_decision_date":"07/10/2010","first_published_date":"26/08/2010","last_updated_date":"22/10/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/pregsure-bvd"},{"category":"Human","referral_name":"Fortum","international_non_proprietary_name_inn_common_name":"ceftazidime","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Cefortam  ;Glazidim  ;Panzim  ;Solvetan","class":"","reference_number":"EMEA/H/A-30/001006","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/10/2010","european_commission_decision_date":"13/01/2011","first_published_date":"22/10/2010","last_updated_date":"22/10/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fortum"},{"category":"Human","referral_name":"Vascace","international_non_proprietary_name_inn_common_name":"cilazapril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Dynorm  ;Inhibace  ;Inibace  ;Justor","class":"","reference_number":"EMEA/H/A-30/001151","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/04/2010","european_commission_decision_date":"07/07/2010","first_published_date":"23/04/2010","last_updated_date":"19/10/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vascace"},{"category":"Veterinary","referral_name":"Poulvac Bursa Plus","international_non_proprietary_name_inn_common_name":"live infectious bursal disease virus, strain V877","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/698942/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/01/2010","european_commission_decision_date":"25/01/2010","first_published_date":"07/10/2010","last_updated_date":"07/10/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/poulvac-bursa-plus"},{"category":"Human","referral_name":"Escitalopram","international_non_proprietary_name_inn_common_name":"escitalopram","current_status":"CHMP opinion","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1231","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/02/2010","european_commission_decision_date":"","first_published_date":"19/02/2010","last_updated_date":"29/09/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/escitalopram"},{"category":"Human","referral_name":"Methylphenidate","international_non_proprietary_name_inn_common_name":"methylphenidate","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/658285/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/01/2009","european_commission_decision_date":"27/05/2009","first_published_date":"22/01/2009","last_updated_date":"22/09/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate"},{"category":"Veterinary","referral_name":"Porcilis M Hyo","international_non_proprietary_name_inn_common_name":"inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMA/345914/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2010","european_commission_decision_date":"16/08/2010","first_published_date":"18/08/2010","last_updated_date":"18/08/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/porcilis-m-hyo"},{"category":"Veterinary","referral_name":"Porcilis PRRS","international_non_proprietary_name_inn_common_name":"live attenuated PRRS virus strain DV","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMA/344861/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/05/2010","european_commission_decision_date":"16/08/2010","first_published_date":"18/08/2010","last_updated_date":"18/08/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/porcilis-prrs"},{"category":"Veterinary","referral_name":"Tiamutin","international_non_proprietary_name_inn_common_name":"tiamulin hydrogen fumarate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"V-A-042","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/03/2010","european_commission_decision_date":"27/07/2010","first_published_date":"21/07/2010","last_updated_date":"30/07/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/tiamutin"},{"category":"Human","referral_name":"Teicoplanin Hospira","international_non_proprietary_name_inn_common_name":"teicoplanin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1084","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/10/2009","european_commission_decision_date":"29/01/2010","first_published_date":"23/10/2009","last_updated_date":"27/07/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/teicoplanin-hospira"},{"category":"Veterinary","referral_name":"Quinolones","international_non_proprietary_name_inn_common_name":"enrofloxacin;marbofloxacin;danofloxacin mesilate;danofloxacin;flumequine;amoxicillin;difloxacin hydrochloride;oxolinic acid;colistin sulfate;amoxicillin trihydrate;difloxacin;bromhexine;oxytetracycline hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/186029/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/03/2010","european_commission_decision_date":"01/07/2010","first_published_date":"16/07/2010","last_updated_date":"16/07/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/quinolones"},{"category":"Veterinary","referral_name":"Colistin","international_non_proprietary_name_inn_common_name":"colistin sulfate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/189829/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"10/02/2010","european_commission_decision_date":"10/06/2010","first_published_date":"24/06/2010","last_updated_date":"24/06/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/colistin"},{"category":"Human","referral_name":"Diovan","international_non_proprietary_name_inn_common_name":"valsartan","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Angiosan  ;Diovane  ;Tareg  ;Cordinate  ;Provas  ;Dalzad  ;Rixil  ;Kalpress Cardio  ;Diovan Cardio  ;Miten Cardio  ;Valsartan Novartis  ;Kalpress  ;Miten","class":"","reference_number":"EMEA/H/A/-29 PAD/1220","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2009","european_commission_decision_date":"19/04/2010","first_published_date":"31/05/2010","last_updated_date":"31/05/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diovan"},{"category":"Human","referral_name":"Diovan","international_non_proprietary_name_inn_common_name":"valsartan","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Angiosan  ;Diovane  ;Tareg  ;Cordinate  ;Provas  ;Dalzad  ;Rixil  ;Kalpress Cardio  ;Diovan Cardio  ;Miten Cardio  ;Valsartan Novartis","class":"","reference_number":"EMEA/H/A-29 PAD/1219","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/12/2009","european_commission_decision_date":"19/04/2010","first_published_date":"31/05/2010","last_updated_date":"31/05/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diovan-1"},{"category":"Human","referral_name":"Arimidex","international_non_proprietary_name_inn_common_name":"anastrozole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29 paediatrics","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/311974/2010","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"","european_commission_decision_date":"06/11/2009","first_published_date":"28/05/2010","last_updated_date":"28/05/2010","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/arimidex-0"},{"category":"Veterinary","referral_name":"Cevazuril","international_non_proprietary_name_inn_common_name":"toltrazuril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMA/214243/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/12/2009","european_commission_decision_date":"26/03/2010","first_published_date":"05/05/2010","last_updated_date":"05/05/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/cevazuril"},{"category":"Veterinary","referral_name":"Pharmasin","international_non_proprietary_name_inn_common_name":"tylosin tartrate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"macrolide antibiotic","reference_number":"EMA/214243/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/03/2009","european_commission_decision_date":"08/01/2010","first_published_date":"30/04/2010","last_updated_date":"30/04/2010","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/pharmasin"},{"category":"Veterinary","referral_name":"Pulmotil AC","international_non_proprietary_name_inn_common_name":"tilmicosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/608943/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2009","european_commission_decision_date":"15/10/2010","first_published_date":"22/12/2009","last_updated_date":"22/12/2009","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/pulmotil-ac"},{"category":"Veterinary","referral_name":"Pulmotil Premix","international_non_proprietary_name_inn_common_name":"tilmicosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/608931/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2009","european_commission_decision_date":"15/10/2009","first_published_date":"22/12/2009","last_updated_date":"22/12/2009","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/pulmotil-premix"},{"category":"Human","referral_name":"Topamax","international_non_proprietary_name_inn_common_name":"topiramate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/239500/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/06/2009","european_commission_decision_date":"01/10/2009","first_published_date":"15/12/2009","last_updated_date":"15/12/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/topamax"},{"category":"Human","referral_name":"Loratadine Sandoz 10","international_non_proprietary_name_inn_common_name":"loratadine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1060","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"29/05/2009","european_commission_decision_date":"06/08/2009","first_published_date":"12/12/2009","last_updated_date":"12/12/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/loratadine-sandoz-10"},{"category":"Human","referral_name":"Meronem","international_non_proprietary_name_inn_common_name":"meropenem","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-30/1003","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/07/2009","european_commission_decision_date":"15/10/2009","first_published_date":"12/12/2009","last_updated_date":"12/12/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/meronem"},{"category":"Human","referral_name":"Extraneal","international_non_proprietary_name_inn_common_name":"icodextrin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/683039/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/10/2009","european_commission_decision_date":"20/01/2010","first_published_date":"27/10/2009","last_updated_date":"27/10/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/extraneal"},{"category":"Veterinary","referral_name":"Ivermectin","international_non_proprietary_name_inn_common_name":"ivermectin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/471056/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"05/06/2009","european_commission_decision_date":"01/10/2009","first_published_date":"26/10/2009","last_updated_date":"26/10/2009","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/ivermectin"},{"category":"Human","referral_name":"Rapinyl","international_non_proprietary_name_inn_common_name":"fentanyl citrate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/336144/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"11/09/2008","first_published_date":"25/09/2009","last_updated_date":"25/09/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/rapinyl"},{"category":"Human","referral_name":"Prokanazol","international_non_proprietary_name_inn_common_name":"itraconazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/454809/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/04/2009","european_commission_decision_date":"14/07/2009","first_published_date":"06/08/2009","last_updated_date":"06/08/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/prokanazol"},{"category":"Human","referral_name":"Octegra","international_non_proprietary_name_inn_common_name":"moxifloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/150525/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/03/2009","european_commission_decision_date":"02/10/2009","first_published_date":"25/06/2009","last_updated_date":"25/06/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/octegra"},{"category":"Human","referral_name":"Budesonide Sandoz","international_non_proprietary_name_inn_common_name":"budesonide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1062","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/02/2009","european_commission_decision_date":"07/05/2009","first_published_date":"25/06/2009","last_updated_date":"25/06/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/budesonide-sandoz"},{"category":"Human","referral_name":"Fentrix","international_non_proprietary_name_inn_common_name":"fentanyl","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/393579/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/06/2009","european_commission_decision_date":"06/10/2009","first_published_date":"25/06/2009","last_updated_date":"25/06/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fentrix"},{"category":"Human","referral_name":"Gluscan 500","international_non_proprietary_name_inn_common_name":"fludeoxyglucose (18F)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1123","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2009","european_commission_decision_date":"29/05/2009","first_published_date":"23/06/2009","last_updated_date":"23/06/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gluscan-500"},{"category":"Veterinary","referral_name":"Alpha2-adrenoreceptor agonists","international_non_proprietary_name_inn_common_name":"xylazine;medetomidine;detomidine;romifidine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/681319/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/11/2008","european_commission_decision_date":"30/04/2009","first_published_date":"22/06/2009","last_updated_date":"22/06/2009","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/alpha2-adrenoreceptor-agonists"},{"category":"Human","referral_name":"Diovan Comp","international_non_proprietary_name_inn_common_name":"valsartan;hydrochlorothiazide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/113861/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/03/2009","european_commission_decision_date":"26/05/2009","first_published_date":"11/06/2009","last_updated_date":"11/06/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diovan-comp"},{"category":"Human","referral_name":"Zoloft","international_non_proprietary_name_inn_common_name":"sertraline","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/634674/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/12/2008","european_commission_decision_date":"27/03/2009","first_published_date":"07/05/2009","last_updated_date":"07/05/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zoloft"},{"category":"Human","referral_name":"Tritace","international_non_proprietary_name_inn_common_name":"ramipril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/233264/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/12/2008","european_commission_decision_date":"06/03/2009","first_published_date":"24/04/2009","last_updated_date":"24/04/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tritace"},{"category":"Human","referral_name":"Tritazide","international_non_proprietary_name_inn_common_name":"ramipril;hydrochlorothiazide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/204584/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/12/2008","european_commission_decision_date":"06/03/2009","first_published_date":"14/04/2009","last_updated_date":"14/04/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/tritazide"},{"category":"Human","referral_name":"Bleomycin","international_non_proprietary_name_inn_common_name":"bleomycin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/173797/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2008","european_commission_decision_date":"12/03/2009","first_published_date":"31/03/2009","last_updated_date":"31/03/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bleomycin"},{"category":"Human","referral_name":"Sanohex","international_non_proprietary_name_inn_common_name":"salbutamol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/194790/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2008","european_commission_decision_date":"12/03/2009","first_published_date":"30/03/2009","last_updated_date":"30/03/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sanohex"},{"category":"Human","referral_name":"Sabumalin","international_non_proprietary_name_inn_common_name":"salbutamol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/194784/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2008","european_commission_decision_date":"12/03/2009","first_published_date":"30/03/2009","last_updated_date":"30/03/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sabumalin"},{"category":"Human","referral_name":"Uman Big","international_non_proprietary_name_inn_common_name":"human hepatitis B immunoglobulin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/173455/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/2008","european_commission_decision_date":"06/03/2009","first_published_date":"21/03/2009","last_updated_date":"21/03/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/uman-big"},{"category":"Human","referral_name":"Diovan","international_non_proprietary_name_inn_common_name":"valsartan","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/137577/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2008","european_commission_decision_date":"16/02/2009","first_published_date":"13/03/2009","last_updated_date":"13/03/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/diovan-0"},{"category":"Human","referral_name":"Implanon","international_non_proprietary_name_inn_common_name":"etonogestrel","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/85200/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2008","european_commission_decision_date":"06/02/2009","first_published_date":"27/02/2009","last_updated_date":"27/02/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/implanon"},{"category":"Human","referral_name":"Trimetadizine ratiopharm","international_non_proprietary_name_inn_common_name":"trimetazidine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/45404/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/01/2009","european_commission_decision_date":"19/03/2009","first_published_date":"22/01/2009","last_updated_date":"22/01/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/trimetadizine-ratiopharm"},{"category":"Human","referral_name":"Mephatrim","international_non_proprietary_name_inn_common_name":"trimetazidine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/45405/2009","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/01/2009","european_commission_decision_date":"19/03/2009","first_published_date":"22/01/2009","last_updated_date":"22/01/2009","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/mephatrim"},{"category":"Human","referral_name":"Efexor depot","international_non_proprietary_name_inn_common_name":"venlafaxine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/384876/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"28/11/2008","first_published_date":"20/12/2008","last_updated_date":"20/12/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/efexor-depot"},{"category":"Human","referral_name":"Lisonorm","international_non_proprietary_name_inn_common_name":"lisinopril;amlodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/633842/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/07/2008","european_commission_decision_date":"12/11/2008","first_published_date":"18/12/2008","last_updated_date":"18/12/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lisonorm"},{"category":"Human","referral_name":"Efexor","international_non_proprietary_name_inn_common_name":"venlafaxine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/384875/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"28/11/2008","first_published_date":"18/12/2008","last_updated_date":"18/12/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/efexor"},{"category":"Human","referral_name":"Arcoxia","international_non_proprietary_name_inn_common_name":"etoricoxib","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/438258/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"09/09/2008","first_published_date":"21/11/2008","last_updated_date":"21/11/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/arcoxia"},{"category":"Human","referral_name":"Etoricoxib","international_non_proprietary_name_inn_common_name":"etoricoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/329177/2008, CHMP/542169/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"","first_published_date":"21/11/2008","last_updated_date":"21/11/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib"},{"category":"Veterinary","referral_name":"Sodium Salicylate","international_non_proprietary_name_inn_common_name":"sodium salicylate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/436209/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2008","european_commission_decision_date":"26/09/2008","first_published_date":"19/11/2008","last_updated_date":"19/11/2008","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/sodium-salicylate"},{"category":"Human","referral_name":"Risperdal","international_non_proprietary_name_inn_common_name":"risperidone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/384877/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"07/10/2008","first_published_date":"13/11/2008","last_updated_date":"13/11/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/risperdal"},{"category":"Human","referral_name":"Ciprofloxacin Bayer","international_non_proprietary_name_inn_common_name":"ciprofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/384874/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"07/10/2008","first_published_date":"23/10/2008","last_updated_date":"23/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-bayer"},{"category":"Human","referral_name":"Risperdal Consta","international_non_proprietary_name_inn_common_name":"risperidone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/384879/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"07/10/2008","first_published_date":"22/10/2008","last_updated_date":"22/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/risperdal-consta"},{"category":"Human","referral_name":"Zyrtec","international_non_proprietary_name_inn_common_name":"cetirizine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/296484/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"30/05/2008","european_commission_decision_date":"06/10/2008","first_published_date":"16/10/2008","last_updated_date":"16/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zyrtec"},{"category":"Veterinary","referral_name":"Suramox 15 % LA and its associated name Stabox 15 % LA","international_non_proprietary_name_inn_common_name":"amoxicillin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/344321/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/06/2008","european_commission_decision_date":"05/09/2008","first_published_date":"15/10/2008","last_updated_date":"15/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/suramox-15-la-its-associated-name-stabox-15-la"},{"category":"Human","referral_name":"Avelox","international_non_proprietary_name_inn_common_name":"moxifloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/524251/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2008","european_commission_decision_date":"14/07/2008","first_published_date":"13/10/2008","last_updated_date":"13/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/avelox"},{"category":"Human","referral_name":"Octegra","international_non_proprietary_name_inn_common_name":"moxifloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/524284/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2008","european_commission_decision_date":"14/07/2008","first_published_date":"13/10/2008","last_updated_date":"13/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/octegra-0"},{"category":"Human","referral_name":"Actira","international_non_proprietary_name_inn_common_name":"moxifloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/524135/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2008","european_commission_decision_date":"14/07/2008","first_published_date":"13/10/2008","last_updated_date":"13/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/actira"},{"category":"Human","referral_name":"Remeron","international_non_proprietary_name_inn_common_name":"mirtazapine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/336158/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"15/09/2008","first_published_date":"13/10/2008","last_updated_date":"13/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/remeron"},{"category":"Veterinary","referral_name":"Tribrissen","international_non_proprietary_name_inn_common_name":"trimethoprim;sulfadiazine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CVMP/457286/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"12/12/2007","european_commission_decision_date":"11/03/2008","first_published_date":"09/10/2008","last_updated_date":"09/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/tribrissen"},{"category":"Veterinary","referral_name":"Methoxasol-T","international_non_proprietary_name_inn_common_name":"trimethoprim;sulfamethoxazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/458933/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"11/10/2007","european_commission_decision_date":"11/01/2008","first_published_date":"09/10/2008","last_updated_date":"09/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/methoxasol-t"},{"category":"Human","referral_name":"Gemzar","international_non_proprietary_name_inn_common_name":"gemcitabine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/512295/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"23/09/2008","first_published_date":"06/10/2008","last_updated_date":"06/10/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gemzar"},{"category":"Human","referral_name":"Activelle","international_non_proprietary_name_inn_common_name":"estradiol;norethisterone acetate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/336151/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"11/09/2008","first_published_date":"25/09/2008","last_updated_date":"25/09/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/activelle"},{"category":"Human","referral_name":"Cozaar","international_non_proprietary_name_inn_common_name":"losartan","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/495795/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/04/2008","european_commission_decision_date":"03/09/2008","first_published_date":"25/09/2008","last_updated_date":"25/09/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cozaar"},{"category":"Human","referral_name":"Cozaar Comp","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/495840/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/04/2008","european_commission_decision_date":"03/09/2008","first_published_date":"25/09/2008","last_updated_date":"25/09/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cozaar-comp"},{"category":"Human","referral_name":"Lamictal","international_non_proprietary_name_inn_common_name":"lamotrigine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/212114/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/04/2008","european_commission_decision_date":"23/07/2008","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lamictal"},{"category":"Human","referral_name":"Oracea","international_non_proprietary_name_inn_common_name":"doxycycline monohydrate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/428671/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/04/2008","european_commission_decision_date":"22/07/2008","first_published_date":"21/08/2008","last_updated_date":"21/08/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/oracea"},{"category":"Human","referral_name":"Singulair","international_non_proprietary_name_inn_common_name":"montelukast","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/212107/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/04/2008","european_commission_decision_date":"11/07/2008","first_published_date":"05/08/2008","last_updated_date":"05/08/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/singulair"},{"category":"Human","referral_name":"Alvesco","international_non_proprietary_name_inn_common_name":"ciclesonide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/151554/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2008","european_commission_decision_date":"11/07/2008","first_published_date":"05/08/2008","last_updated_date":"05/08/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/alvesco"},{"category":"Veterinary","referral_name":"Toltrazuril","international_non_proprietary_name_inn_common_name":"toltrazuril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"EMEA/402698/2008","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/07/2008","european_commission_decision_date":"26/09/2008","first_published_date":"26/07/2008","last_updated_date":"26/07/2008","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/toltrazuril"},{"category":"Human","referral_name":"Moxifloxacin","international_non_proprietary_name_inn_common_name":"moxifloxacin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Avalox  ;Avelox","class":"","reference_number":"CHMP/380454/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"24/10/2008","first_published_date":"24/07/2008","last_updated_date":"24/07/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/moxifloxacin"},{"category":"Human","referral_name":"Norfloxacin","international_non_proprietary_name_inn_common_name":"norfloxacin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/262776/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2008","european_commission_decision_date":"19/11/2008","first_published_date":"29/08/2006","last_updated_date":"24/07/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/norfloxacin"},{"category":"Human","referral_name":"Belanette","international_non_proprietary_name_inn_common_name":"drospirenone;ethinyl estradiol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 5(11) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/332403/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/12/2007","european_commission_decision_date":"17/06/2008","first_published_date":"03/07/2008","last_updated_date":"03/07/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/belanette"},{"category":"Human","referral_name":"Yasminelle","international_non_proprietary_name_inn_common_name":"drospirenone;ethinylestradiol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 5(11) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/40502/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/12/2007","european_commission_decision_date":"17/06/2008","first_published_date":"03/07/2008","last_updated_date":"03/07/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/yasminelle"},{"category":"Human","referral_name":"Ergot-derived dopamine agonists","international_non_proprietary_name_inn_common_name":"bromocriptine;cabergoline;dihydroergocryptine;lisuride;pergolide","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/319054/08","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2008","european_commission_decision_date":"","first_published_date":"26/06/2008","last_updated_date":"26/06/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ergot-derived-dopamine-agonists"},{"category":"Human","referral_name":"Menitorix","international_non_proprietary_name_inn_common_name":"haemophilus type b and Meningococcal group C conjugate vaccine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/498198/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/11/2007","european_commission_decision_date":"01/04/2008","first_published_date":"18/04/2008","last_updated_date":"18/04/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/menitorix"},{"category":"Human","referral_name":"Ciprofloxacin Nycomed","international_non_proprietary_name_inn_common_name":"ciprofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/350278/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/11/2006","european_commission_decision_date":"18/01/2008","first_published_date":"18/02/2008","last_updated_date":"18/02/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-nycomed"},{"category":"Human","referral_name":"Xeomin","international_non_proprietary_name_inn_common_name":"clostridium botulinum neurotoxin type A","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/350251/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2007","european_commission_decision_date":"24/10/2007","first_published_date":"08/02/2008","last_updated_date":"08/02/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/xeomin"},{"category":"Human","referral_name":"Bicaluplex","international_non_proprietary_name_inn_common_name":"bicalutamide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/433691/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/09/2007","european_commission_decision_date":"22/11/2007","first_published_date":"07/02/2008","last_updated_date":"07/02/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bicaluplex"},{"category":"Human","referral_name":"Piroxicam","international_non_proprietary_name_inn_common_name":"piroxicam","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/380917/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/06/2007","european_commission_decision_date":"07/09/2007","first_published_date":"31/01/2008","last_updated_date":"31/01/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/piroxicam"},{"category":"Human","referral_name":"Agreal","international_non_proprietary_name_inn_common_name":"veralipride","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/432352/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2007","european_commission_decision_date":"01/10/2007","first_published_date":"07/01/2008","last_updated_date":"07/01/2008","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/agreal"},{"category":"Human","referral_name":"Fentanyl-ratiopharm TTS","international_non_proprietary_name_inn_common_name":"fentanyl","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/331678/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2007","european_commission_decision_date":"23/10/2007","first_published_date":"14/12/2007","last_updated_date":"14/12/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fentanyl-ratiopharm-tts"},{"category":"Human","referral_name":"Lansoprazole","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/283378/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/06/2007","european_commission_decision_date":"18/09/2007","first_published_date":"14/12/2007","last_updated_date":"14/12/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazole"},{"category":"Human","referral_name":"Fentanyl-ratiopharm Matrixpflaster","international_non_proprietary_name_inn_common_name":"fentanyl","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/338591/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/07/2007","european_commission_decision_date":"23/10/2007","first_published_date":"14/12/2007","last_updated_date":"14/12/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fentanyl-ratiopharm-matrixpflaster"},{"category":"Human","referral_name":"Lumiracoxib","international_non_proprietary_name_inn_common_name":"lumiracoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Prexige","class":"","reference_number":"EMEA/H/A-107","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2007","european_commission_decision_date":"","first_published_date":"14/12/2007","last_updated_date":"14/12/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lumiracoxib"},{"category":"Human","referral_name":"Aprotinin","international_non_proprietary_name_inn_common_name":"aprotinin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Trasylol","class":"","reference_number":"EMEA/533599/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/11/2007","european_commission_decision_date":"15/02/2008","first_published_date":"22/11/2007","last_updated_date":"22/11/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/aprotinin"},{"category":"Human","referral_name":"Carisoprodol","international_non_proprietary_name_inn_common_name":"carisoprodol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Somadril","class":"","reference_number":"CHMP/520140/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/11/2007","european_commission_decision_date":"05/02/2008","first_published_date":"16/11/2007","last_updated_date":"16/11/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/carisoprodol"},{"category":"Veterinary","referral_name":"Suvaxyn Parvo/E","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/532267/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/01/2007","european_commission_decision_date":"17/04/2007","first_published_date":"15/11/2007","last_updated_date":"15/11/2007","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/suvaxyn-parvo-e"},{"category":"Veterinary","referral_name":"Suvaxyn Ery","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CVMP/532233/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/01/2007","european_commission_decision_date":"19/04/2007","first_published_date":"15/11/2007","last_updated_date":"15/11/2007","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/suvaxyn-ery"},{"category":"Human","referral_name":"Gadograf, Gadovist","international_non_proprietary_name_inn_common_name":"gadobutrol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/508212/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/11/2006","european_commission_decision_date":"13/04/2007","first_published_date":"09/11/2007","last_updated_date":"09/11/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/gadograf-gadovist"},{"category":"Human","referral_name":"Clobutinol","international_non_proprietary_name_inn_common_name":"clobutinol","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Silomat","class":"","reference_number":"CHMP/471052/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/10/2007","european_commission_decision_date":"30/11/2007","first_published_date":"19/10/2007","last_updated_date":"19/10/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/clobutinol"},{"category":"Human","referral_name":"Bicalutamide 150 mg","international_non_proprietary_name_inn_common_name":"bicalutamide","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/378451/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/05/2007","european_commission_decision_date":"03/09/2007","first_published_date":"03/10/2007","last_updated_date":"03/10/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bicalutamide-150-mg"},{"category":"Human","referral_name":"Xefo","international_non_proprietary_name_inn_common_name":"lornoxicam","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/144030/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/02/2007","european_commission_decision_date":"29/05/2007","first_published_date":"28/09/2007","last_updated_date":"28/09/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/xefo"},{"category":"Human","referral_name":"Cefuroximaxetil","international_non_proprietary_name_inn_common_name":"cefuroxime (as axetil)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/248862/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/04/2007","european_commission_decision_date":"22/08/2007","first_published_date":"24/09/2007","last_updated_date":"24/09/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cefuroximaxetil"},{"category":"Human","referral_name":"Nimesulide","international_non_proprietary_name_inn_common_name":"nimesulide","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 107 procedures (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"Aulin  ;Nimed","class":"","reference_number":"CHMP/430988/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/09/2007","european_commission_decision_date":"16/10/2009","first_published_date":"21/09/2007","last_updated_date":"21/09/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide"},{"category":"Human","referral_name":"Vantas","international_non_proprietary_name_inn_common_name":"histrelin acetate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/247760/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/05/2007","european_commission_decision_date":"30/07/2007","first_published_date":"06/09/2007","last_updated_date":"06/09/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vantas"},{"category":"Human","referral_name":"Ciprofloxacin Hikma","international_non_proprietary_name_inn_common_name":"ciprofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/75066/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/01/2007","european_commission_decision_date":"11/06/2007","first_published_date":"06/09/2007","last_updated_date":"06/09/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-hikma"},{"category":"Human","referral_name":"Alendronate HEXAL","international_non_proprietary_name_inn_common_name":"alendronic acid (as sodium alendronate trihydrate)","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/75285/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/01/2007","european_commission_decision_date":"13/04/2007","first_published_date":"20/08/2007","last_updated_date":"20/08/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/alendronate-hexal"},{"category":"Veterinary","referral_name":"Suramox","international_non_proprietary_name_inn_common_name":"amoxicillin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CVMP/301122/07","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"14/03/2007","european_commission_decision_date":"13/06/2007","first_published_date":"25/07/2007","last_updated_date":"25/07/2007","referral_url":"https://www.ema.europa.eu/en/medicines/veterinary/referrals/suramox"},{"category":"Human","referral_name":"Seretide Evohaler","international_non_proprietary_name_inn_common_name":"salmeterol;fluticasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(13) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/306351/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/04/2006","european_commission_decision_date":"04/07/2006","first_published_date":"14/07/2007","last_updated_date":"14/07/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/seretide-evohaler"},{"category":"Human","referral_name":"Viani Evohaler","international_non_proprietary_name_inn_common_name":"salmeterol;fluticasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(13) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/306455/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/04/2006","european_commission_decision_date":"04/07/2006","first_published_date":"14/07/2007","last_updated_date":"14/07/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/viani-evohaler"},{"category":"Human","referral_name":"Seretide Diskus","international_non_proprietary_name_inn_common_name":"salmeterol;fluticasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(13) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/306065/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/04/2006","european_commission_decision_date":"04/07/2006","first_published_date":"14/07/2007","last_updated_date":"14/07/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/seretide-diskus"},{"category":"Human","referral_name":"Betavert N","international_non_proprietary_name_inn_common_name":"betahistine dihydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/H/A-29/1094","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2009","european_commission_decision_date":"02/06/2009","first_published_date":"01/07/2007","last_updated_date":"01/07/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/betavert-n"},{"category":"Human","referral_name":"Ciprofloxacin Kabi","international_non_proprietary_name_inn_common_name":"ciprofloxacin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/515890/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/11/2006","european_commission_decision_date":"24/01/2007","first_published_date":"06/02/2007","last_updated_date":"06/02/2007","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-kabi"},{"category":"Human","referral_name":"Agopton","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/407636/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/09/2006","european_commission_decision_date":"13/12/2006","first_published_date":"20/12/2006","last_updated_date":"20/12/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/agopton"},{"category":"Human","referral_name":"Glucomed","international_non_proprietary_name_inn_common_name":"glucosamine hydrochloride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/405628/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/09/2006","european_commission_decision_date":"13/12/2006","first_published_date":"20/12/2006","last_updated_date":"20/12/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/glucomed"},{"category":"Human","referral_name":"Sortis","international_non_proprietary_name_inn_common_name":"atorvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/477258/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/03/2006","european_commission_decision_date":"22/05/2006","first_published_date":"09/12/2006","last_updated_date":"09/12/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sortis"},{"category":"Human","referral_name":"Doxagamma 4mg","international_non_proprietary_name_inn_common_name":"doxazosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/423308/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/06/2006","european_commission_decision_date":"11/10/2006","first_published_date":"11/10/2006","last_updated_date":"11/10/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/doxagamma-4mg"},{"category":"Human","referral_name":"Doxazosin \"Winthrop\" 4mg","international_non_proprietary_name_inn_common_name":"doxazosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/423591/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/06/2006","european_commission_decision_date":"11/10/2006","first_published_date":"11/10/2006","last_updated_date":"11/10/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/doxazosin-winthrop-4mg"},{"category":"Human","referral_name":"Cardoreg 4mg","international_non_proprietary_name_inn_common_name":"doxazosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/422351/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/06/2006","european_commission_decision_date":"11/10/2006","first_published_date":"11/10/2006","last_updated_date":"11/10/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cardoreg-4mg"},{"category":"Human","referral_name":"Doxazosin Retard \"Arrow\" 4 mg","international_non_proprietary_name_inn_common_name":"doxazosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/423796/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/06/2006","european_commission_decision_date":"11/10/2006","first_published_date":"11/10/2006","last_updated_date":"11/10/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/doxazosin-retard-arrow-4-mg"},{"category":"Human","referral_name":"Doxastad 4 mg","international_non_proprietary_name_inn_common_name":"doxazosin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/423384/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"28/06/2006","european_commission_decision_date":"11/10/2006","first_published_date":"11/10/2006","last_updated_date":"11/10/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/doxastad-4-mg"},{"category":"Human","referral_name":"Neurontin","international_non_proprietary_name_inn_common_name":"gabapentin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/142335/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"01/06/2006","european_commission_decision_date":"04/08/2006","first_published_date":"06/09/2006","last_updated_date":"06/09/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/neurontin"},{"category":"Human","referral_name":"Prozac","international_non_proprietary_name_inn_common_name":"fluoxetine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/46089/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"01/06/2006","european_commission_decision_date":"21/08/2006","first_published_date":"05/09/2006","last_updated_date":"05/09/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/prozac"},{"category":"Human","referral_name":"Ceftriaxone Tyrol Pharma","international_non_proprietary_name_inn_common_name":"rabbit","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/212746/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"01/06/2006","european_commission_decision_date":"21/08/2006","first_published_date":"30/08/2006","last_updated_date":"30/08/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ceftriaxone-tyrol-pharma"},{"category":"Human","referral_name":"Elidel","international_non_proprietary_name_inn_common_name":"pimecrolimus","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/80270/06, CHMP/262776/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/03/2006","european_commission_decision_date":"","first_published_date":"29/08/2006","last_updated_date":"29/08/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/elidel"},{"category":"Human","referral_name":"Viani Diskus","international_non_proprietary_name_inn_common_name":"salmeterol;fluticasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(13) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/306421/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/04/2006","european_commission_decision_date":"04/07/2006","first_published_date":"14/07/2006","last_updated_date":"14/07/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/viani-diskus"},{"category":"Human","referral_name":"Stamaril","international_non_proprietary_name_inn_common_name":"live attenuated yellow fever virus","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/169383/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/04/2006","european_commission_decision_date":"04/07/2006","first_published_date":"14/07/2006","last_updated_date":"14/07/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/stamaril"},{"category":"Human","referral_name":"Prograf","international_non_proprietary_name_inn_common_name":"tacrolimus","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/85997/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/01/2006","european_commission_decision_date":"10/04/2006","first_published_date":"16/05/2006","last_updated_date":"16/05/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/prograf"},{"category":"Human","referral_name":"Nifedipine Pharmamatch 30 and 60 mg","international_non_proprietary_name_inn_common_name":"nifedipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/106563/06","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/01/2006","european_commission_decision_date":"03/04/2006","first_published_date":"05/05/2006","last_updated_date":"05/05/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nifedipine-pharmamatch-30-60-mg"},{"category":"Human","referral_name":"Adartrel","international_non_proprietary_name_inn_common_name":"ropinirole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/CHMP/416317/2005","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/09/2005","european_commission_decision_date":"03/04/2006","first_published_date":"21/04/2006","last_updated_date":"21/04/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/adartrel"},{"category":"Human","referral_name":"Lansoprazol CT-Arzneimittel 15 mg and 30 mg","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/373108/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/09/2005","european_commission_decision_date":"21/02/2006","first_published_date":"25/02/2006","last_updated_date":"25/02/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-ct-arzneimittel-15-mg-30-mg"},{"category":"Human","referral_name":"Lansoprazol-ratiopharm 15 mg and 30 mg","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/373061/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/09/2005","european_commission_decision_date":"21/02/2006","first_published_date":"25/02/2006","last_updated_date":"25/02/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-ratiopharm-15-mg-30-mg"},{"category":"Human","referral_name":"Lansoprazol AbZ-Pharma 15 mg and 30 mg","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/373083/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"15/09/2005","european_commission_decision_date":"21/02/2006","first_published_date":"25/02/2006","last_updated_date":"25/02/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-abz-pharma-15-mg-30-mg"},{"category":"Human","referral_name":"Actilyse","international_non_proprietary_name_inn_common_name":"alteplase","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3346/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2002","european_commission_decision_date":"30/09/2002","first_published_date":"25/01/2006","last_updated_date":"25/01/2006","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/actilyse"},{"category":"Human","referral_name":"Coversyl","international_non_proprietary_name_inn_common_name":"perindopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/408150/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/07/2005","european_commission_decision_date":"07/11/2005","first_published_date":"23/12/2005","last_updated_date":"23/12/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/coversyl"},{"category":"Human","referral_name":"Celecoxib","international_non_proprietary_name_inn_common_name":"celecoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/323166/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2005","european_commission_decision_date":"28/11/2005","first_published_date":"06/12/2005","last_updated_date":"06/12/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/celecoxib"},{"category":"Human","referral_name":"Etoricoxib","international_non_proprietary_name_inn_common_name":"etoricoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CHMP/324317/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2005","european_commission_decision_date":"28/11/2005","first_published_date":"06/12/2005","last_updated_date":"06/12/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib-0"},{"category":"Human","referral_name":"Lumiracoxib","international_non_proprietary_name_inn_common_name":"lumiracoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/324332/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2005","european_commission_decision_date":"28/11/2005","first_published_date":"06/12/2005","last_updated_date":"06/12/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lumiracoxib-0"},{"category":"Human","referral_name":"Paroxetine","international_non_proprietary_name_inn_common_name":"paroxetine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/187488/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"09/12/2004","european_commission_decision_date":"29/03/2005","first_published_date":"22/11/2005","last_updated_date":"22/11/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/paroxetine"},{"category":"Human","referral_name":"Serotonin-specific reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors","international_non_proprietary_name_inn_common_name":"atomoxetine;citalopram;escitalopram;fluoxetine;fluvoxamine;mianserine;milnacipran;mirtazapine;paroxetine;reboxetine;sertraline;venlafaxine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Serotonin-specific reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors","reference_number":"CHMP/287837/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/04/2005","european_commission_decision_date":"19/08/2005","first_published_date":"03/11/2005","last_updated_date":"03/11/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/serotonin-specific-reuptake-inhibitors-serotonin-noradrenaline-reuptake-inhibitors"},{"category":"Human","referral_name":"Lansopon 15 mg and 30 mg","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/308522/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2005","european_commission_decision_date":"15/09/2005","first_published_date":"13/10/2005","last_updated_date":"13/10/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lansopon-15-mg-30-mg"},{"category":"Human","referral_name":"Lansoprazol HEXAL 15 mg and 30 mg","international_non_proprietary_name_inn_common_name":"lansoprazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/308176/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/06/2005","european_commission_decision_date":"15/09/2005","first_published_date":"15/09/2005","last_updated_date":"15/09/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-hexal-15-mg-30-mg"},{"category":"Human","referral_name":"Crestor 5 mg","international_non_proprietary_name_inn_common_name":"rosuvastatin calcium","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/145829/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/04/2005","european_commission_decision_date":"09/08/2005","first_published_date":"09/08/2005","last_updated_date":"09/08/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/crestor-5-mg"},{"category":"Human","referral_name":"Calcium Sandoz","international_non_proprietary_name_inn_common_name":"calcium lactate gluconate;calcium carbonate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/289490/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/04/2005","european_commission_decision_date":"09/08/2005","first_published_date":"09/08/2005","last_updated_date":"09/08/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/calcium-sandoz"},{"category":"Human","referral_name":"Rigevidon","international_non_proprietary_name_inn_common_name":"levonorgestrel;ethinylestradiol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/94618/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2005","european_commission_decision_date":"10/05/2005","first_published_date":"08/06/2005","last_updated_date":"08/06/2005","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/rigevidon"},{"category":"Human","referral_name":"Lopid","international_non_proprietary_name_inn_common_name":"gemfibrozil","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CHMP/289490/05","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/03/2004","european_commission_decision_date":"29/07/2004","first_published_date":"18/08/2004","last_updated_date":"18/08/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lopid"},{"category":"Human","referral_name":"Zestril","international_non_proprietary_name_inn_common_name":"lisinopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/423/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/09/2003","european_commission_decision_date":"16/01/2004","first_published_date":"09/08/2004","last_updated_date":"09/08/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zestril"},{"category":"Human","referral_name":"Loratadine and pseudoephedrine","international_non_proprietary_name_inn_common_name":"loratadine;pseudoephedrine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4060/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2003","european_commission_decision_date":"28/04/2004","first_published_date":"14/07/2004","last_updated_date":"14/07/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/loratadine-pseudoephedrine"},{"category":"Human","referral_name":"Loratadine","international_non_proprietary_name_inn_common_name":"loratadine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1333/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2003","european_commission_decision_date":"28/04/2004","first_published_date":"14/07/2004","last_updated_date":"14/07/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/loratadine"},{"category":"Human","referral_name":"Amlodipin Woerwag","international_non_proprietary_name_inn_common_name":"amlodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/538/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2004","european_commission_decision_date":"27/04/2004","first_published_date":"30/06/2004","last_updated_date":"30/06/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/amlodipin-woerwag"},{"category":"Human","referral_name":"Talam","international_non_proprietary_name_inn_common_name":"amlodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/540/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2004","european_commission_decision_date":"27/04/2004","first_published_date":"30/06/2004","last_updated_date":"30/06/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/talam"},{"category":"Human","referral_name":"Zocord","international_non_proprietary_name_inn_common_name":"simvastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/459/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/01/2004","european_commission_decision_date":"28/04/2004","first_published_date":"09/06/2004","last_updated_date":"09/06/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zocord"},{"category":"Human","referral_name":"Etoricoxib","international_non_proprietary_name_inn_common_name":"etoricoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1748/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/02/2004","european_commission_decision_date":"28/04/2004","first_published_date":"09/06/2004","last_updated_date":"09/06/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib-1"},{"category":"Human","referral_name":"Rofecoxib","international_non_proprietary_name_inn_common_name":"rofecoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1749/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2003","european_commission_decision_date":"28/04/2004","first_published_date":"09/06/2004","last_updated_date":"09/06/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/rofecoxib"},{"category":"Human","referral_name":"Celecoxib","international_non_proprietary_name_inn_common_name":"celecoxib","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1747/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2003","european_commission_decision_date":"29/04/2004","first_published_date":"09/06/2004","last_updated_date":"09/06/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/celecoxib-0"},{"category":"Human","referral_name":"Nimesulide","international_non_proprietary_name_inn_common_name":"nimesulide","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1724/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/12/2003","european_commission_decision_date":"26/04/2004","first_published_date":"13/05/2004","last_updated_date":"13/05/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide-0"},{"category":"Human","referral_name":"Pravachol","international_non_proprietary_name_inn_common_name":"pravastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/6214/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/11/2003","european_commission_decision_date":"02/03/2004","first_published_date":"13/05/2004","last_updated_date":"13/05/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pravachol"},{"category":"Human","referral_name":"Pidolma","international_non_proprietary_name_inn_common_name":"amlodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3122/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2004","european_commission_decision_date":"27/04/2004","first_published_date":"27/04/2004","last_updated_date":"27/04/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/pidolma"},{"category":"Human","referral_name":"Amlovita","international_non_proprietary_name_inn_common_name":"amlodipine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"EMEA/CPMP/539/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/01/2004","european_commission_decision_date":"26/04/2004","first_published_date":"26/04/2004","last_updated_date":"26/04/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/amlovita"},{"category":"Human","referral_name":"Calcitonins","international_non_proprietary_name_inn_common_name":"calcitonin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/867/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/11/2002","european_commission_decision_date":"12/06/2003","first_published_date":"02/03/2004","last_updated_date":"02/03/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/calcitonins"},{"category":"Human","referral_name":"Laurina","international_non_proprietary_name_inn_common_name":"desogestrel;ethinyl estradiol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1390/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/09/2003","european_commission_decision_date":"05/02/2004","first_published_date":"01/03/2004","last_updated_date":"01/03/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/laurina"},{"category":"Human","referral_name":"Fluconazol Tiefenbacher 50mg, 100mg, 150mg, 200mg capsules, hard","international_non_proprietary_name_inn_common_name":"fluconazole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/6236/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2003","european_commission_decision_date":"01/12/2003","first_published_date":"11/02/2004","last_updated_date":"11/02/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fluconazol-tiefenbacher-50mg-100mg-150mg-200mg-capsules-hard"},{"category":"Human","referral_name":"Calcichew D3 mite","international_non_proprietary_name_inn_common_name":"calcium;colecalciferol","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3258/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2003","european_commission_decision_date":"01/12/2003","first_published_date":"21/01/2004","last_updated_date":"21/01/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/calcichew-d3-mite"},{"category":"Human","referral_name":"Calcichew D3","international_non_proprietary_name_inn_common_name":"colecalciferol;calcium","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3257/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2003","european_commission_decision_date":"01/12/2003","first_published_date":"21/01/2004","last_updated_date":"21/01/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/calcichew-d3"},{"category":"Human","referral_name":"Calcitugg","international_non_proprietary_name_inn_common_name":"calcium carbonate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3256/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/06/2003","european_commission_decision_date":"01/12/2003","first_published_date":"21/01/2004","last_updated_date":"21/01/2004","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/calcitugg"},{"category":"Human","referral_name":"Coversyl","international_non_proprietary_name_inn_common_name":"perindopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CPMP/32703/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2003","european_commission_decision_date":"04/12/2003","first_published_date":"23/12/2003","last_updated_date":"23/12/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/coversyl-0"},{"category":"Human","referral_name":"Renitec","international_non_proprietary_name_inn_common_name":"enalapril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CPMP/3175/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/09/2002","european_commission_decision_date":"21/05/2003","first_published_date":"02/12/2003","last_updated_date":"02/12/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/renitec"},{"category":"Human","referral_name":"Roaccutane","international_non_proprietary_name_inn_common_name":"isotretinoin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/2846/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/04/2003","european_commission_decision_date":"17/10/2003","first_published_date":"02/12/2003","last_updated_date":"02/12/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/roaccutane"},{"category":"Human","referral_name":"Isotretinoin","international_non_proprietary_name_inn_common_name":"isotretinoin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/2811/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/04/2003","european_commission_decision_date":"17/10/2003","first_published_date":"02/12/2003","last_updated_date":"02/12/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/isotretinoin"},{"category":"Human","referral_name":"Botox","international_non_proprietary_name_inn_common_name":"Clostridium botulinum type A neurotoxin complex","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4260/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/02/2003","european_commission_decision_date":"25/06/2003","first_published_date":"16/10/2003","last_updated_date":"16/10/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/botox"},{"category":"Human","referral_name":"Lisinopril Biochemie","international_non_proprietary_name_inn_common_name":"lisinopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/886/04/Final","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2003","european_commission_decision_date":"23/02/2004","first_published_date":"01/09/2003","last_updated_date":"01/09/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lisinopril-biochemie"},{"category":"Human","referral_name":"Norditropin","international_non_proprietary_name_inn_common_name":"somatropin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3478/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2003","european_commission_decision_date":"","first_published_date":"29/08/2003","last_updated_date":"29/08/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/norditropin"},{"category":"Human","referral_name":"Genotropin","international_non_proprietary_name_inn_common_name":"somatropin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3477/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2003","european_commission_decision_date":"26/06/2003","first_published_date":"29/08/2003","last_updated_date":"29/08/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/genotropin"},{"category":"Human","referral_name":"Lederfoline","international_non_proprietary_name_inn_common_name":"calcium folinate","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3736/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/03/2003","european_commission_decision_date":"30/06/2003","first_published_date":"14/08/2003","last_updated_date":"14/08/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/lederfoline"},{"category":"Human","referral_name":"Salmeterol and Fluticasone Propionate","international_non_proprietary_name_inn_common_name":"salmeterol;fluticasone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"Salmeterol and fluticasone","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/01/2003","european_commission_decision_date":"21/05/2003","first_published_date":"31/07/2003","last_updated_date":"31/07/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/salmeterol-fluticasone-propionate"},{"category":"Human","referral_name":"Prozac","international_non_proprietary_name_inn_common_name":"fluoxetine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3263/03","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/09/2002","european_commission_decision_date":"","first_published_date":"18/06/2003","last_updated_date":"18/06/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/prozac-0"},{"category":"Human","referral_name":"Cardiostad","international_non_proprietary_name_inn_common_name":"lisinopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/869/04","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"24/07/2003","european_commission_decision_date":"23/02/2004","first_published_date":"01/03/2003","last_updated_date":"01/03/2003","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cardiostad"},{"category":"Human","referral_name":"Cerivastatin","international_non_proprietary_name_inn_common_name":"cerivastatin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/3962/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"21/03/2002","european_commission_decision_date":"22/08/2002","first_published_date":"20/12/2002","last_updated_date":"20/12/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cerivastatin"},{"category":"Human","referral_name":"Sibutramine","international_non_proprietary_name_inn_common_name":"","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4514/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2002","european_commission_decision_date":"26/03/2001","first_published_date":"13/12/2002","last_updated_date":"13/12/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sibutramine-0"},{"category":"Human","referral_name":"Bupropion hydrochloride","international_non_proprietary_name_inn_common_name":"bupropion","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/2852/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/07/2002","european_commission_decision_date":"25/10/2002","first_published_date":"06/12/2002","last_updated_date":"06/12/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bupropion-hydrochloride"},{"category":"Human","referral_name":"Leponex","international_non_proprietary_name_inn_common_name":"clozapine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/6034/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"02/08/2002","european_commission_decision_date":"12/11/2002","first_published_date":"27/11/2002","last_updated_date":"27/11/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/leponex"},{"category":"Human","referral_name":"Cisapride","international_non_proprietary_name_inn_common_name":"cisapride","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/24844/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/12/2001","european_commission_decision_date":"30/05/2002","first_published_date":"29/10/2002","last_updated_date":"29/10/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cisapride"},{"category":"Human","referral_name":"Motilium","international_non_proprietary_name_inn_common_name":"domperidone","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4786/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/06/2002","european_commission_decision_date":"17/10/2002","first_published_date":"17/10/2002","last_updated_date":"17/10/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/motilium"},{"category":"Human","referral_name":"Ecazide","international_non_proprietary_name_inn_common_name":"captopril;hydrochlorothiazide","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CPMP/4717/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/04/2002","european_commission_decision_date":"22/08/2002","first_published_date":"19/09/2002","last_updated_date":"19/09/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ecazide"},{"category":"Human","referral_name":"Sertindole","international_non_proprietary_name_inn_common_name":"sertindole","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 36 referrals (prior to July 2012)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/2852/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/10/2000","european_commission_decision_date":"20/01/2000","first_published_date":"19/09/2002","last_updated_date":"19/09/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/sertindole"},{"category":"Human","referral_name":"Dacarbazine Faulding","international_non_proprietary_name_inn_common_name":"dacarbazine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/2020/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/04/2002","european_commission_decision_date":"21/08/2002","first_published_date":"19/09/2002","last_updated_date":"19/09/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/dacarbazine-faulding"},{"category":"Human","referral_name":"Hypnovel","international_non_proprietary_name_inn_common_name":"midazolam","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4620/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"22/02/2002","european_commission_decision_date":"26/06/2002","first_published_date":"16/09/2002","last_updated_date":"16/09/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/hypnovel"},{"category":"Human","referral_name":"Floxyfral","international_non_proprietary_name_inn_common_name":"fluvoxamine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"-","reference_number":"CPMP/600/02","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/01/2002","european_commission_decision_date":"30/05/2002","first_published_date":"25/07/2002","last_updated_date":"25/07/2002","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/floxyfral"},{"category":"Human","referral_name":"Glucophage/Glucophage Forte/Risidon/Dianben","international_non_proprietary_name_inn_common_name":"metformin","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4082/00","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/10/2000","european_commission_decision_date":"06/02/2001","first_published_date":"07/02/2001","last_updated_date":"07/02/2001","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/glucophage-glucophage-forte-risidon-dianben"},{"category":"Human","referral_name":"Ketoprofene Ethypharm LP","international_non_proprietary_name_inn_common_name":"ketoprofen","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1988/00","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"29/06/2000","european_commission_decision_date":"27/12/2000","first_published_date":"28/12/2000","last_updated_date":"28/12/2000","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/ketoprofene-ethypharm-lp"},{"category":"Human","referral_name":"MultiHance","international_non_proprietary_name_inn_common_name":"gadobenic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1361/00","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/05/2000","european_commission_decision_date":"15/09/2000","first_published_date":"15/12/2000","last_updated_date":"15/12/2000","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/multihance"},{"category":"Human","referral_name":"Zofenil, Zopranol, Bifril","international_non_proprietary_name_inn_common_name":"zofenopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/2011/00","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/07/2000","european_commission_decision_date":"29/11/2000","first_published_date":"29/11/2000","last_updated_date":"29/11/2000","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zofenil-zopranol-bifril"},{"category":"Human","referral_name":"Bifril, Teoula, Zofepril, Zopranol","international_non_proprietary_name_inn_common_name":"zofenopril","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 6(12) referrals (prior to January 2010)","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/4362/00","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"27/07/2000","european_commission_decision_date":"29/11/2000","first_published_date":"29/11/2000","last_updated_date":"29/11/2000","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/bifril-teoula-zofepril-zopranol"},{"category":"Human","referral_name":"Engerix B","international_non_proprietary_name_inn_common_name":"hepatitis B recombinant vaccine, adsorbed","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 30 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1493/01","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"13/04/2000","european_commission_decision_date":"28/08/2000","first_published_date":"28/08/2000","last_updated_date":"28/08/2000","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/engerix-b"},{"category":"Human","referral_name":"Cyklo-f","international_non_proprietary_name_inn_common_name":"tranexamic acid","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/902/00","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"25/05/2000","european_commission_decision_date":"12/09/2000","first_published_date":"27/07/2000","last_updated_date":"27/07/2000","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/cyklo-f"},{"category":"Human","referral_name":"Aggrastat","international_non_proprietary_name_inn_common_name":"tirofiban","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/990/99","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"26/03/1999","european_commission_decision_date":"18/06/1999","first_published_date":"18/06/1999","last_updated_date":"18/06/1999","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/aggrastat"},{"category":"Human","referral_name":"Vigabatrin","international_non_proprietary_name_inn_common_name":"vigabatrin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1357/99","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/05/1999","european_commission_decision_date":"05/10/1999","first_published_date":"12/10/1998","last_updated_date":"12/10/1998","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/vigabatrin"},{"category":"Human","referral_name":"Amaryl","international_non_proprietary_name_inn_common_name":"glimepiride","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1416/98","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"17/04/1996","european_commission_decision_date":"29/08/1996","first_published_date":"03/08/1998","last_updated_date":"03/08/1998","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/amaryl"},{"category":"Human","referral_name":"Mizollen","international_non_proprietary_name_inn_common_name":"mizalostine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1500/98","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/1996","european_commission_decision_date":"01/04/1997","first_published_date":"03/08/1998","last_updated_date":"03/08/1998","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/mizollen"},{"category":"Human","referral_name":"Fluoxetin NM","international_non_proprietary_name_inn_common_name":"fluoxetine","current_status":"European Commission final decision","safety_referral":"No","referral_type":"Article 29(4) referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/1154/98","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"18/12/1997","european_commission_decision_date":"09/06/1998","first_published_date":"19/06/1998","last_updated_date":"19/06/1998","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/fluoxetin-nm"},{"category":"Human","referral_name":"Terfenadine","international_non_proprietary_name_inn_common_name":"terfenadine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/34168/98","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"20/11/1997","european_commission_decision_date":"22/09/1998","first_published_date":"22/01/1998","last_updated_date":"22/01/1998","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/terfenadine"},{"category":"Human","referral_name":"Chlormezanone","international_non_proprietary_name_inn_common_name":"chlormezanone","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/375/97","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"23/01/1997","european_commission_decision_date":"27/08/1997","first_published_date":"22/09/1997","last_updated_date":"22/09/1997","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/chlormezanone"},{"category":"Human","referral_name":"Anorectics","international_non_proprietary_name_inn_common_name":"phentermine;amfepramome;clobenzorex;dexfenfluramine;fenbutrazate;fenfluramine;fenproporex;mazindol;mefenorex;norpseudoephedrine;phenmetrazine;phendimetrazine;propylhexedrine","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"Anorectics","reference_number":"CPMP/101-109/96, CPMP/111-112/96, CPMP/113-114/96","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"16/02/1996","european_commission_decision_date":"09/12/1996","first_published_date":"10/12/1996","last_updated_date":"10/12/1996","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/anorectics"},{"category":"Human","referral_name":"Naftidrofuryl","international_non_proprietary_name_inn_common_name":"naftidrofuryl","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/578/95","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/10/1995","european_commission_decision_date":"26/06/1996","first_published_date":"26/06/1996","last_updated_date":"26/06/1996","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/naftidrofuryl"},{"category":"Human","referral_name":"Zagam","international_non_proprietary_name_inn_common_name":"sparfloxacin","current_status":"European Commission final decision","safety_referral":"Yes","referral_type":"Article 31 referrals","associated_names_centrally_authorised_medicines":"","associated_names_non_centrally_authorised_medicines":"","class":"","reference_number":"CPMP/931/95","non_prac_decision_making_model":"","prac_decision_making_model":"","authorisation_model":"","prac_recommendation":"","procedure_start_date":"","prac_recommendation_date":"","cmdh_position_date":"","chmp_cvmp_opinion_date":"19/12/1995","european_commission_decision_date":"","first_published_date":"06/05/1996","last_updated_date":"06/05/1996","referral_url":"https://www.ema.europa.eu/en/medicines/human/referrals/zagam"}]